

A Rating Scale for Drug-Induced Akathisia

British Journal of Psychiatry

154, 672-676

DOI: [10.1192/bjp.154.5.672](https://doi.org/10.1192/bjp.154.5.672)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Negative Symptoms, Tardive Dyskinesia and Depression in Chronic Schizophrenia. <i>British Journal of Psychiatry</i> , 1989, 155, 99-103.	1.7	32
2	Pharmacological characterization of tardive akathisia. <i>Biological Psychiatry</i> , 1990, 28, 809-818.	0.7	28
3	Efficacy of betaxolol in neuroleptic-induced akathisia. <i>Psychiatry Research</i> , 1991, 39, 193-198.	1.7	6
4	The Emergence of Suicidal Ideation and Behavior During Antidepressant Pharmacotherapy. <i>Archives of General Psychiatry</i> , 1991, 48, 1027.	13.8	93
5	The Hillside Akathisia Scale: a reliability comparison of the English and German versions. <i>Psychopharmacology</i> , 1991, 105, 141-144.	1.5	19
6	Acute drug-induced akathisia is not associated with low serum iron status. <i>Psychopharmacology</i> , 1991, 103, 138-139.	1.5	31
7	Successful Treatment of Tardive Akathisia with Moclobemide, a Reversible and Selective Monoamine-Oxidase-A Inhibitor. <i>Pharmacopsychiatry</i> , 1991, 24, 229-231.	1.7	5
8	Positron Emission Tomographic Analysis of Central D1 and D2 Dopamine Receptor Occupancy in Patients Treated With Classical Neuroleptics and Clozapine. <i>Archives of General Psychiatry</i> , 1992, 49, 538.	13.8	1,357
9	Clinical assessment of the extrapyramidal side effects of antipsychotic drugs. <i>Journal of Psychopharmacology</i> , 1992, 6, 214-221.	2.0	15
10	The Nithsdale Schizophrenia Surveys. IX: Akathisia, Parkinsonism, Tardive Dyskinesia and Plasma Neuroleptic Levels. <i>British Journal of Psychiatry</i> , 1992, 160, 793-799.	1.7	43
11	Relationship Between Iron Status and Chronic Akathisia in an In-patient Population with Chronic Schizophrenia. <i>British Journal of Psychiatry</i> , 1992, 161, 791-796.	1.7	31
12	A double-blind comparison of raclopride and haloperidol in the acute phase of schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1992, 86, 391-398.	2.2	14
13	Drug-Induced Movement Disorders in Institutionalised Adults with Mental Retardation: Clinical Characteristics and Risk Factors. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 242-248.	1.3	23
14	Pharmacokinetics of Raclopride Formulations. <i>Clinical Pharmacokinetics</i> , 1992, 22, 152-161.	1.6	15
15	Quantitative assessment of psychomotor activity in patients with neuroleptic-induced akathisia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992, 16, IN1-37.	2.5	21
16	Akathisia: Clinical phenomenology and relationship to tardive dyskinesia. <i>Comprehensive Psychiatry</i> , 1992, 33, 233-236.	1.5	13
17	Drug-Induced Movement Disorders in Institutionalised Adults with Mental Retardation: Clinical Characteristics and Risk Factors. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 242-248.	1.3	22
18	The Nithsdale Schizophrenia Surveys X: Obstetric Complications, Family History and Abnormal Movements. <i>British Journal of Psychiatry</i> , 1992, 160, 799-805.	1.7	59

#	ARTICLE	IF	CITATIONS
19	The Nithsdale schizophrenia surveys. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1992, 27, 40-45.	1.6	19
20	Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. <i>Psychopharmacology</i> , 1992, 106, 433-438.	1.5	147
21	Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans – a PET study with [11C]SCH 23390 and [11C]raclopride. <i>Psychopharmacology</i> , 1992, 107, 23-29.	1.5	76
22	Tardive and chronically recurrent oculogyric crises. <i>Movement Disorders</i> , 1993, 8, 93-97.	2.2	55
23	An open study of the pharmacokinetics and the tolerability of raclopride extended release capsules in psychiatric patients. <i>Psychopharmacology</i> , 1993, 112, 371-374.	1.5	4
24	Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. <i>Psychopharmacology</i> , 1993, 111, 359-366.	1.5	33
25	5-HT ₂ and D2 dopamine receptor occupancy in the living human brain. <i>Psychopharmacology</i> , 1993, 110, 265-272.	1.5	225
26	Therapeutic effect of clonazepam in neuroleptic-induced akathisia. <i>European Neuropsychopharmacology</i> , 1993, 3, 386.	0.3	0
27	Phenomenology and Prevalence of Neuroleptic-Induced Akathisia in Late Life. <i>American Journal of Geriatric Psychiatry</i> , 1993, 1, 136-142.	0.6	8
28	Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. <i>Biological Psychiatry</i> , 1993, 33, 227-235.	0.7	482
29	Placebo Response in Refractory Tardive Akathisia. <i>Canadian Journal of Psychiatry</i> , 1993, 38, 248-250.	0.9	13
30	Clinical characteristics of 15 patients with tardive dystonia. <i>American Journal of Psychiatry</i> , 1993, 150, 498-500.	4.0	24
31	Reliability and applicability of movement disorder rating scales in the elderly. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1993, 5, 56-60.	0.9	45
32	Risk factors for tardive dystonia: a case-control comparison with tardive dyskinesia. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 98-103.	2.2	26
33	Efficacy of maintenance use of anticholinergic agents. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 381-384.	2.2	31
34	Dyspraxia and Agnosia in Schizophrenia. <i>Behavioural Neurology</i> , 1993, 6, 49-54.	1.1	14
35	Adjunctive Medication in the Maintenance Treatment of Schizophrenia and its Conceptual Implications. <i>British Journal of Psychiatry</i> , 1993, 163, 66-78.	1.7	51
36	Drug-Induced Akathisia: Subjective Experience and Objective Findings. <i>Military Medicine</i> , 1994, 159, 286-291.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Influence of rate of administration of raclopride on akathisia and prolactin response. <i>Psychopharmacology</i> , 1994, 114, 248-256.	1.5	5
38	Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. <i>Psychopharmacology</i> , 1994, 116, 291-296.	1.5	10
39	Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale and proposal. <i>Psychopharmacology</i> , 1994, 114, 181-186.	1.5	54
40	The clinical characteristics of schizophrenic patients consenting or not consenting to a placebo controlled trial of antipsychotic medication. <i>Human Psychopharmacology</i> , 1994, 9, 423-433.	0.7	25
41	A retrospective study of risk factors of akathisia in terminally ill patients. <i>Journal of Pain and Symptom Management</i> , 1994, 9, 454-461.	0.6	23
42	A rating scale for acute drug-induced akathisia: development, reliability, and validity. <i>Biological Psychiatry</i> , 1994, 35, 263-271.	0.7	71
43	Akathisia: Prevalence and Associated Dysphoria in an In-patient Population with Chronic Schizophrenia. <i>British Journal of Psychiatry</i> , 1994, 164, 177-183.	1.7	95
44	Movement Disorder in Never and Minimally Treated Nigerian Schizophrenic Patients. <i>British Journal of Psychiatry</i> , 1994, 164, 184-189.	1.7	35
45	Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. <i>American Journal of Psychiatry</i> , 1994, 151, 756-759.	4.0	41
46	Neuroleptics in the Elderly: Guidelines for Monitoring. <i>Harvard Review of Psychiatry</i> , 1995, 2, 327-335.	0.9	18
47	Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride – an 123I-IBZM single photon emission tomography (SPET) study. <i>Psychopharmacology</i> , 1995, 117, 55-61.	1.5	54
48	Oral administration of NNC 756 – a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. <i>Psychopharmacology</i> , 1995, 119, 1-8.	1.5	27
49	Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. <i>Psychopharmacology</i> , 1995, 121, 309-316.	1.5	138
50	A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. <i>Psychopharmacology</i> , 1995, 119, 345-348.	1.5	43
51	Cyproheptadine Treatment in Neuroleptic-Induced Akathisia. <i>British Journal of Psychiatry</i> , 1995, 167, 483-486.	1.7	53
52	The Evaluation and Treatment of Neuroleptic-Induced Movement Disorders. <i>Harvard Review of Psychiatry</i> , 1995, 3, 130-139.	0.9	11
53	Duration of Neuroleptic Treatment and Prevalence of Tardive Dyskinesia in Late Life. <i>Archives of General Psychiatry</i> , 1995, 52, 478.	13.8	38
54	The Epidemiology of Drug-induced Akathisia: Part II. Chronic, Tardive, and Withdrawal Akathisias. <i>Schizophrenia Bulletin</i> , 1995, 21, 451-461.	2.3	58

#	ARTICLE	IF	CITATIONS
55	A Self-Rating Scale for Measuring Neuroleptic Side-Effects. <i>British Journal of Psychiatry</i> , 1995, 166, 650-653.	1.7	264
56	The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. <i>Life Sciences</i> , 1995, 57, PL103-PL107.	2.0	204
57	Paroxetine and akathisia. <i>Biological Psychiatry</i> , 1995, 37, 336-337.	0.7	36
58	The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The CuraÃ§ao extrapyramidal syndromes study: I. <i>Schizophrenia Research</i> , 1996, 19, 195-203.	1.1	106
59	Prospective study of FK506 side effects: Anxiety or akathisia?. <i>Biological Psychiatry</i> , 1996, 40, 407-411.	0.7	28
60	Nefazodone and akathisia. <i>Biological Psychiatry</i> , 1996, 40, 798-799.	0.7	13
61	Akathisia: A review and case report following paroxetine treatment. <i>Comprehensive Psychiatry</i> , 1996, 37, 122-124.	1.5	39
62	Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. <i>Psychiatry Research - Neuroimaging</i> , 1996, 68, 23-30.	0.9	28
63	Extrapyramidal Syndromes. <i>CNS Drugs</i> , 1996, 5, 1-12.	2.7	21
64	Large Variations of Plasma Levels During Maintenance Treatment with Depot Neuroleptics. <i>British Journal of Psychiatry</i> , 1996, 169, 618-621.	1.7	22
65	Use of Clozapine in a Child with Treatment-Resistant Schizophrenia. <i>British Journal of Psychiatry</i> , 1996, 168, 376-378.	1.7	15
66	Olanzapine versus Placebo and Haloperidol. <i>Neuropsychopharmacology</i> , 1996, 14, 111-123.	2.8	689
67	Tardive dystonia. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 409-418.	0.1	13
68	Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine â€” a123 IBZM single photon emission tomography (SPET) study. <i>Psychopharmacology</i> , 1996, 124, 148-153.	1.5	151
69	Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. <i>Psychopharmacology</i> , 1996, 124, 159-167.	1.5	367
70	An open trial of adjunctive sertraline in the treatment of chronic schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1996, 94, 194-197.	2.2	21
71	Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dvskinesia. <i>Acta Psychiatrica Scandinavica</i> , 1996, 93, 451-459.	2.2	21
72	Movement Disorder in Down's syndrome: A possible marker of the severity of mental handicap. <i>Movement Disorders</i> , 1996, 11, 395-403.	2.2	26

#	ARTICLE	IF	CITATIONS
73	Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 675-685.	2.3	7
74	Psychological Predictors of Insight and Compliance in Psychotic Patients. <i>British Journal of Psychiatry</i> , 1996, 169, 444-450.	1.7	247
75	Drug Evaluations: Drug Evaluation Central & Peripheral Nervous Systems: "Seroquel"™ (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic. <i>Expert Opinion on Investigational Drugs</i> , 1996, 5, 939-957.	1.9	45
76	Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. <i>British Journal of Psychiatry</i> , 1997, 170, 18-22.	1.7	190
77	Hyperkinesias in a Prepubertal Boy with Autistic Disorder Treated with Haloperidol and Valproic Acid. <i>Psychological Reports</i> , 1997, 80, 163-170.	0.9	20
78	Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. <i>American Journal of Psychiatry</i> , 1997, 154, 782-791.	4.0	316
79	Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. <i>American Journal of Psychiatry</i> , 1997, 154, 457-465.	4.0	862
80	Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. <i>American Journal of Psychiatry</i> , 1997, 154, 466-474.	4.0	283
81	Quetiapine in Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 1997, 54, 549.	13.8	484
82	Recent Advances in the Pharmacotherapy of Schizophrenia. <i>Harvard Review of Psychiatry</i> , 1997, 4, 255-271.	0.9	33
83	Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. <i>American Journal of Psychiatry</i> , 1997, 154, 1248-1254.	4.0	287
85	One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. <i>British Journal of Psychiatry</i> , 1997, 171, 564-568.	1.7	102
86	A PET study of voluntary movement in schizophrenic patients experiencing passivity phenomena (delusions of alien control). <i>Brain</i> , 1997, 120, 1997-2011.	3.7	412
87	Olanzapine. <i>Drugs</i> , 1997, 53, 281-298.	4.9	225
88	Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. <i>Schizophrenia Research</i> , 1997, 25, 71-78.	1.1	18
89	The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. <i>Schizophrenia Research</i> , 1997, 26, 41-54.	1.1	171
90	The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapiramidal Syndromes Study II. <i>Schizophrenia Research</i> , 1997, 26, 235-242.	1.1	36
91	Choosing an antipsychotic in the treatment of schizophrenia: Conversions to olanzapine. <i>Journal of the American Psychiatric Nurses Association</i> , 1997, 3, S18-S23.	0.4	1

#	ARTICLE	IF	CITATIONS
92	A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 1997, 337, 809-815.	13.9	515
93	Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. <i>European Neuropsychopharmacology</i> , 1997, 7, 125-137.	0.3	247
94	Sertraline and akathisia: Spontaneous resolution. <i>Biological Psychiatry</i> , 1997, 41, 241-242.	0.7	17
95	Aggressive behaviour in schizophrenia: role of state versus trait factors. <i>Psychiatry Research</i> , 1997, 72, 41-50.	1.7	14
96	Choosing an Antipsychotic in the treatment of Schizophrenia: Conversions to Olanzapine. <i>Journal of the American Psychiatric Nurses Association</i> , 1997, 3, S18-S23.	0.4	0
97	Management of acute extrapyramidal effects induced by antipsychotic drugs. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 2461-2477.	0.5	64
98	The role of the general practitioner in the treatment of schizophrenia: specific issues. <i>Medical Journal of Australia</i> , 1997, 166, 143-146.	0.8	13
99	lloperidone: Preclinical Profile and Early Clinical Evaluation. <i>CNS Neuroscience & Therapeutics</i> , 1997, 3, 120-147.	4.0	25
100	A PET Study of 5-HT ₂ and D ₂ Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects. <i>Neuropsychopharmacology</i> , 1997, 16, 1-7.	2.8	117
101	Observations on switching patients with schizophrenia to risperidone treatment. <i>Acta Psychiatrica Scandinavica</i> , 1997, 95, 439-443.	2.2	19
102	Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. <i>Acta Psychiatrica Scandinavica</i> , 1997, 96, 347-353.	2.2	9
103	A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1997, 96, 265-273.	2.2	240
104	Neuroleptic-induced akathisia and early onset tardive dyskinesia in affective disorder due to Cushing's syndrome. <i>General Hospital Psychiatry</i> , 1997, 19, 445-447.	1.2	3
105	Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. <i>Psychopharmacology</i> , 1997, 131, 174-179.	1.5	100
106	Open clinical trial on the sigma ligand panamesine in patients with schizophrenia. <i>Psychopharmacology</i> , 1997, 132, 82-88.	1.5	48
107	Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. <i>Psychopharmacology</i> , 1997, 132, 396-401.	1.5	138
108	IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1997, 133, 323-328.	1.5	65
109	Treatment of neuroleptic-induced akathisia with nicotine patches. <i>Psychopharmacology</i> , 1997, 134, 153-156.	1.5	32

#	ARTICLE	IF	CITATIONS
110	Case report: akathisia abolished by passive movement. <i>Acta Psychiatrica Scandinavica</i> , 1998, 97, 168-169.	2.2	7
111	Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a doseâ€ranging study vs. haloperidol. <i>Acta Psychiatrica Scandinavica</i> , 1998, 98, 65-72.	2.2	133
113	Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-HBZM SPECT study. <i>Psychopharmacology</i> , 1998, 136, 367-373.	1.5	51
114	Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. <i>Psychopharmacology</i> , 1998, 140, 173-184.	1.5	260
115	Tardive dyskinesia and serum iron indices. <i>Biological Psychiatry</i> , 1998, 44, 493-498.	0.7	39
116	A Double-Blind, Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol or Placebo on Anxious and Depressive Symptoms Accompanying Schizophrenia. <i>Biological Psychiatry</i> , 1998, 43, 803-810.	0.7	124
117	Predictors of differential response to clozapine and haloperidol. <i>Biological Psychiatry</i> , 1998, 44, 475-482.	0.7	32
118	D-serine added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 1998, 44, 1081-1089.	0.7	586
121	A Structured Trial of Risperidone for the Treatment of Agitation in Dementia. <i>American Journal of Geriatric Psychiatry</i> , 1998, 6, 127-135.	0.6	38
122	Randomised controlled trial of compliance therapy. <i>British Journal of Psychiatry</i> , 1998, 172, 413-419.	1.7	484
123	A case of paroxetine-induced akathisia and a review of SSRI-induced akathisia. <i>European Psychiatry</i> , 1998, 13, 109-111.	0.1	10
124	Clozapine effectiveness in a psychiatric service in Italy. <i>European Psychiatry</i> , 1998, 13, 317-319.	0.1	2
125	Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia. <i>American Journal of Psychiatry</i> , 1998, 155, 914-920.	4.0	223
126	Psychopharmacological Treatment of Schizophrenia: What Social Workers Need to Know. <i>Research on Social Work Practice</i> , 1998, 8, 384-405.	1.1	4
127	D2- and 5-HT ₂ receptor occupancy in high-dose neuroleptic-treated patients. <i>International Journal of Neuropsychopharmacology</i> , 1998, 1, 95-101.	1.0	24
128	Clinical Assessment of Adventitious Movements. <i>Psychological Reports</i> , 1998, 83, 739-750.	0.9	7
129	Measuring the Quality of Outpatient Treatment for Schizophrenia. <i>Archives of General Psychiatry</i> , 1998, 55, 611.	13.8	159
131	5-HT ₂ and D ₂ Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. <i>American Journal of Psychiatry</i> , 1998, 155, 921-928.	4.0	359

#	ARTICLE	IF	CITATIONS
132	Depressive Signs and Symptoms in Schizophrenia. Archives of General Psychiatry, 1998, 55, 250.	13.8	259
133	Cost-effectiveness evaluation of compliance therapy for people with psychosis. British Journal of Psychiatry, 1998, 172, 420-424.	1.7	61
134	Prefrontal cortex activity in people with schizophrenia and control subjects. British Journal of Psychiatry, 1998, 172, 316-323.	1.7	110
135	Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?. Archives of General Psychiatry, 1998, 55, 618.	13.8	67
136	Assessment and Management of Antipsychotic-Induced Adverse Events. Canadian Journal of Psychiatry, 1998, 43, 15S-20S.	0.9	17
137	5-HT _{2A} receptor blockade in patients with schizophrenia treated with risperidone or clozapine. British Journal of Psychiatry, 1998, 173, 236-241.	1.7	97
138	A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychological Medicine, 1998, 28, 437-446.	2.7	227
139	Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. American Journal of Health-System Pharmacy, 1998, 55, 1003-1016.	0.5	52
140	Olanzapine: Psychopharmacology, Clinical Efficacy, and Adverse Effects. Hospital Pharmacy, 1999, 34, 423-436.	0.4	3
141	Review of recent clinical studies with olanzapine. British Journal of Psychiatry, 1999, 174, 30-35.	1.7	53
142	Treatment of tardive akathisia with clonidine: a case report. International Journal of Neuropsychopharmacology, 1999, 2, 151-153.	1.0	6
143	Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics*. British Journal of Psychiatry, 1999, 174, 34-43.	1.7	82
144	Glucose-Induced Increase in Memory Performance in Patients With Schizophrenia. Schizophrenia Bulletin, 1999, 25, 321-335.	2.3	78
145	Spontaneous dyskinesia in first episode schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 76-78.	0.9	56
146	effects of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. Journal of Psychopharmacology, 1999, 13, 398-405.	2.0	84
147	Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology, 1999, 52, 782-782.	1.5	131
148	In vivo occupancy of striatal and temporal cortical D ₂ /D ₃ dopamine receptors by typical antipsychotic drugs. British Journal of Psychiatry, 1999, 175, 231-238.	1.7	49
149	Suggested Minimal Effective Dose of Risperidone Based on PET-Measured D ₂ and 5-HT _{2A} Receptor Occupancy in Schizophrenic Patients. American Journal of Psychiatry, 1999, 156, 869-875.	4.0	258

#	ARTICLE	IF	CITATIONS
150	Patient, provider, and treatment factors associated with poor-quality care for schizophrenia. Administration and Policy in Mental Health and Mental Health Services Research, 1999, 1, 201-211.	2.2	19
151	Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research, 1999, 8, 417-426.	1.5	125
152	Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology, 1999, 142, 393-398.	1.5	169
153	Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology, 1999, 145, 193-204.	1.5	224
154	The incidence of akathisia in bipolar affective disorder treated with neuroleptics "a preliminary report. Journal of Affective Disorders, 1999, 53, 175-177.	2.0	13
155	Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled Trial. Neuropsychopharmacology, 1999, 20, 491-505.	2.8	339
156	Measuring side effects of psychopharmacologic medication in individuals with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 1999, 5, 348-359.	3.5	30
157	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. , 1999, 2, 111-121.		23
158	Behavioural Problems Associated With Dementia. Drugs and Aging, 1999, 14, 41-54.	1.3	81
159	Clinical characteristics and insight in a group of severely ill schizophrenics. Nordic Journal of Psychiatry, 1999, 53, 377-382.	0.7	4
160	Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy. Annals of Pharmacotherapy, 1999, 33, 73-85.	0.9	195
161	Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. International Journal of Psychiatry in Clinical Practice, 1999, 3, 159-169.	1.2	9
162	Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Research - Neuroimaging, 1999, 90, 31-39.	0.9	26
163	Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Research - Neuroimaging, 1999, 92, 33-44.	0.9	42
164	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research, 1999, 88, 107-117.	1.7	174
165	Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Research, 1999, 89, 275-280.	1.7	19
166	The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: An open label study. European Neuropsychopharmacology, 1999, 9, 475-477.	0.3	20
167	Does akathisia influence psychopathology in psychotic patients treated with clozapine?. Biological Psychiatry, 1999, 45, 1376-1383.	0.7	22

#	ARTICLE	IF	CITATIONS
168	Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia—See accompanying Editorial, in this issue.. Biological Psychiatry, 1999, 45, 403-411.	0.7	131
169	Olanzapine. Clinical Pharmacokinetics, 1999, 37, 177-193.	1.6	460
170	Symptom dimensions in old-age schizophrenics Relationship to neuropsychological and motor abnormalities. Schizophrenia Research, 1999, 39, 31-38.	1.1	21
171	Measuring neuroleptic-induced akathisia by three-channel actometry. Schizophrenia Research, 1999, 40, 105-110.	1.1	19
172	Treatment of neuroleptic-induced akathisia with the 5-HT ₂ antagonist mianserin. British Journal of Psychiatry, 1999, 174, 238-242.	1.7	71
173	Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis. American Journal of Psychiatry, 1999, 156, 79-87.	4.0	209
174	Benzodiazepines for neuroleptic-induced acute akathisia. The Cochrane Library, 1999, , CD001950.	1.5	26
175	Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry, 1999, 174, 23-30.	1.7	226
176	Olanzapine versus haloperidol in the treatment of schizoaffective disorder. British Journal of Psychiatry, 1999, 174, 15-22.	1.7	65
177	Vitamin E Treatment for Tardive Dyskinesia. Archives of General Psychiatry, 1999, 56, 836.	13.8	112
178	Ziprasidone for schizophrenia and severe mental illness. The Cochrane Library, 2000, , CD001945.	1.5	21
179	Quetiapine for schizophrenia. , 2000, , CD000967.		7
180	Olanzapine for schizophrenia. , 2000, , CD001359.		25
181	The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. International Journal of Neuropsychopharmacology, 2000, 3, 285-296.	1.0	34
182	Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: A generalization of Steen's study on DRD3 and tardive dyskinesia. , 2000, 96, 187-191.		77
183	Extrapyramidal symptoms and residual psychopathology with low-dose neuroleptics. , 2000, 15, 79-85.		6
184	Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients. Psychiatry and Clinical Neurosciences, 2000, 54, 467-478.	1.0	15
185	Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. British Journal of Clinical Pharmacology, 2000, 49, 5-13.	1.1	69

#	ARTICLE	IF	CITATIONS
186	What can we do about acute extrapyramidal symptoms?. Journal of Psychiatric and Mental Health Nursing, 2000, 7, 205-211.	1.2	35
187	Abnormal Movements in First Episode Psychosis. Australasian Psychiatry, 2000, 8, 38-41.	0.4	2
188	Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study. General Hospital Psychiatry, 2000, 22, 107-114.	1.2	19
189	Is akathisia associated with poor clinical response to antipsychotics during acute hospital treatment?. General Hospital Psychiatry, 2000, 22, 276-280.	1.2	4
190	Varieties of repetitive behavior in autism: comparisons to mental retardation. Journal of Autism and Developmental Disorders, 2000, 30, 237-243.	1.7	932
191	Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [¹²³ I]epidepride single photon emission tomography (SPET) study. Psychopharmacology, 2000, 150, 132-140.	1.5	78
192	High 5HT 2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology, 2000, 148, 400-403.	1.5	57
195	Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo. British Journal of Psychiatry, 2000, 177, 408-415.	1.7	85
196	Assessment of drug-related movement disorders in schizophrenia. Advances in Psychiatric Treatment, 2000, 6, 332-341.	0.6	42
197	Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. American Journal of Psychiatry, 2000, 157, 514-520.	4.0	982
198	Neuromotor Assessment and Autistic Disorder. Autism, 2000, 4, 287-298.	2.4	12
199	Intravenous Biperiden in Akathisia: An Open Pilot Study. International Journal of Psychiatry in Medicine, 2000, 30, 185-194.	0.8	16
200	Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities. Archives of General Psychiatry, 2000, 57, 968.	13.8	524
201	Efficacy of Olanzapine in Acute Bipolar Mania_{title>A Double-blind, Placebo-Controlled Study}. Archives of General Psychiatry, 2000, 57, 841.	13.8	506
202	Olanzapine: an atypical antipsychotic for schizophrenia. Expert Opinion on Pharmacotherapy, 2000, 1, 305-323.	0.9	19
203	Akathisia Masked by Hypokinesia. Pharmacopsychiatry, 2000, 33, 147-149.	1.7	8
204	Consistent performance over time of schizophrenic patients on a neuropsychological set of tests. Nordic Journal of Psychiatry, 2000, 54, 207-211.	0.7	0
205	The safety and efficacy of zotepine in the treatment of schizophrenia: Results of a one-year naturalistic clinical trial. International Journal of Psychiatry in Clinical Practice, 2000, 4, 299-306.	1.2	16

#	ARTICLE	IF	CITATIONS
206	The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. <i>Clinical Therapeutics</i> , 2000, 22, 1021-1034.	1.1	51
207	The Greek version of the Calgary Depression Scale for Schizophrenia. <i>Psychiatry Research</i> , 2000, 94, 163-171.	1.7	21
208	Pseudoakathisia: A review and two case reports. <i>Comprehensive Psychiatry</i> , 2000, 41, 70-72.	1.5	9
209	Olanzapine versus Risperidone. <i>Pharmacoeconomics</i> , 2000, 18, 567-579.	1.7	57
210	Relationship of akathisia to aggressive and self-injurious behaviour: A prevalence study in a UK tertiary referral centre. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 319-325.	1.2	3
211	Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 47-54.	1.2	17
212	Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. <i>Schizophrenia Research</i> , 2000, 42, 223-230.	1.1	51
213	Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. <i>Schizophrenia Research</i> , 2000, 43, 135-145.	1.1	229
214	Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. <i>Schizophrenia Research</i> , 2000, 45, 47-56.	1.1	124
215	Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia. <i>European Neuropsychopharmacology</i> , 2000, 10, 171-176.	0.3	32
216	Prevalence and characteristics of patients with pseudoakathisia. <i>European Neuropsychopharmacology</i> , 2000, 10, 333-336.	0.3	8
218	Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. <i>Schizophrenia Research</i> , 2001, 47, 59-67.	1.1	79
219	Conditioned blocking and schizophrenia: a replication and study of the role of symptoms, age, onset-age of psychosis and illness-duration. <i>Schizophrenia Research</i> , 2001, 49, 157-170.	1.1	93
220	Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. <i>European Psychiatry</i> , 2001, 16, 293-298.	0.1	98
221	Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. <i>European Psychiatry</i> , 2001, 16, 474-482.	0.1	23
222	Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. <i>Biological Psychiatry</i> , 2001, 49, 52-63.	0.7	184
223	Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. <i>Clinical Therapeutics</i> , 2001, 23, 942-956.	1.1	21
224	Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia. <i>Psychiatry Research</i> , 2001, 102, 49-57.	1.7	150

#	ARTICLE	IF	CITATIONS
225	Olanzapine treatment for patients with schizophrenia and substance abuse. <i>Journal of Substance Abuse Treatment</i> , 2001, 21, 217-221.	1.5	82
226	Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [¹²³ I]IBZM SPECT study. <i>Psychiatry Research - Neuroimaging</i> , 2001, 107, 87-97.	0.9	28
227	Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2001, 107, 135-149.	0.9	53
228	National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. <i>American Journal of Geriatric Psychiatry</i> , 2001, 9, 346-360.	0.6	156
229	Continuation Treatment of Delusional Depression in Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2001, 9, 415-422.	0.6	42
230	Neuropsychological indicators of heteromodal cortex (dys)function relevant to conditioned blocking measures of attention in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2001, 6, 41-61.	0.7	3
231	Acute akathisia and sodium valproate. <i>International Journal of Psychiatry in Clinical Practice</i> , 2001, 5, 219-222.	1.2	5
232	A Prospective Open-Label Treatment Trial of Olanzapine Monotherapy in Children and Adolescents with Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2001, 11, 239-250.	0.7	186
233	Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: A new approach to an old problem. <i>British Journal of Psychiatry</i> , 2001, 179, 4-8.	1.7	74
234	Comorbid non-alcohol substance misuse among people with schizophrenia. <i>British Journal of Psychiatry</i> , 2001, 179, 509-513.	1.7	111
235	Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, 1309-1316.	0.5	55
236	Acute tryptophan depletion in schizophrenia. <i>Psychological Medicine</i> , 2001, 31, 75-84.	2.7	43
238	Lithium Augmentation in Venlafaxine-Refractory Depression. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 242-243.	0.7	5
239	Piracetam in the Treatment of Tardive Dyskinesia and Akathisia: A Case Report. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 248-249.	0.7	15
240	Effects of Selective Serotonin Reuptake Inhibitors on Sexual Function. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 241-242.	0.7	6
241	Reply to Comments on "Olanzapine Treatment of Children, Adolescents, and Adults With Pervasive Developmental Disorders: An Open-Label Pilot Study". <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 246-247.	0.7	3
242	Olanzapine-Associated Priapism. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 247.	0.7	14
244	A Double-Blind, Randomized Comparison of the Efficacy and Safety of Intramuscular Injections of Olanzapine, Lorazepam, or Placebo in Treating Acutely Agitated Patients Diagnosed With Bipolar Mania. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 389-397.	0.7	221

#	ARTICLE	IF	CITATIONS
245	Cyproheptadine Versus Propranolol for the Treatment of Acute Neuroleptic-Induced Akathisia: A Comparative Double-Blind Study. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 612-615.	0.7	65
246	Olanzapine Plasma Concentrations and Clinical Response: Acute Phase Results of the North American Olanzapine Trial. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 14-20.	0.7	125
247	Venlafaxine-Associated Mania. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 239-241.	0.7	12
248	Ziprasidone in the Short-Term Treatment of Patients with Schizoaffective Disorder: Results from Two Double-Blind, Placebo-Controlled, Multicenter Studies. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 27-35.	0.7	75
249	Topiramate in the Treatment of Acute Mania. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 243-244.	0.7	10
250	Olanzapine and Huntington's Disease. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 245-246.	0.7	25
251	Zotepine in the treatment of acute hospitalized schizophrenic episodes. <i>International Clinical Psychopharmacology</i> , 2001, 16, 163-168.	0.9	7
252	Olanzapine treatment for post-traumatic stress disorder: an open-label study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 331-337.	0.9	94
253	Antidepressive Treatment With Amitriptyline and Paroxetine: Comparable Effects On Heart Rate Variability. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 238-239.	0.7	32
254	Olanzapine as Alternative Therapy for Patients With Haloperidol-Induced Extrapyramidal Symptoms: Results of a Multicenter, Collaborative Trial in Latin America. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 375-381.	0.7	32
255	Which Side Effects Really Matter? Screening for Common and Distressing Side Effects of Antipsychotic Medications. <i>Journal of Psychiatric Practice</i> , 2001, 7, 41-47.	0.3	71
256	Treatment of Borderline Personality Disorder With Mood Instability With Divalproex Sodium: Series of Ten Cases. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 249-251.	0.7	12
257	Patient and Rater Education of Expectations in Clinical Trials (PREECT). <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 251-252.	0.7	17
258	Saccadic Disinhibition in Patients With Acute and Remitted Schizophrenia and Their First-Degree Biological Relatives. <i>American Journal of Psychiatry</i> , 2001, 158, 100-106.	4.0	156
259	Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. <i>American Journal of Psychiatry</i> , 2001, 158, 311-314.	4.0	99
260	The impact of olanzapine on attitude to medication and quality of life in schizophrenia. <i>Psychiatric Bulletin</i> , 2001, 25, 378-381.	0.3	6
261	Clinical Assessment of TICS. <i>Psychological Reports</i> , 2001, 89, 48-50.	0.9	8
262	Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 197-203.	0.9	142

#	ARTICLE	IF	CITATIONS
263	The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): inter-rater reliability and construct validity. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 347-60.	1.0	23
264	Novel antipsychotics and acute dystonic reactions. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 393-7.	1.0	30
265	The Relationship of Akathisia With Suicidality and Depersonalization Among Patients With Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 336-341.	0.9	51
266	Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. <i>Psychopharmacology</i> , 2001, 155, 128-134.	1.5	163
267	Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. <i>Psychopharmacology</i> , 2001, 156, 53-57.	1.5	40
268	In vivo 123I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. <i>Psychopharmacology</i> , 2001, 157, 236-242.	1.5	19
269	Saccadic disinhibition in schizophrenia patients and their first-degree biological relatives. <i>Experimental Brain Research</i> , 2001, 137, 228-236.	0.7	72
270	Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 217-224.	1.8	22
271	The accuracy of medical record documentation in schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2001, 28, 456-465.	0.6	52
272	Restlessness in suboccipital muscles as a manifestation of akathisia. <i>Psychiatry and Clinical Neurosciences</i> , 2001, 55, 81-82.	1.0	3
273	Neuropsychological impairment in patients treated with depot neuroleptics: a longitudinal study. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 75-80.	2.2	7
274	A randomized, controlled trial of a brief interventional package for schizophrenic out-patients. <i>Acta Psychiatrica Scandinavica</i> , 2001, 103, 362-369.	2.2	54
275	A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 1156-1162.	1.3	106
276	Drug induced akathisia, suicidal ideation and its treatment in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 231-232.	1.3	24
277	Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, S71-S77.	1.3	35
278	Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, S62-S70.	1.3	71
279	A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, S33-S61.	1.3	35
280	Asperger's disorder in the emergency psychiatric setting. <i>General Hospital Psychiatry</i> , 2001, 23, 285-293.	1.2	38

#	ARTICLE	IF	CITATIONS
281	Subjective Effects of AMPT-induced Dopamine Depletion in Schizophrenia Correlation between Dysphoric Responses and Striatal D2 Binding Ratios on SPECT Imaging. <i>Neuropsychopharmacology</i> , 2001, 25, 642-650.	2.8	80
282	Clozapine and Haloperidol in Moderately Refractory Schizophrenia. <i>Archives of General Psychiatry</i> , 2001, 58, 965.	13.8	163
283	The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 239-50.	1.0	44
284	Akathisia – A Brief Review. <i>Scottish Medical Journal</i> , 2001, 46, 133-134.	0.7	10
285	Clinical Advantages of Amisulpride in the Treatment of Acute Schizophrenia. <i>Journal of International Medical Research</i> , 2001, 29, 451-466.	0.4	14
286	The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. <i>Journal of Psychopharmacology</i> , 2001, 15, 265-271.	2.0	63
287	A Study of Quetiapine: Efficacy and Tolerability in Psychotic Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2001, 11, 415-424.	0.7	94
288	Clozapine-Induced Akathisia in Children with Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2002, 12, 347-349.	0.7	15
289	Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 107-111.	1.2	16
290	A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia. <i>Archives of General Psychiatry</i> , 2002, 59, 441.	13.8	265
291	Evidence for Impaired Cortical Inhibition in Schizophrenia Using Transcranial Magnetic Stimulation. <i>Archives of General Psychiatry</i> , 2002, 59, 347.	13.8	256
292	Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. <i>Archives of General Psychiatry</i> , 2002, 59, 62.	13.8	410
293	Cost-Effectiveness of Risperidone, Olanzapine, and Conventional Antipsychotic Medications. <i>Schizophrenia Bulletin</i> , 2002, 28, 589-605.	2.3	41
294	Efficacy of olanzapine in social anxiety disorder: a pilot study. <i>Journal of Psychopharmacology</i> , 2002, 16, 365-368.	2.0	104
295	Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: an evaluation using confirmatory factor analysis. <i>International Clinical Psychopharmacology</i> , 2002, 17, 249-261.	0.9	16
296	Nithsdale Schizophrenia Surveys 23: movement disorders. <i>British Journal of Psychiatry</i> , 2002, 181, 422-427.	1.7	73
297	Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. <i>International Clinical Psychopharmacology</i> , 2002, 17, 227-237.	0.9	55
298	Open-Label Study of Olanzapine in Children with Pervasive Developmental Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 455-460.	0.7	110

#	ARTICLE	IF	CITATIONS
299	A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. <i>International Clinical Psychopharmacology</i> , 2002, 17, 207-215.	0.9	160
300	Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 554-560.	0.7	26
301	Amisulpride for schizophrenia. <i>The Cochrane Library</i> , 2002, , CD001357.	1.5	29
302	Olanzapine Versus Divalproex in the Treatment of Acute Mania. <i>American Journal of Psychiatry</i> , 2002, 159, 1011-1017.	4.0	231
303	Treatment Predictors of Extrapyrimal Side Effects in Patients With Tardive Dyskinesia: Results From Veterans Affairs Cooperative Study 394. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 196-200.	0.7	10
304	Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. <i>Schizophrenia Research</i> , 2002, 53, 25-30.	1.1	21
305	Depression measures and motor side-effects in patients with acute schizophrenia. <i>Schizophrenia Research</i> , 2002, 56, 197-198.	1.1	3
306	Procedural learning in schizophrenia: a functional magnetic resonance imaging investigation. <i>Schizophrenia Research</i> , 2002, 57, 97-107.	1.1	91
307	Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2002, 57, 307-309.	1.1	15
308	Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. <i>Schizophrenia Research</i> , 2002, 58, 313-321.	1.1	61
309	Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. <i>European Psychiatry</i> , 2002, 17, 148-154.	0.1	87
310	Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication. <i>European Psychiatry</i> , 2002, 17, 459-465.	0.1	11
311	Patients' Subjective Experiences of Antipsychotics. <i>CNS Drugs</i> , 2002, 16, 457-471.	2.7	63
313	Subjective emotional experience and cognitive impairment in drug-induced akathisia. <i>Comprehensive Psychiatry</i> , 2002, 43, 456-462.	1.5	18
314	Olanzapine for the treatment of chronic refractory schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 1055-1062.	2.5	12
315	A Double-Blind, Randomized, Placebo-Controlled Study of Quetiapine as Adjunctive Treatment for Adolescent Mania. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 1216-1223.	0.3	375
316	Recent Developments in Pharmacotherapy for the Acutely Psychotic Patient. <i>Journal of the American Psychiatric Nurses Association</i> , 2002, 8, S40-S47.	0.4	0
317	Economic evaluations of olanzapine and risperidone. <i>American Journal of Health-System Pharmacy</i> , 2002, 59, 1366-1375.	0.5	5

#	ARTICLE	IF	CITATIONS
318	Comparison of Risperidone with Olanzapine in Elderly Patients with Dementia and Psychosis. <i>Pharmacotherapy</i> , 2002, 22, 1-5.	1.2	32
319	Recent developments in pharmacotherapy for the acutely psychotic patient. <i>Journal of Emergency Nursing</i> , 2002, 28, S12-S20.	0.5	4
320	A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. <i>Journal of Psychiatric Research</i> , 2002, 36, 7-18.	1.5	285
321	Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study. <i>Neuropsychopharmacology</i> , 2002, 27, 1071-1081.	2.8	103
322	Temporal modulation of cerebral hemodynamics under prefrontal challenge in schizophrenia: a transcranial Doppler sonography study. <i>Psychiatry Research - Neuroimaging</i> , 2002, 115, 155-170.	0.9	15
323	Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders. <i>Movement Disorders</i> , 2002, 17, 1354-1359.	2.2	54
324	Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. <i>Human Psychopharmacology</i> , 2002, 17, 61-63.	0.7	9
325	Olanzapine in the treatment of anorexia nervosa: An open label trial. <i>International Journal of Eating Disorders</i> , 2002, 32, 146-154.	2.1	125
326	Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. <i>Psychopharmacology</i> , 2002, 162, 37-41.	1.5	45
327	Depression, emotional blunting, and akinesia in schizophrenia. <i>European Journal of Health Economics</i> , 2002, 3, s99-s103.	1.4	9
328	Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. <i>Bipolar Disorders</i> , 2002, 4, 328-334.	1.1	10
329	Medication adherence of individuals with a first episode of psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2002, 106, 286-290.	2.2	346
330	Managing adverse drug reactions: an orphan task. <i>Journal of Advanced Nursing</i> , 2002, 38, 437-448.	1.5	40
331	Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 695-705.	4.1	86
332	The impact of the polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 72, 438-452.	2.3	173
333	Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. <i>Psychopharmacology</i> , 2003, 166, 391-399.	1.5	229
334	Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. <i>Psychiatry Research - Neuroimaging</i> , 2003, 122, 99-113.	0.9	153
335	Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. <i>Journal of Affective Disorders</i> , 2003, 73, 155-161.	2.0	64

#	ARTICLE	IF	CITATIONS
336	The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 432-440.	1.3	79
337	The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. <i>Human Psychopharmacology</i> , 2003, 18, 551-557.	0.7	25
338	Unilateral subthalamic deep brain stimulation in advanced Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 713-716.	2.2	44
339	Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 712-713.	2.2	16
340	Reproducibility of 1H-MRS measurements in schizophrenic patients. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 704-707.	1.9	42
341	Clinical correlates of early medication adherence: West London first episode schizophrenia study. <i>Acta Psychiatrica Scandinavica</i> , 2003, 108, 439-446.	2.2	115
342	Features of obsessive-compulsive disorder in patients primarily diagnosed with schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 67-74.	1.0	66
343	Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial. <i>Psychiatry and Clinical Neurosciences</i> , 2003, 57, 478-484.	1.0	18
344	Amoxapine shows atypical antipsychotic effects in patients with schizophrenia: results from a prospective open-label study. <i>Schizophrenia Research</i> , 2003, 59, 35-39.	1.1	18
345	Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. <i>Schizophrenia Research</i> , 2003, 59, 67-71.	1.1	13
346	Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. <i>Schizophrenia Research</i> , 2003, 61, 303-314.	1.1	76
347	Perseveration and over-switching in schizophrenia. <i>Schizophrenia Research</i> , 2003, 61, 315-321.	1.1	27
348	The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. <i>Schizophrenia Research</i> , 2003, 61, 7-18.	1.1	182
349	Serum iron levels in schizophrenic patients with or without akathisia. <i>European Neuropsychopharmacology</i> , 2003, 13, 67-71.	0.3	37
350	Effect of the 5-HT ₂ antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. <i>European Neuropsychopharmacology</i> , 2003, 13, 123-128.	0.3	70
351	A Prospective, Open-Label Trial of Olanzapine in Adolescents With Schizophrenia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 170-175.	0.3	59
352	Aripiprazole: An Antipsychotic with a Novel Mechanism of Action. <i>Journal of Pharmacy Technology</i> , 2003, 19, 365-372.	0.5	1
353	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. <i>Biological Psychiatry</i> , 2003, 54, 453-464.	0.7	194

#	ARTICLE	IF	CITATIONS
354	Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. <i>Biological Psychiatry</i> , 2003, 54, 879-883.	0.7	163
355	Tardive dyskinesia in Chinese inpatients with chronic schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1029-1036.	2.5	11
356	A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. <i>Clinical Therapeutics</i> , 2003, 25, 1420-1428.	1.1	51
357	A pilot trial of olanzapine for the treatment of cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2003, 70, 265-273.	1.6	78
358	Neurological soft signs and neuropsychological performance in patients with first episode schizophrenia. <i>Psychiatry Research</i> , 2003, 121, 21-30.	1.7	60
359	A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. <i>Archives of General Psychiatry</i> , 2003, 60, 1218.	13.8	198
360	Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial. <i>American Journal of Psychiatry</i> , 2003, 160, 741-748.	4.0	325
361	Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol. <i>American Journal of Psychiatry</i> , 2003, 160, 1396-1404.	4.0	380
362	The Barnes Akathisia Rating Scale—Revisited. <i>Journal of Psychopharmacology</i> , 2003, 17, 365-370.	2.0	150
363	A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. <i>Journal of Psychopharmacology</i> , 2003, 17, 107-112.	2.0	40
364	Glasgow's Community Care Programme: 10 Year Follow up of Discharged Patients with Schizophrenia. <i>Scottish Medical Journal</i> , 2003, 48, 38-40.	0.7	1
365	A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania. <i>American Journal of Psychiatry</i> , 2003, 160, 1651-1658.	4.0	419
366	Effectiveness, Safety, and Tolerability of Risperidone in Adolescents with Schizophrenia: An Open-Label Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2003, 13, 319-327.	0.7	47
367	Olanzapine Versus Divalproex Sodium for the Treatment of Acute Mania and Maintenance of Remission: A 47-Week Study. <i>American Journal of Psychiatry</i> , 2003, 160, 1263-1271.	4.0	294
368	Treatment of Weight Gain with Fluoxetine in Olanzapine-Treated Schizophrenic Outpatients. <i>Neuropsychopharmacology</i> , 2003, 28, 527-529.	2.8	59
369	Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo. <i>Neuropsychopharmacology</i> , 2003, 28, 787-794.	2.8	105
370	Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 97-102.	1.0	57
371	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. <i>Schizophrenia Bulletin</i> , 2003, 29, 15-31.	2.3	549

#	ARTICLE	IF	CITATIONS
372	Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 353-360.	1.0	15
373	New generation antipsychotics for first episode schizophrenia. <i>The Cochrane Library</i> , 2003, , CD004410.	1.5	24
374	Changing Environments and Alternative Perspectives in Evaluating the Cost-Effectiveness of New Antipsychotic Drugs. <i>Schizophrenia Bulletin</i> , 2003, 29, 81-93.	2.3	18
375	Transient Restless Legs-like Syndrome as a Complication of Opiate Withdrawal. <i>Pharmacopsychiatry</i> , 2003, 36, 70-72.	1.7	37
376	Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2693.	3.8	281
377	Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia. <i>Neuropsychopharmacology</i> , 2003, 28, 182-192.	2.8	223
378	Maintenance Treatment of Schizophrenia With Risperidone or Haloperidol: 2-Year Outcomes. <i>American Journal of Psychiatry</i> , 2003, 160, 1405-1412.	4.0	85
379	Antisocial Violent Offenders With Attention Deficit Hyperactivity Disorder Demonstrate Akathisia-Like Hyperactivity in Three-Channel Actometry. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2003, 15, 194-199.	0.9	12
380	Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 305-308.	0.7	38
381	Valproate for acute mood episodes in bipolar disorder. <i>The Cochrane Library</i> , 2003, , CD004052.	1.5	70
382	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial. <i>Schizophrenia Bulletin</i> , 2003, 29, 57-72.	2.3	55
383	Risk Adjustment in Studies Using Administrative Data. <i>Schizophrenia Bulletin</i> , 2003, 29, 267-271.	2.3	13
384	The Causes of Underdiagnosing Akathisia. <i>Schizophrenia Bulletin</i> , 2003, 29, 547-558.	2.3	50
385	High-Dose Olanzapine for Treatment-Refractory Schizophrenia. <i>Clinical Neuropharmacology</i> , 2003, 26, 58-61.	0.2	27
386	Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. <i>International Clinical Psychopharmacology</i> , 2003, 18, 39-48.	0.9	50
387	Title is missing!. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 223-228.	0.7	4
388	Title is missing!. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 305-308.	0.7	20
389	Investigation of Target Plasma Concentration-Effect Relationships for Olanzapine in Schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 682-689.	1.0	44

#	ARTICLE	IF	CITATIONS
390	Corpus callosum in first-episode patients with schizophrenia – a magnetic resonance imaging study. <i>Psychological Medicine</i> , 2003, 33, 1019-1027.	2.7	84
391	Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. <i>Schizophrenia Bulletin</i> , 2003, 29, 33-43.	2.3	102
392	Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 5-14.	0.7	74
393	Quetiapine Treatment in Patients with Posttraumatic Stress Disorder: An Open Trial of Adjunctive Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 15-20.	0.7	123
394	Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. <i>International Clinical Psychopharmacology</i> , 2003, 18, 341-346.	0.9	27
395	Prevalence and Characteristics of Subjective Akathisia, Objective Akathisia, and Mixed Akathisia in Chronic Schizophrenic Subjects. <i>Clinical Neuropharmacology</i> , 2003, 26, 312-316.	0.2	21
396	Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. <i>International Clinical Psychopharmacology</i> , 2003, 18, 1-8.	0.9	142
397	Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 403-408.	1.0	19
398	Treatment of Neuroleptic-Induced Akathisia With the 5-HT _{2A} Antagonist Trazodone. <i>Clinical Neuropharmacology</i> , 2003, 26, 137-141.	0.2	27
399	Eye movements and neurocognitive function in treatment resistant schizophrenia: a pilot study. <i>Irish Journal of Psychological Medicine</i> , 2003, 20, 6-10.	0.7	4
400	Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients. <i>American Journal of Psychiatry</i> , 2003, 160, 1413-1420.	4.0	112
401	Effectiveness of Rapid Initial Dose Escalation of up to Forty Milligrams per Day of Oral Olanzapine in Acute Agitation. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 342-348.	0.7	83
402	A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 582-594.	0.7	79
403	Tolerability and Efficacy of Clozapine Combined with Lithium in Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 223-228.	0.7	77
404	Restless Legs Syndrome and Drug-Induced Akathisia in Headache Patients. <i>CNS Spectrums</i> , 2003, 8, 450-456.	0.7	48
405	Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 716-721.	0.9	49
406	A Random-Assignment, Double-Blind, Clinical Trial of Once- vs Twice-Daily Administration of Quetiapine Fumarate in Patients with Schizophrenia or Schizoaffective Disorder: A Pilot Study. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 187-194.	0.9	21
407	Attenuation of Olanzapine-Induced Weight Gain With Reboxetine in Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study. <i>American Journal of Psychiatry</i> , 2003, 160, 297-302.	4.0	114

#	ARTICLE	IF	CITATIONS
408	Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. <i>International Clinical Psychopharmacology</i> , 2003, 18, 1-8.	0.9	112
409	Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. <i>International Clinical Psychopharmacology</i> , 2003, 18, 39-48.	0.9	21
410	Signs of catatonia are identifiable. , 2003, , 19-32.		1
412	List of patient vignettes. , 2003, , viii-ix.		0
415	Catatonia: A history. , 2003, , 1-18.		0
416	The many faces of catatonia. , 2003, , 33-70.		0
417	The differential diagnosis of catatonia. , 2003, , 71-113.		0
418	Catatonia is measurable and common. , 2003, , 114-132.		2
419	Past treatments for catatonia. , 2003, , 133-146.		0
420	Management of catatonia today. , 2003, , 147-176.		1
421	The neurology of catatonia. , 2003, , 177-192.		0
424	Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. <i>International Clinical Psychopharmacology</i> , 2003, 18, 341-346.	0.9	4
425	Reliability and clinical utility of a Portuguese version of the Abnormal Involuntary Movements Scale (AIMS) for tardive dyskinesia in Brazilian patients. <i>Brazilian Journal of Medical and Biological Research</i> , 2003, 36, 511-514.	0.7	10
426	Neurobehavioral Assessment of Children and Adolescents Attending a Developmental Disabilities Clinic. <i>Psychological Reports</i> , 2004, 95, 1079-1086.	0.9	6
428	Akathisia treated with olanzapine: Three case reports. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 123-125.	1.2	0
429	Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. <i>Journal of Psychopharmacology</i> , 2004, 18, 124-127.	2.0	43
430	Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2004, 161, 975-984.	4.0	330
431	Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol. <i>American Journal of Psychiatry</i> , 2004, 161, 985-995.	4.0	289

#	ARTICLE	IF	CITATIONS
432	Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2004, 161, 1837-1847.	4.0	157
433	Latent Inhibition and Overswitching in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2004, 30, 713-726.	2.3	20
434	The structural brain correlates of neurological soft signs in AeSOP first-episode psychoses study. <i>Brain</i> , 2004, 127, 143-153.	3.7	211
435	Olanzapine in the Treatment of Developmental Stuttering: A Double-Blind, Placebo-Controlled Trial. <i>Annals of Clinical Psychiatry</i> , 2004, 16, 63-67.	0.6	62
436	Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. <i>Bipolar Disorders</i> , 2004, 6, 213-223.	1.1	236
437	Monitoring adverse drug reactions: scales, profiles, and checklists. <i>International Nursing Review</i> , 2004, 51, 208-221.	1.5	39
438	Neurological soft signs in schizophrenic patients with obsessive-compulsive disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 274-279.	1.0	34
439	Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 108-118.	2.2	55
440	Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. <i>Acta Psychiatrica Scandinavica</i> , 2004, 110, 292-298.	2.2	111
441	An open-label trial of olanzapine for corticosteroid-induced mood symptoms. <i>Journal of Affective Disorders</i> , 2004, 83, 277-281.	2.0	57
442	A Network-Based System to Improve Care for Schizophrenia: The Medical Informatics Network Tool (MINT). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2004, 11, 358-367.	2.2	33
443	Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. <i>Psychopharmacology</i> , 2004, 172, 324-332.	1.5	74
444	A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. <i>Psychopharmacology</i> , 2004, 175, 148-153.	1.5	18
445	Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. <i>Psychopharmacology</i> , 2004, 175, 367-373.	1.5	38
446	Switching to quetiapine in patients with acute mania who were intolerant to risperidone. <i>Human Psychopharmacology</i> , 2004, 19, 47-51.	0.7	8
447	Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 349-356.	1.1	81
448	Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. <i>Schizophrenia Research</i> , 2004, 69, 325-331.	1.1	17
449	Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. <i>Biological Psychiatry</i> , 2004, 55, 452-456.	0.7	325

#	ARTICLE	IF	CITATIONS
450	Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. <i>Biological Psychiatry</i> , 2004, 55, 445-451.	0.7	94
451	Cortical effects of quetiapine in first-episode schizophrenia: A preliminary functional magnetic resonance imaging study. <i>Biological Psychiatry</i> , 2004, 56, 938-942.	0.7	51
452	Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder. <i>Clinical Drug Investigation</i> , 2004, 24, 275-286.	1.1	43
453	Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 985-996.	2.5	45
454	Lower limb motor restlessness in Asperger's disorder, measured using actometry. <i>Psychiatry Research</i> , 2004, 128, 63-70.	1.7	10
455	Standard therapies for acute agitation. <i>Journal of Emergency Medicine</i> , 2004, 27, S9-S12.	0.3	16
456	Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. <i>American Journal of Emergency Medicine</i> , 2004, 22, 181-186.	0.7	52
457	Tools for measuring clinical effectiveness. <i>European Neuropsychopharmacology</i> , 2004, 14, S435-S444.	0.3	13
458	Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. <i>European Psychiatry</i> , 2004, 19, 516-518.	0.1	17
459	Brief Evaluation of Medication Influences and Beliefs. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 404-409.	0.7	68
460	SSRI-Induced Enuresis. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 564-565.	0.7	11
461	Baclofen as Adjunctive Treatment for a Patient With Cocaine Dependence and Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 574-575.	0.7	11
462	Acute Dystonic Reaction With Moderate-Dose Ziprasidone. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 563-564.	0.7	8
463	The Changing Pattern of Inpatient Antipsychotic Drug Use in Italy. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 559-561.	0.7	2
464	Chronic Interictal Psychosis Responsive to Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 573-574.	0.7	4
465	Mania Induction Associated With Atomoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 567-568.	0.7	26
466	Discrete State Analysis for Interpretation of Data From Clinical Trials. <i>Medical Care</i> , 2004, 42, 183-196.	1.1	17
467	Adjunctive Risperidone Treatment in Combat Veterans With Chronic PTSD. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 556-559.	0.7	16

#	ARTICLE	IF	CITATIONS
468	Haloperidol plus promethazine for psychosis-induced aggression. , 2004, , CD005146.		20
469	A Prospective Multicentric Trial for Effectiveness and Tolerance of a N2O/O2 Premix Used as a Sedative Drug. Journal of Clinical Psychopharmacology, 2004, 24, 552-554.	0.7	25
470	Effectiveness of Orlistat Versus Diet and Exercise for Weight Gain Associated With Antidepressant Use. Journal of Clinical Psychopharmacology, 2004, 24, 555-556.	0.7	6
471	Multidimensional Sensory Phenomena in Antipsychotic-Induced Akathisia. Journal of Clinical Psychopharmacology, 2004, 24, 618-623.	0.7	13
472	The Reliability of the Mini-International Neuropsychiatric Interview-Italian Version. Journal of Clinical Psychopharmacology, 2004, 24, 561-563.	0.7	74
473	Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D ₂ Receptor Occupancy in Schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2004, 16, 47-56.	0.9	38
474	Reply to "Risperidone-Induced Obsessive-Compulsive Symptoms. Journal of Clinical Psychopharmacology, 2004, 24, 549.	0.7	3
475	Clinical Rating Scales and Instruments. Journal of Clinical Psychopharmacology, 2004, 24, 298-304.	0.7	31
476	Elevated Quetiapine Serum Concentrations in a Patient Treated Concomitantly With Doxepin, Lorazepam, and Pantoprazole. Journal of Clinical Psychopharmacology, 2004, 24, 568-571.	0.7	5
477	Prevalence of Neuroleptic-Induced Movement Disorders in Chronic Schizophrenia Inpatients. American Journal of Psychiatry, 2004, 161, 160-163.	4.0	133
478	Neurologic Soft Signs and Olanzapine Treatment in Chronic Schizophrenia. Journal of Clinical Psychopharmacology, 2004, 24, 571-572.	0.7	2
479	Topiramate Can Cause Lithium Toxicity. Journal of Clinical Psychopharmacology, 2004, 24, 565-567.	0.7	26
480	A PET Study of Dopamine D ₂ and Serotonin 5-HT ₂ Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone. American Journal of Psychiatry, 2004, 161, 818-825.	4.0	188
481	Fluvoxamine and Graded Psychotherapy in the Treatment of Bulimia Nervosa. Journal of Clinical Psychopharmacology, 2004, 24, 549-552.	0.7	26
482	Olanzapine-Induced Clitoral Priapism. Journal of Clinical Psychopharmacology, 2004, 24, 572-573.	0.7	14
483	High striatal occupancy of D ₂ -like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology, 2004, 7, 421-430.	1.0	50
484	Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. British Journal of Psychiatry, 2004, 184, 337-345.	1.7	288
485	Caffeine Intake in Outpatients With Schizophrenia. Schizophrenia Bulletin, 2004, 30, 935-945.	2.3	41

#	ARTICLE	IF	CITATIONS
486	Double-Blind Comparison of the Continued Use of Antipsychotic Treatment Versus Its Discontinuation in Remitted Manic Patients. <i>American Journal of Psychiatry</i> , 2004, 161, 169-171.	4.0	125
487	Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. <i>International Clinical Psychopharmacology</i> , 2004, 19, 23-26.	0.9	50
488	Benefits of Adjunct Modafinil in an Open-Label, Pilot Study in Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2004, 27, 38-43.	0.2	64
489	The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. <i>International Clinical Psychopharmacology</i> , 2004, 19, 9-15.	0.9	32
490	Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. <i>British Journal of Psychiatry</i> , 2004, 185, 465-471.	1.7	35
491	Quetiapine for schizophrenia. <i>The Cochrane Library</i> , 2004, , CD000967.	1.5	64
492	Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. <i>British Journal of Psychiatry</i> , 2004, 185, 63-69.	1.7	162
493	Suicidal Ideation in Inpatients with Acute Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 476-479.	0.9	50
494	Outcome Measures for Clinical Drug Trials in Autism. <i>CNS Spectrums</i> , 2004, 9, 36-47.	0.7	82
495	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 529-536.	1.7	74
497	Dosing of Second-Generation Antipsychotic Medication in a State Hospital System. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 388-391.	0.7	32
498	Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. <i>The Cochrane Library</i> , 2005, , CD003729.	1.5	52
499	Mirtazapine for Akathisia in Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 394-395.	0.7	7
500	Flexible-Dose Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 381-386.	0.7	16
501	Risperidone versus olanzapine for schizophrenia. , 2005, , CD005237.		9
502	Effects of Rivastigmine on Sustained Attention in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 311-317.	0.7	33
503	Biochemical Evidence of the Placebo Effect During the Treatment of Menstrual Migraines. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 400-401.	0.7	2
504	First-time Diagnosis of Severe Depression. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 399-400.	0.7	10

#	ARTICLE	IF	CITATIONS
505	Regular-Dose Risperidone on QTc Intervals. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 391-393.	0.7	12
506	Comments on "Prolactin Levels and Erectile Function in Patients Treated With Risperidone" (<i>J Clin Tj ETQq1 1 0.784314 rgBT₁ /Overlo</i>	0.7	1
507	A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo on Eating Behaviors. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 413-418.	0.7	42
508	Effectiveness of Milnacipran for SSRI-Intolerant Patients With Premenstrual Dysphoric Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 398-399.	0.7	3
509	A Double-blind Placebo-Controlled Trial of Bupropion Sustained-Release for Smoking Cessation in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 218-225.	0.7	176
510	Ziprasidone in Acute Bipolar Mania. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 301-310.	0.7	142
511	Mirtazapine-Induced Arthralgia and Coagulopathy. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 395-396.	0.7	5
512	Quetiapine Improves Sleep Disturbances in Combat Veterans With PTSD. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 387-388.	0.7	54
513	Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 463-467.	0.7	129
514	Decision-Making Capacity of Inpatients With Schizophrenia in Hong Kong. <i>Journal of Nervous and Mental Disease</i> , 2005, 193, 316-322.	0.5	26
515	Cocaine Abuse in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol. <i>Journal of Nervous and Mental Disease</i> , 2005, 193, 379-386.	0.5	60
516	Amisulpride May Help Alcoholics in the Early Postdetoxification Phase. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 396-398.	0.7	4
517	The Use of Olanzapine in the Treatment of Negative Symptoms in Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2005, 17, 423-424.	0.9	2
518	Modafinil modulates anterior cingulate function in chronic schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 55-61.	1.7	100
519	Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D ₂ Receptor Occupancy in First-Episode Psychosis. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 462-469.	0.9	24
520	Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2005, 20, 27-31.	0.9	44
521	Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. <i>International Clinical Psychopharmacology</i> , 2005, 20, 335-338.	0.9	15
522	The 5-HT _{1D} receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study. <i>International Clinical Psychopharmacology</i> , 2005, 20, 23-25.	0.9	8

#	ARTICLE	IF	CITATIONS
523	Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. <i>International Clinical Psychopharmacology</i> , 2005, 20, 327-330.	0.9	8
524	Nicotine dependence and symptoms in schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 186, 215-221.	1.7	118
525	Sertindole for schizophrenia. <i>The Cochrane Library</i> , 2005, , CD001715.	1.5	26
526	Haloperidol Prophylaxis for Elderly Hip-Surgery Patients at Risk for Delirium: A Randomized Placebo-Controlled Study. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1658-1666.	1.3	604
527	Mental health nurse prescribing: issues for the UK. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2005, 12, 527-535.	1.2	28
528	Reduced cerebellar volume and neurological soft signs in first-episode schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 239-250.	0.9	145
529	Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. <i>BMC Neurology</i> , 2005, 5, 5.	0.8	88
530	The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study. <i>BMC Psychiatry</i> , 2005, 5, 22.	1.1	10
531	Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1020-1027.	1.3	35
532	Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. <i>Human Psychopharmacology</i> , 2005, 20, 41-45.	0.7	20
533	Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study. <i>Human Psychopharmacology</i> , 2005, 20, 401-408.	0.7	12
534	Potential effectiveness and safety of olanzapine in refractory panic disorder. <i>Depression and Anxiety</i> , 2005, 21, 33-40.	2.0	45
535	Neuroleptic-induced acute and chronic akathisia: A clinical comparison. <i>Movement Disorders</i> , 2005, 20, 1667-1670.	2.2	8
536	A positron emission tomography (PET) study of cerebral dopamine D2 and serotonin 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). <i>Psychopharmacology</i> , 2005, 180, 377-384.	1.5	169
537	Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2005, 181, 358-363.	1.5	67
538	The European Schizophrenia Cohort. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2005, 40, 707-717.	1.6	58
539	Risperidone plasma levels, clinical response and side-effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 261-268.	1.8	111
540	The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: An application of random effect regression models and propensity scores in an observational prospective trial. <i>Quality of Life Research</i> , 2005, 14, 1275-1289.	1.5	27

#	ARTICLE	IF	CITATIONS
542	Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. <i>Journal of Psychopharmacology</i> , 2005, 19, 277-285.	2.0	55
543	Amoxapine as an Atypical Antipsychotic: A Comparative Study Vs Risperidone. <i>Neuropsychopharmacology</i> , 2005, 30, 2236-2244.	2.8	28
544	Drug-Induced Movement Disorders. , 2005, , 713-724.		0
545	Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia. <i>Archives of General Psychiatry</i> , 2005, 62, 1196.	13.8	263
546	Patients'™ Opinions of Olanzapine and Risperidone Following Long-term Treatment: Results from a Cross-sectional Survey. <i>Pharmacopsychiatry</i> , 2005, 38, 147-157.	1.7	13
547	Neurological Soft Signs in First-Episode Schizophrenia: A Follow-Up Study. <i>American Journal of Psychiatry</i> , 2005, 162, 2337-2343.	4.0	133
548	Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study. <i>American Journal of Psychiatry</i> , 2005, 162, 110-117.	4.0	51
549	Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2005, 56, 273-282.	1.1	106
550	A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression. <i>American Journal of Psychiatry</i> , 2005, 162, 1351-1360.	4.0	790
551	Hostility and violence of acute psychiatric inpatients. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2005, 1, 11.	0.6	66
552	Effectiveness of aripiprazole v. Haloperidol in acute bipolar mania. <i>British Journal of Psychiatry</i> , 2005, 187, 235-242.	1.7	166
553	Olanzapine Versus Ziprasidone: Results of a 28-Week Double-Blind Study in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2005, 162, 1879-1887.	4.0	129
554	Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia. <i>European Neuropsychopharmacology</i> , 2005, 15, 39-41.	0.3	21
555	Quetiapine or haloperidol as monotherapy for bipolar mania" a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2005, 15, 573-585.	0.3	195
556	Expanding the response space in chronic schizophrenia: the relevance of left prefrontal cortex. <i>NeuroImage</i> , 2005, 25, 952-957.	2.1	14
557	Hidden Markov Models for Longitudinal Comparisons. <i>Journal of the American Statistical Association</i> , 2005, 100, 359-369.	1.8	65
558	Olanzapine for schizophrenia. <i>The Cochrane Library</i> , 2005, , CD001359.	1.5	140
559	Schizophrenia with prominent catatonic features (ã~catatonic schizophreniaã~™). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 27-38.	2.5	60

#	ARTICLE	IF	CITATIONS
560	Effects of quetiapine on cognitive functions in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 233-238.	2.5	33
561	Long-term treatment of adjunctive quetiapine for bipolar mania. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 763-766.	2.5	9
563	Extrapyramidal Symptoms with Atypical Antipsychotics. <i>Drug Safety</i> , 2005, 28, 191-208.	1.4	170
564	Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. <i>Biological Psychiatry</i> , 2005, 57, 474-479.	0.7	164
565	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. <i>Biological Psychiatry</i> , 2005, 57, 594-608.	0.7	524
566	Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2005, 57, 1594-1596.	0.7	125
567	Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo. <i>Biological Psychiatry</i> , 2005, 58, 41-46.	0.7	59
568	A 3-year prospective study of neurological soft signs in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2005, 75, 45-54.	1.1	83
569	Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. <i>Schizophrenia Research</i> , 2005, 74, 125-134.	1.1	69
570	Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 33-43.	1.1	146
571	Comparison of Olanzapine and Risperidone in the Treatment of Psychosis and Associated Behavioral Disturbances in Patients With Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 722-730.	0.6	98
572	Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. <i>Journal of Psychopharmacology</i> , 2006, 20, 536-546.	2.0	233
573	Smoking and Schizophrenia: Is Symptom Profile Related to Smoking and which Antipsychotic Medication is of Benefit in Reducing Cigarette use?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 575-580.	1.3	80
574	Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study. <i>NeuroImage</i> , 2006, 29, 545-556.	2.1	53
575	Diminished neurocardiac dynamics associated with antipsychotic-induced extrapyramidal syndrome. <i>European Neuropsychopharmacology</i> , 2006, 16, 459-463.	0.3	6
576	A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. <i>European Psychiatry</i> , 2006, 21, 523-530.	0.1	29
577	Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2006, 15, 177-206.	1.0	163
578	Effectiveness, Safety, and Pharmacokinetics of Quetiapine in Aggressive Children With Conduct Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 792-800.	0.3	63

#	ARTICLE	IF	CITATIONS
579	D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia. <i>Biological Psychiatry</i> , 2006, 59, 230-234.	0.7	310
580	Olanzapine Augmentation of Fluoxetine for Refractory Generalized Anxiety Disorder: A Placebo Controlled Study. <i>Biological Psychiatry</i> , 2006, 59, 211-215.	0.7	132
581	Low-Dose Mirtazapine: A New Option in the Treatment of Antipsychotic-Induced Akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial. <i>Biological Psychiatry</i> , 2006, 59, 1071-1077.	0.7	107
582	Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia. <i>Biological Psychiatry</i> , 2006, 60, 645-649.	0.7	182
583	Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. <i>Schizophrenia Research</i> , 2006, 83, 53-63.	1.1	135
584	Evidence for impaired mnemonic strategy use among patients with schizophrenia using the part-list cuing paradigm. <i>Schizophrenia Research</i> , 2006, 85, 1-11.	1.1	27
585	Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist. <i>Schizophrenia Research</i> , 2006, 85, 213-221.	1.1	23
586	A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. <i>Schizophrenia Research</i> , 2006, 85, 254-265.	1.1	81
587	Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. <i>Schizophrenia Research</i> , 2006, 86, 256-268.	1.1	33
588	Olanzapine and haloperidol in first episode psychosis: Two-year data. <i>Schizophrenia Research</i> , 2006, 86, 234-243.	1.1	112
589	Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia – Findings from an in vivo SPECT study. <i>Schizophrenia Research</i> , 2006, 88, 179-186.	1.1	46
590	A Double-Blind Randomized Pilot Study Comparing Quetiapine and Divalproex for Adolescent Mania. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2006, 45, 305-313.	0.3	186
591	Cannabidiol monotherapy for treatment-resistant schizophrenia. <i>Journal of Psychopharmacology</i> , 2006, 20, 683-686.	2.0	168
592	Case report of unrecognized akathisia resulting in an emergency landing and RSI during air medical transport. <i>Air Medical Journal</i> , 2006, 25, 85-87.	0.3	2
593	Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine. <i>Journal of Emergency Medicine</i> , 2006, 31, 139-145.	0.3	11
594	Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses. <i>Psychiatry Research</i> , 2006, 142, 191-199.	1.7	70
595	Schizo-obsessive and obsessive-compulsive disorder: Comparison of clinical characteristics and neurological soft signs. <i>Psychiatry Research</i> , 2006, 145, 241-248.	1.7	38
596	Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 141-143.	2.5	12

#	ARTICLE	IF	CITATIONS
597	Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 251-264.	2.5	43
598	Perospirone in the treatment of schizophrenia: Effect on verbal memory organization. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 204-208.	2.5	29
599	Abnormal neurological signs, visual contrast sensitivity, and the deficit syndrome of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2006, 30, 1225-1230.	2.5	23
600	A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. <i>International Clinical Psychopharmacology</i> , 2006, 21, 49-56.	0.9	44
601	Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 135-142.	0.7	33
602	Predictors of Neuroleptic-induced Dyskinesia and Parkinsonism. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 560-565.	0.7	13
603	Use of Long-acting Risperidone in the Treatment of Bipolar Patients. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 530-531.	0.7	23
604	Perospirone Is a New Generation Antipsychotic. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 531-533.	0.7	11
605	Early Intervention for psychosis. , 2006, , CD004718.		62
606	Risperidone versus olanzapine for schizophrenia. <i>The Cochrane Library</i> , 2006, , CD005237.	1.5	42
607	Vitamin B6 Versus Mianserin and Placebo in Acute Neuroleptic-induced Akathisia. <i>Clinical Neuropharmacology</i> , 2006, 29, 68-72.	0.2	40
608	Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. <i>Psychiatric Services</i> , 2006, 57, 1094-1101.	1.1	112
609	Antipsychotic medication for elderly people with schizophrenia. <i>The Cochrane Library</i> , 2006, , CD005580.	1.5	23
610	Neuropsychological Normalization With Long-Term Atypical Antipsychotic Treatment: Results of a Six-Month Randomized, Double-Blind Comparison of Ziprasidone vs. Olanzapine. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 54-63.	0.9	36
611	Association Between Attitude Toward Medication and Neurocognitive Function in Schizophrenia. <i>Clinical Neuropharmacology</i> , 2006, 29, 197-205.	0.2	29
612	Lack of Effect of Chromium Supplementation on Mental State and Body Weight in People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 544-545.	0.7	4
613	Atypical Neuroleptic Malignant Syndrome Associated With Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 534.	0.7	8
614	Sustained Effects of Phenelzine and Tranylcypromine on Orthostatic Challenge in Antidepressant-refractory Depression. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 542-544.	0.7	4

#	ARTICLE	IF	CITATIONS
615	An Exploratory Open Trial on Safety and Efficacy of the Anticonvulsant Retigabine in Acute Manic Patients. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 534-536.	0.7	17
616	Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 600-609.	0.7	455
617	Excretion of Escitalopram in Breast Milk. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 536-538.	0.7	16
618	Anxiolytic Effect of Rescue Remedy for Psychiatric Patients. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 541-542.	0.7	2
619	Randomized, Double-blind 6-Month Comparison of Olanzapine and Quetiapine in Patients With Schizophrenia or Schizoaffective Disorder With Prominent Negative Symptoms and Poor Functioning. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 453-461.	0.7	59
620	Panic Disorder, Treatment With Selective Serotonin Reuptake Inhibitors, and Cholesterol Levels. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 538-540.	0.7	8
621	High-dose Quetiapine and Photopsia. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 546-547.	0.7	9
622	Physical anhedonia in the acute phase of schizophrenia. <i>Annals of General Psychiatry</i> , 2006, 5, 1.	1.2	22
623	Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. <i>Bipolar Disorders</i> , 2006, 8, 467-474.	1.1	22
624	Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial. <i>Value in Health</i> , 2006, 9, 77-89.	0.1	50
625	Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent. <i>CNS Neuroscience & Therapeutics</i> , 2000, 6, 303-363.	4.0	9
626	A Systematic Review of the Efficacy and Safety of Atypical Antipsychotics in Patients with Psychological and Behavioral Symptoms of Dementia. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 354-361.	1.3	88
627	The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. <i>Acta Psychiatrica Scandinavica</i> , 2006, 114, 319-327.	2.2	80
628	Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2006, 13, 26-32.	1.2	17
629	Obstetric complications and neurological abnormalities in neuroleptic-naïve psychotic patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 407-413.	1.8	13
630	Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. <i>European Child and Adolescent Psychiatry</i> , 2006, 15, 371-382.	2.8	34
631	Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. <i>Psychopharmacology</i> , 2006, 188, 281-292.	1.5	109
632	Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2006, 147, 47-55.	0.9	36

#	ARTICLE	IF	CITATIONS
633	Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. <i>Psychoneuroendocrinology</i> , 2006, 31, 577-588.	1.3	90
634	Association between two distinct executive tasks in schizophrenia: a functional transcranial Doppler sonography study. <i>BMC Psychiatry</i> , 2006, 6, 25.	1.1	18
635	A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. <i>Depression and Anxiety</i> , 2006, 23, 364-372.	2.0	153
636	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 171-179.	1.3	30
637	Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2006, 21, 227-234.	0.7	28
638	Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. <i>Human Psychopharmacology</i> , 2006, 21, 235-243.	0.7	26
639	Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia. <i>Psychiatric Services</i> , 2006, 57, 1117-1125.	1.1	97
640	Sudden Akathisia After a Ziprasidone Dose Reduction. <i>American Journal of Psychiatry</i> , 2006, 163, 546-546.	4.0	16
641	Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers. <i>American Journal of Psychiatry</i> , 2006, 163, 488-493.	4.0	117
642	Barriers to Employment for People With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 411-417.	4.0	390
643	Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. <i>Current Medical Research and Opinion</i> , 2006, 22, 1277-1285.	0.9	63
644	Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. <i>British Journal of Psychiatry</i> , 2006, 189, 433-440.	1.7	75
645	Neurochemical Effects of Olanzapine in First-Hospitalization Manic Adolescents: A Proton Magnetic Resonance Spectroscopy Study. <i>Neuropsychopharmacology</i> , 2006, 31, 1264-1273.	2.8	119
646	Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 796-798.	0.9	47
647	Weight loss in overweight patients maintained on atypical antipsychotic agents. <i>International Journal of Obesity</i> , 2006, 30, 1011-1016.	1.6	69
648	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 472-482.	13.9	249
649	Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. <i>Neurology</i> , 2006, 66, 366-372.	1.5	461
650	Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. <i>American Journal of Psychiatry</i> , 2006, 163, 790-799.	4.0	500

#	ARTICLE	IF	CITATIONS
651	Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study. <i>Neuropsychobiology</i> , 2006, 54, 247-251.	0.9	12
652	An Open-Label Randomized Comparison of Olanzapine Versus Risperidone in the Treatment of Childhood-Onset Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 393-403.	0.7	51
653	Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. <i>Neuropsychopharmacology</i> , 2006, 31, 2505-2513.	2.8	129
654	A Double-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive Developmental Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 541-548.	0.7	171
655	Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. <i>Brain</i> , 2006, 129, 2017-2028.	3.7	224
656	Correspondence. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 770-774.	1.3	1
657	A Prospective 12-Week Study of Quetiapine in Adolescents with Schizophrenia Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 768-778.	0.7	34
658	Aripiprazole in the treatment of the psychosis prodrome. <i>British Journal of Psychiatry</i> , 2007, 191, s96-s101.	1.7	91
659	Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. <i>Neurology</i> , 2007, 68, 797-797.	1.5	69
660	Olanzapine Versus Placebo in the Treatment of Adolescents With Bipolar Mania. <i>American Journal of Psychiatry</i> , 2007, 164, 1547-1556.	4.0	238
661	Chronic Restlessness With Antipsychotics. <i>American Journal of Psychiatry</i> , 2007, 164, 1648-1654.	4.0	37
662	Differential Effects of Aripiprazole on D ₂ , 5-HT ₂ , and 5-HT _{1A} Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study. <i>American Journal of Psychiatry</i> , 2007, 164, 1411-1417.	4.0	235
663	Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. <i>American Journal of Psychiatry</i> , 2007, 164, 1050-1060.	4.0	329
664	Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. <i>American Journal of Psychiatry</i> , 2007, 164, 1061-1071.	4.0	234
665	Clinical and Social Determinants of Antipsychotic Polypharmacy for Chinese Patients with Schizophrenia. <i>Pharmacopsychiatry</i> , 2007, 40, 47-52.	1.7	48
666	Clinical and Social Determinants of Long-Term Use of Benzodiazepines and its Impact on Quality of Life of Chinese Schizophrenia Patients. <i>Pharmacopsychiatry</i> , 2007, 40, 269-274.	1.7	14
667	The Safety, Tolerability, and Subject-Rated Effects of Acute Intranasal Cocaine Administration During Aripiprazole Maintenance. <i>American Journal of Drug and Alcohol Abuse</i> , 2007, 33, 769-776.	1.1	28
668	On the relationship of atypical and low-dose conventional antipsychotics with akathisia in a clinical patient population. <i>Nordic Journal of Psychiatry</i> , 2007, 61, 152-157.	0.7	7

#	ARTICLE	IF	CITATIONS
669	Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Responseâ€”A Double-Blind PET Study in Schizophrenia. <i>Neuropsychopharmacology</i> , 2007, 32, 1209-1215.	2.8	118
670	Quality of Life of Chinese Schizophrenia Outpatients in Hong Kong: Relationship to Sociodemographic Factors and Symptomatology. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 442-449.	1.3	45
671	Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2007, 164, 1404-1410.	4.0	203
672	Adverse effects of antipsychotics as outcome measures. <i>British Journal of Psychiatry</i> , 2007, 191, s64-s70.	1.7	49
673	ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 863-876.	0.5	12
674	Interventions to reduce weight gain in schizophrenia. <i>The Cochrane Library</i> , 2007, , CD005148.	1.5	112
675	AmÃ©liorer les symptÃ©mes et le tabagisme chez les personnes souffrant de schizophrÃ©nie: un manque d'effet synergique du mÃ©dicament antipsychotique. <i>Sante Mentale Au Quebec</i> , 0, 32, 165-176.	0.1	1
676	Akathisia: Problem of History or Concern of Today. <i>CNS Spectrums</i> , 2007, 12, 1-16.	0.7	42
677	Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 519-528.	0.7	44
678	Outcomes for Latin American Versus White Patients Suffering From Acute Mania in a Randomized, Double-Blind Trial Comparing Olanzapine and Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 126-134.	0.7	18
679	Impact of Sociodemographic and Clinical Factors on Subjective Quality of Life in Schizophrenia Patients in Beijing, China. <i>Journal of Nervous and Mental Disease</i> , 2007, 195, 853-856.	0.5	10
680	Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. <i>International Clinical Psychopharmacology</i> , 2007, 22, 363-370.	0.9	44
681	A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2007, 22, 299-308.	0.9	70
682	The Effectiveness of Intramuscular Biperiden in Acute Akathisia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 289-294.	0.7	23
683	Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. <i>International Clinical Psychopharmacology</i> , 2007, 22, 238-243.	0.9	83
684	Acute Nocturnal Akathisia Induced By Clozapine. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 205.	0.7	8
685	Intramuscular Aripiprazole in the Control of Agitation. <i>Journal of Psychiatric Practice</i> , 2007, 13, 159-169.	0.3	28
686	Measuring Movement Disorders in Antipsychotic Drug Trials. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 423-430.	0.7	34

#	ARTICLE	IF	CITATIONS
687	Lamotrigine as Add-On Therapy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 582-589.	0.7	112
688	A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. <i>International Clinical Psychopharmacology</i> , 2007, 22, 212-220.	0.9	64
689	Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 321.	1.0	17
690	Amoxapine as an Antipsychotic. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 575-581.	0.7	17
691	A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 463.	1.0	104
692	Schizophrenia with prominent catatonic features (â€˜catatonic schizophreniaâ€™).II. Factor analysis of the catatonic syndrome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 462-468.	2.5	42
693	Clinical and social determinants of psychotropic drug prescription for schizophrenia outpatients in China. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 756-760.	2.5	16
694	Characteristics and clinical correlates of restless legs syndrome in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1078-1083.	2.5	58
695	Quetiapine as monotherapy for social anxiety disorder: A placebo-controlled study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1464-1469.	2.5	45
696	The impact of ï‰-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: An open-label pilot study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1493-1499.	2.5	84
697	Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: A randomized, open-label, controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1504-1509.	2.5	31
699	Impaired rapid modulation of cerebral hemodynamics during a planning task in schizophrenia. <i>Clinical Neurophysiology</i> , 2007, 118, 1449-1459.	0.7	14
700	EfficacitÃ©, efficence au long cours. <i>L'Encephale</i> , 2007, 33, 58-60.	0.3	1
701	A26-Week Open-Label Study of Quetiapine in Children with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 1-9.	0.7	33
702	Psychotropic Medication Effects and Side Effects. <i>International Review of Research in Mental Retardation</i> , 2007, , 227-251.	0.7	5
703	Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: A 4-week open-label parallel-group study. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 112-122.	1.3	22
704	Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007, 46, 969-978.	0.3	64
705	Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 1005-1014.	0.6	32

#	ARTICLE	IF	CITATIONS
706	Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. <i>Schizophrenia Research</i> , 2007, 90, 198-202.	1.1	65
707	The use of electronic monitoring (MEMSÂ®) to evaluate antipsychotic compliance in outpatients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 90, 229-237.	1.1	128
708	Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2007, 92, 90-94.	1.1	101
709	Double-blind donepezilâ€“placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2007, 93, 131-135.	1.1	23
710	Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine. <i>Schizophrenia Research</i> , 2007, 96, 146-155.	1.1	40
711	Antipsychotics for delirium. , 2007, , CD005594.		244
712	Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 809-815.	1.1	46
713	Clinical correlates of clozapine prescription for schizophrenia in China. <i>Human Psychopharmacology</i> , 2007, 22, 17-25.	0.7	28
714	Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia. <i>Human Psychopharmacology</i> , 2007, 22, 173-180.	0.7	22
715	Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. <i>Depression and Anxiety</i> , 2007, 24, 522-526.	2.0	30
716	Quetiapine in anorexia nervosa patients: An open label outpatient pilot study. <i>International Journal of Eating Disorders</i> , 2007, 40, 21-26.	2.1	38
717	Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. <i>Bipolar Disorders</i> , 2007, 9, 413-425.	1.1	102
718	A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. <i>Bipolar Disorders</i> , 2007, 9, 609-617.	1.1	29
719	Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 461-467.	0.7	11
720	Propranolol-responsive akathisia following acute encephalitis. <i>General Hospital Psychiatry</i> , 2007, 29, 273-274.	1.2	7
721	Open-label aripiprazole in the treatment of acute bipolar depression: A prospective pilot trial. <i>Journal of Affective Disorders</i> , 2007, 101, 275-281.	2.0	50
722	Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial. <i>Psychoneuroendocrinology</i> , 2007, 32, 96-105.	1.3	77
723	Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. <i>Journal of Psychiatric Research</i> , 2007, 41, 305-310.	1.5	18

#	ARTICLE	IF	CITATIONS
724	Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. <i>Psychopharmacology</i> , 2007, 192, 441-448.	1.5	66
725	Measurement of quality of life in schizophrenia: a comparison of two scales. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007, 42, 819-823.	1.6	26
726	Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors. <i>Quality of Life Research</i> , 2008, 17, 27-36.	1.5	50
727	Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of δ^9 -tetrahydrocannabinol in humans. <i>Psychopharmacology</i> , 2008, 198, 587-603.	1.5	105
728	Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. <i>Psychopharmacology</i> , 2008, 197, 675-681.	1.5	62
729	Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. <i>European Child and Adolescent Psychiatry</i> , 2008, 17, 44-53.	2.8	12
730	The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: A preliminary trial. <i>BMC Psychiatry</i> , 2008, 8, 73.	1.1	21
731	Adjunct extended-release valproate semisodium in late life schizophrenia. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 142-147.	1.3	15
732	An fMRI study of face encoding and recognition in first-episode schizophrenia. <i>Acta Neuropsychiatrica</i> , 2008, 20, 129-138.	1.0	14
733	Olanzapine versus Droperidol for the Treatment of Primary Headache in the Emergency Department. <i>Academic Emergency Medicine</i> , 2008, 15, 806-811.	0.8	27
734	Quetiapine for the treatment of bipolar mania in older adults. <i>Bipolar Disorders</i> , 2008, 10, 662-671.	1.1	55
735	Partial agonists and suicide: the role of the mental health nurse. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 253-259.	1.2	5
736	Do partial agonists cause akathisia: the role of the mental health nurse who prescribes. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2008, 15, 417-423.	1.2	2
737	A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. <i>Journal of Affective Disorders</i> , 2008, 110, 70-74.	2.0	38
738	Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). <i>Journal of Affective Disorders</i> , 2008, 109, 251-263.	2.0	221
739	Socio-demographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2008, 42, 495-502.	1.5	51
740	Prospective memory deficits in subjects with schizophrenia spectrum disorders: A comparison study with schizophrenic subjects, psychometrically defined schizotypal subjects, and healthy controls. <i>Schizophrenia Research</i> , 2008, 106, 70-80.	1.1	51
741	A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: The QUERISOLA trial. <i>Schizophrenia Research</i> , 2008, 98, 55-65.	1.1	16

#	ARTICLE	IF	CITATIONS
742	Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. <i>Schizophrenia Research</i> , 2008, 100, 97-107.	1.1	36
743	Gabapentin for ultra resistant schizophrenia with aggressive behavior. <i>Schizophrenia Research</i> , 2008, 100, 349-350.	1.1	11
744	Prospective memory in schizophrenia: Further clarification of nature of impairment. <i>Schizophrenia Research</i> , 2008, 105, 114-124.	1.1	46
745	Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study. <i>Biological Psychiatry</i> , 2008, 63, 9-12.	0.7	161
746	Objective measures of prospective memory do not correlate with subjective complaints in schizophrenia. <i>Schizophrenia Research</i> , 2008, 103, 229-239.	1.1	80
747	Olanzapine in the Treatment of Behavioral Problems Associated with Autism: An Open-Label Trial in Kuwait. <i>Medical Principles and Practice</i> , 2008, 17, 415-418.	1.1	44
749	A new rating scale for negative symptoms: The Motor-Affective-Social Scale. <i>Psychiatry Research</i> , 2008, 160, 346-355.	1.7	20
750	Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 239-242.	1.1	11
751	Combination therapy with amisulpride and antidepressants: Clinical observations in case series of elderly patients with psychotic depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1227-1230.	2.5	10
752	One-Year Outcome and Its Prediction in First-Episode Schizophrenia – A Naturalistic Study. <i>Psychopathology</i> , 2008, 41, 115-123.	1.1	33
754	Randomized Controlled Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 140-156.	0.7	70
755	Impact of the Priority Follow-Up System on Quality of Life in Chinese Schizophrenia Patients. <i>Australian and New Zealand Journal of Psychiatry</i> , 2008, 42, 154-158.	1.3	0
756	Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 31-43.	0.6	79
757	Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 180-186.	1.2	5
758	Olanzapine in the treatment of depression with psychotic features: A prospective open-label study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 202-209.	1.2	2
759	Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 198-211.	1.3	55
760	Oral paliperidone for schizophrenia. <i>The Cochrane Library</i> , 2008, , CD006369.	1.5	22
761	Real-world use of quetiapine in early psychosis: An acute inpatient and community follow-up effectiveness study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 65-73.	1.2	1

#	ARTICLE	IF	CITATIONS
762	Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence. <i>Journal of Psychiatric Practice</i> , 2008, 14, 345-367.	0.3	49
763	Dysfunctional Neural Plasticity in Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 2008, 65, 378.	13.8	119
764	Association Study between Antipsychotics- Induced Restless Legs Syndrome and Polymorphisms of Dopamine D1, D2, D3, and D4 Receptor Genes in Schizophrenia. <i>Neuropsychobiology</i> , 2008, 57, 49-54.	0.9	24
765	Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study. <i>American Journal of Psychiatry</i> , 2008, 165, 1420-1431.	4.0	414
766	Variations of rest-Activity rhythm and sleep-Wake in schizophrenic patients versus healthy subjects: An actigraphic comparative study. <i>Biological Rhythm Research</i> , 2008, 39, 69-78.	0.4	18
767	Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 491-499.	0.7	47
768	An open multicentre pilot study examining the safety, efficacy and tolerability of fast titrated (800) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Journal of Psychiatry in Clinical Practice</i> , 2008, 12, 261-267.	1.2	3
769	A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. <i>Journal of Psychopharmacology</i> , 2008, 22, 238-243.	2.0	116
770	Olanzapine plus carbamazepine <i>v.</i> carbamazepine alone in treating manic episodes. <i>British Journal of Psychiatry</i> , 2008, 192, 135-143.	1.7	75
771	Neuropsychiatric complications of commonly used palliative care drugs. <i>Postgraduate Medical Journal</i> , 2008, 84, 121-126.	0.9	40
772	PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 163-71.	1.0	35
773	Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2008, 33, 1217-1228.	2.8	135
774	Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. <i>Journal of Psychopharmacology</i> , 2008, 22, 323-329.	2.0	34
775	Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia. <i>Annals of Pharmacotherapy</i> , 2008, 42, 841-846.	0.9	33
776	The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 156-165.	0.7	478
777	Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S20-S28.	0.7	94
778	Safety Profile of Iloperidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S12-S19.	0.7	87
779	Tolerability of antipsychotic drugs: does patients perspective deserve consideration?. <i>Epidemiologia E Psichiatria Sociale</i> , 2008, 17, 182-185.	1.0	3

#	ARTICLE	IF	CITATIONS
780	A Psychoeducational Program for Weight Loss in Patients who have Experienced Weight Gain during Antipsychotic Treatment with Olanzapine. <i>Pharmacopsychiatry</i> , 2008, 41, 17-23.	1.7	54
781	Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 1033-1039.	4.0	430
782	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 978-987.	4.0	182
783	A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 465-472.	2.8	170
784	Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia. <i>Neuropsychopharmacology</i> , 2008, 33, 2456-2466.	2.8	74
785	Aripiprazole in Children with Attention-Deficit/Hyperactivity Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 347-354.	0.7	38
786	The Safety, Tolerability, and Subject-Rated Effects of Acute Intranasal Cocaine Administration During Aripiprazole Maintenance II: Increased Aripiprazole Dose and Maintenance Period. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 721-729.	1.1	20
787	Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis. <i>Brain Injury</i> , 2008, 22, 99-102.	0.6	13
788	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008, 193, 279-288.	1.7	228
789	Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 1037.	1.0	51
790	Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. <i>British Journal of Psychiatry</i> , 2008, 193, 485-492.	1.7	104
791	Grasping behavior in schizophrenia suggests selective impairment in the dorsal visual pathway.. <i>Journal of Abnormal Psychology</i> , 2008, 117, 799-811.	2.0	19
792	Neurological abnormalities and cognitive ability in first-episode psychosis. <i>British Journal of Psychiatry</i> , 2008, 193, 197-202.	1.7	57
793	Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics. <i>Psychiatric Bulletin</i> , 2008, 32, 53-56.	0.3	9
794	Markers of D2 and D3 Receptor Activity in vivo: PET Scan and Prolactin. <i>Therapie</i> , 2008, 63, 237-242.	0.6	5
795	Clinical and pharmacogenetic studies of iloperidone. <i>Personalized Medicine</i> , 2008, 5, 367-375.	0.8	8
796	Reduction in Neuroleptic-Induced Movement Disorders After a Switch to Quetiapine in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 69-73.	0.7	37
797	Amisulpride Improves Obsessive-Compulsive Symptoms in Schizophrenia Patients Taking Atypical Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 349-352.	0.7	38

#	ARTICLE	IF	CITATIONS
798	Illness Intrusiveness and Subjective Well-Being in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 798-805.	0.5	9
799	Bexarotene as Add-On to Antipsychotic Treatment in Schizophrenia Patients. <i>Clinical Neuropharmacology</i> , 2008, 31, 25-33.	0.2	39
800	Long-Term Efficacy and Safety of Iloperidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, S29-S35.	0.7	239
801	Olanzapine Versus Aripiprazole for the Treatment of Agitation in Acutely Ill Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 601-607.	0.7	50
802	The Effectiveness of Guideline Implementation Strategies on Improving Antipsychotic Medication Management for Schizophrenia. <i>Medical Care</i> , 2008, 46, 686-691.	1.1	24
803	Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2008, 23, 95-105.	0.9	18
804	Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. <i>International Clinical Psychopharmacology</i> , 2008, 23, 343-356.	0.9	75
806	Are Second Generation Antipsychotics a Distinct Class?. <i>Journal of Psychiatric Practice</i> , 2008, 14, 225-231.	0.3	7
807	An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. <i>Journal of Psychiatric Practice</i> , 2008, 14, 271-280.	0.3	44
808	Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 441-446.	0.7	56
809	A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 540-543.	0.7	32
810	A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2008, 23, 269-275.	0.9	30
811	Amisulpride plus valproate vs haloperidol plus valproate in the treatment of acute mania of bipolar I patients: a multicenter, open-label, randomized, comparative trial. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 675.	1.0	13
812	New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 1181.	1.0	18
813	Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 949.	1.0	16
814	Evaluating Treatment. , 0, , 169-188.		1
816	Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 47.	1.0	37
817	Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 369.	1.0	14

#	ARTICLE	IF	CITATIONS
818	Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 344-352.	0.6	25
819	Clinical significance of neurological abnormalities in psychosis. Advances in Psychiatric Treatment, 2009, 15, 419-427.	0.6	7
820	Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychological Medicine, 2009, 39, 1065.	2.7	175
821	Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. Journal of Psychopharmacology, 2009, 23, 6-13.	2.0	63
822	An open label study of quetiapine in patients with schizophrenia and alcohol disorders. Mental Health and Substance Use: Dual Diagnosis, 2009, 2, 203-211.	0.5	7
823	Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder. Pediatrics, 2009, 124, 1533-1540.	1.0	497
824	Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127). American Journal of Psychiatry, 2009, 166, 476-488.	4.0	207
825	Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opinion on Pharmacotherapy, 2009, 10, 2145-2159.	0.9	18
826	Neurological soft signs and brain morphology in first-episode schizophrenia. Psychological Medicine, 2009, 39, 371-379.	2.7	101
827	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. Australian and New Zealand Journal of Psychiatry, 2009, 43, 956-967.	1.3	9
828	Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine. Journal of Psychopharmacology, 2009, 23, 597-601.	2.0	45
829	Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia. American Journal of Psychiatry, 2009, 166, 691-701.	4.0	66
830	Relationship between Neuroleptic Extrapyramidal Syndromes and Patients' All-Cause Mortality. Pharmacopsychiatry, 2009, 42, 57-60.	1.7	3
831	Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. British Journal of Psychiatry, 2009, 194, 158-164.	1.7	94
832	Brain-Performance Correlates of Working Memory Retrieval in Schizophrenia: A Cognitive Modeling Approach. Schizophrenia Bulletin, 2009, 35, 32-46.	2.3	21
833	Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology, 2009, 34, 1885-1903.	2.8	168
834	Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants. CNS Spectrums, 2009, 14, 197-206.	0.7	254
835	Cerebellar substructures and neurological soft signs in first-episode schizophrenia. Psychiatry Research - Neuroimaging, 2009, 173, 83-87.	0.9	66

#	ARTICLE	IF	CITATIONS
836	Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol – A double-blind multicenter trial. <i>Journal of Psychiatric Research</i> , 2009, 43, 702-710.	1.5	30
837	Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. <i>BMC Neurology</i> , 2009, 9, 62.	0.8	133
838	Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. <i>Journal of Affective Disorders</i> , 2009, 112, 36-49.	2.0	141
839	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. <i>Journal of Affective Disorders</i> , 2009, 115, 376-385.	2.0	59
840	Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 518-522.	1.3	20
841	Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. <i>Human Psychopharmacology</i> , 2009, 24, 129-133.	0.7	15
842	Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT _{1A} receptor agonist. <i>Human Psychopharmacology</i> , 2009, 24, 437-446.	0.7	32
843	Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 447-452.	0.7	11
844	Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 565-573.	0.7	27
845	Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality. <i>Human Psychopharmacology</i> , 2009, 24, 619-627.	0.7	20
846	Outcome study of first-episode schizophrenia in a developing country: quality of life and antipsychotics. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2009, 44, 143-150.	1.6	11
847	Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 22-28.	2.2	54
848	Amisulpride – dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. <i>Acta Psychiatrica Scandinavica</i> , 2009, 120, 416-428.	2.2	66
849	Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 73-81.	1.0	25
850	A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. <i>Bipolar Disorders</i> , 2009, 11, 483-493.	1.1	117
851	A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. <i>Bipolar Disorders</i> , 2009, 11, 673-686.	1.1	176
852	Asenapine versus olanzapine in acute mania: a double-blind extension study. <i>Bipolar Disorders</i> , 2009, 11, 815-826.	1.1	105
853	Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. <i>Bipolar Disorders</i> , 2009, 11, 687-700.	1.1	137

#	ARTICLE	IF	CITATIONS
854	A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. <i>Bipolar Disorders</i> , 2009, 11, 827-839.	1.1	138
855	Olanzapine in Cocaine Dependence: A Double-Blind, Placebo-Controlled Trial. <i>American Journal on Addictions</i> , 2009, 18, 48-52.	1.3	27
856	Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2009, 25, 709-716.	0.9	12
857	Schizophrenia with prominent catatonic features (catatonic schizophrenia™). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 81-85.	2.5	12
858	No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 276-280.	2.5	20
859	Influence of TAAR6 polymorphisms on response to aripiprazole. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 822-826.	2.5	9
860	Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1022-1031.	2.5	107
861	A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2009, 65, 510-517.	0.7	89
862	The Relationship Between Cortical Inhibition, Antipsychotic Treatment, and the Symptoms of Schizophrenia. <i>Biological Psychiatry</i> , 2009, 65, 503-509.	0.7	81
863	An Exploration of the Effect of Modafinil on Olanzapine Associated Weight Gain in Normal Human Subjects. <i>Biological Psychiatry</i> , 2009, 65, 607-613.	0.7	14
864	Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics. <i>Schizophrenia Research</i> , 2009, 109, 130-133.	1.1	15
865	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. <i>Schizophrenia Research</i> , 2009, 110, 80-89.	1.1	38
866	Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: The MOZART study. <i>Schizophrenia Research</i> , 2009, 113, 112-121.	1.1	34
867	Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2009, 113, 181-188.	1.1	35
868	Motivational deficits as the central link to functioning in schizophrenia: A pilot study. <i>Schizophrenia Research</i> , 2009, 115, 333-337.	1.1	96
869	Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. <i>Pharmacogenomics Journal</i> , 2009, 9, 103-110.	0.9	44
871	Haloperidol plus promethazine for psychosis-induced aggression. , 2009, , CD005146.		42
872	Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 336-346.	2.3	228

#	ARTICLE	IF	CITATIONS
873	The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia. <i>CNS Drugs</i> , 2009, 23, 615-625.	2.7	85
874	A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 611-621.	0.7	109
875	Improvement of aggressive behavior and quality of life impairment following S-Adenosyl-Methionine (SAM-e) augmentation in schizophrenia. <i>European Neuropsychopharmacology</i> , 2009, 19, 14-22.	0.3	45
876	Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study. <i>European Neuropsychopharmacology</i> , 2009, 19, 476-482.	0.3	29
877	Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study. <i>European Neuropsychopharmacology</i> , 2009, 19, 562-570.	0.3	49
878	A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. <i>European Psychiatry</i> , 2009, 24, 149-153.	0.1	21
879	Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 255-263.	0.6	58
880	A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 1110-1119.	0.3	468
881	Prevalence of Extrapyramidal Side Effects in Patients Receiving Depot Antipsychotic Medication. <i>European Psychiatry</i> , 2009, 24, .	0.1	1
882	Olanzapine Versus Placebo in Adolescents With Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 60-70.	0.3	142
883	Antipsychotic Adherence Intervention for Veterans over 40 with Schizophrenia: Results of a Pilot Study. <i>European Psychiatry</i> , 2009, 24, S1171.	0.1	3
884	Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. <i>International Clinical Psychopharmacology</i> , 2009, 24, 229-238.	0.9	36
885	Effects of Aripiprazole on Insight and Subjective Experience in Individuals With an At-Risk Mental State. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 421-425.	0.7	24
886	Improved Body Weight and Metabolic Outcomes in Overweight or Obese Psychiatric Patients Switched to Amisulpride From Other Atypical Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 529-536.	0.7	21
887	Open Trial of Injectable Risperidone for Methamphetamine Dependence. <i>Journal of Addiction Medicine</i> , 2009, 3, 55-65.	1.4	12
888	Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. , 2009, , CD006324.		50
889	Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. <i>British Journal of Psychiatry</i> , 2009, 194, 40-48.	1.7	94
890	Early Predictors of Nonadherence to Antipsychotic Therapy in First-Episode Psychosis. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 28-35.	0.9	74

#	ARTICLE	IF	CITATIONS
891	Selective serotonin reuptake inhibitor-induced akathisia. Journal of the American Pharmacists Association: JAPhA, 2009, 49, e28-e38.	0.7	31
892	Ziprasidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006627.	1.5	45
893	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2009, , CD006569.		57
894	Sertindole versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006752.	1.5	13
895	Prevalence and Correlates of Insomnia and its Impact on Quality of Life in Chinese Schizophrenia Patients. Sleep, 2009, , .	0.6	25
896	Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol. CNS Spectrums, 2009, 14, 93-102.	0.7	14
897	Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. International Journal of Neuropsychopharmacology, 2009, 12, 1233.	1.0	34
898	D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 571-575.	0.7	41
899	A Double-blind Randomized Controlled Trial of Olanzapine Plus Sertraline vs Olanzapine Plus Placebo for Psychotic Depression. Archives of General Psychiatry, 2009, 66, 838.	13.8	188
900	Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia. Clinical Neuropharmacology, 2009, 32, 243-249.	0.2	40
901	Trazodone for the Treatment of Neuroleptic-Induced Acute Akathisia. Clinical Neuropharmacology, 2010, 33, 219-222.	0.2	37
902	The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia. International Clinical Psychopharmacology, 2010, 25, 83-90.	0.9	13
903	Audit on Physical Healthcare Monitoring in a Tertiary Service for People with Learning Disability. British Journal of Developmental Disabilities, 2010, 56, 39-47.	0.1	1
904	Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 106-115.	0.7	104
905	Use of Aripiprazole in a Patient With Multiple Sclerosis Presenting With Paranoid Psychosis. Journal of Psychiatric Practice, 2010, 16, 420-424.	0.3	6
906	Incidence of Extrapiramidal Symptoms and Tardive Dyskinesia in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 531-540.	0.7	68
907	A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 518-525.	0.7	26
908	A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. International Clinical Psychopharmacology, 2010, 25, 1-6.	0.9	46

#	ARTICLE	IF	CITATIONS
909	Akathisia Induced by Mirtazapine After 20 Years of Continuous Treatment. <i>Clinical Neuropharmacology</i> , 2010, 33, 50-51.	0.2	11
910	Effectiveness of Switching From Aripiprazole to Ziprasidone in Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2010, 33, 121-125.	0.2	28
911	Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 247-256.	0.9	133
912	Paliperidone Extended-Release in Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 487-495.	0.7	48
913	Topiramate Augmentation in Clozapine-Treated Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 706-710.	0.7	33
914	Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006625.		122
917	Visualâ€”spatial episodic memory in schizophrenia: A multiple systems framework.. <i>Neuropsychology</i> , 2010, 24, 368-378.	1.0	23
918	Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2010, 49, 583-594.	0.3	2
919	A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 2072-2082.	2.8	131
920	Two subgroups of schizophrenia identified by systematic cognitive neuropsychiatric mapping. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 257-266.	1.8	19
921	Development and Psychometric Evaluation of the Treatment-Emergent Activation and Suicidality Assessment Profile. <i>Child and Youth Care Forum</i> , 2010, 39, 113-124.	0.9	14
922	Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. <i>Journal of Affective Disorders</i> , 2010, 121, 106-115.	2.0	147
923	Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania. <i>Journal of Affective Disorders</i> , 2010, 124, 157-163.	2.0	31
924	Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study. <i>Journal of Affective Disorders</i> , 2010, 126, 358-365.	2.0	103
925	Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placeboâ€”controlled pilot study. <i>Human Psychopharmacology</i> , 2010, 25, 126-132.	0.7	33
926	Association study between antipsychoticâ€”induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. <i>Human Psychopharmacology</i> , 2010, 25, 397-403.	0.7	22
927	Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. <i>Depression and Anxiety</i> , 2010, 27, 964-976.	2.0	68
928	Motor behavior abnormalities in drugâ€”naïve patients with schizophrenia spectrum disorders. <i>Movement Disorders</i> , 2010, 25, 1068-1076.	2.2	118

#	ARTICLE	IF	CITATIONS
929	Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. <i>Movement Disorders</i> , 2010, 25, 2188-2194.	2.2	21
930	Predictors of switching antipsychotic medications in the treatment of schizophrenia. <i>BMC Psychiatry</i> , 2010, 10, 75.	1.1	38
931	The cross-sectional GRAS sample: A comprehensive phenotypical data collection of schizophrenic patients. <i>BMC Psychiatry</i> , 2010, 10, 91.	1.1	53
932	Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. <i>Annals of General Psychiatry</i> , 2010, 9, 11.	1.2	19
933	Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. <i>Annals of General Psychiatry</i> , 2010, 9, 17.	1.2	13
934	A Double-blind, Placebo-Controlled Study With Quetiapine as Adjunct Therapy With Lithium or Divalproex in Bipolar I Patients With Coexisting Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2010, 34, 1822-1831.	1.4	59
935	A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2010, 22, 68-80.	1.0	12
936	1H-MRS at 4 Tesla in minimally treated early schizophrenia. <i>Molecular Psychiatry</i> , 2010, 15, 629-636.	4.1	159
937	Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. <i>Microbial Biotechnology</i> , 2010, 4, 57-63.	0.9	10
938	Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. <i>Microbial Biotechnology</i> , 2010, 4, 64-78.	0.9	16
939	Determinants of subjective quality of life in first-episode schizophrenia: perspective from Malaysia. <i>Microbial Biotechnology</i> , 2010, 4, 111-118.	0.9	11
940	A single-blind, comparative study of zotepine versus haloperidol in combination with a mood stabilizer for patients with moderate-to-severe mania. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 162-169.	1.0	13
941	Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 196-204.	1.1	27
942	Liquid risperidone in the treatment of rages in psychiatrically hospitalized children with possible bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 205-212.	1.1	41
943	A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. <i>Bipolar Disorders</i> , 2010, 12, 230-243.	1.1	92
944	Functioning and disability in bipolar disorders: a systematic review of literature using the ICF as a reference. <i>Bipolar Disorders</i> , 2010, 12, 473-482.	1.1	29
945	Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 593-605.	1.1	71
946	Family outcomes. , 2010, , 133-155.		0

#	ARTICLE	IF	CITATIONS
947	Cost-effectiveness and cost-benefit analysis. , 2010, , 57-79.		0
948	Structured relaxation in the treatment of akathisia: case series. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 269.	1.0	3
949	Role of paliperidone extended-release in treatment of schizoaffective disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 667.	1.0	18
950	Extrapyramidal side effects. , 2010, , 156-172.		1
951	Association between restless legs syndrome and migraine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 473-475.	0.9	10
952	Gender Differences in Sociodemographic and Clinical Characteristic and the Quality of Life of Chinese Schizophrenia Patients. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 450-455.	1.3	15
953	The Relationship Between Akathisia and Subjective Tolerability in Patients With Schizophrenia. <i>International Journal of Neuroscience</i> , 2010, 120, 507-511.	0.8	5
954	No Influence of DTNBP1 Polymorphisms on the Response to Aripiprazole. <i>Neuropsychobiology</i> , 2010, 62, 245-249.	0.9	5
955	Relationship Between Subjective Experiences and Psychopathological Dimensions in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010, 44, 952-957.	1.3	15
956	Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. <i>Journal of Psychopharmacology</i> , 2010, 24, 1019-1029.	2.0	47
957	Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 581-590.	2.8	165
958	Efficacy, safety and tolerability of Symbyax [®] for acute-phase management of treatment-resistant depression. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 651-670.	1.4	18
959	Patient factors associated with receipt of combination antipsychotic drug therapy in the treatment of schizophrenia. <i>Journal of Psychopharmacology</i> , 2010, 24, 83-89.	2.0	6
960	The Appropriateness of Routine Medication Treatment for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2010, 36, 732-739.	2.3	18
961	Adjunctive Risperidone for Partially Responsive People with Schizophrenia Treated with Clozapine. <i>Neuropsychopharmacology</i> , 2010, 35, 2274-2283.	2.8	55
962	Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2010, 167, 181-189.	4.0	181
963	Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. <i>Current Medical Research and Opinion</i> , 2010, 26, 1485-1496.	0.9	44
964	Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder. <i>Pharmacopsychiatry</i> , 2010, 43, 138-146.	1.7	79

#	ARTICLE	IF	CITATIONS
965	Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2010, 341, c4024-c4024.	2.4	125
966	Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. <i>British Journal of Psychiatry</i> , 2010, 197, 67-72.	1.7	46
967	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 451.	1.0	159
968	No influence of FAT polymorphisms in response to aripiprazole. <i>Journal of Human Genetics</i> , 2010, 55, 32-36.	1.1	6
969	Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 917-932.	1.0	145
970	Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 635-647.	1.0	138
971	A student practice experience focusing on the intellectually disabled. <i>Currents in Pharmacy Teaching and Learning</i> , 2010, 2, 138-143.	0.4	2
972	Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects. <i>Biological Psychiatry</i> , 2010, 67, 279-282.	0.7	122
973	Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2010, 116, 107-117.	1.1	225
974	DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: Psychometric validity and response to antipsychotic medication. <i>Schizophrenia Research</i> , 2010, 118, 168-175.	1.1	73
975	Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. <i>Schizophrenia Research</i> , 2010, 120, 101-107.	1.1	79
976	High dose D-serine in the treatment of schizophrenia. <i>Schizophrenia Research</i> , 2010, 121, 125-130.	1.1	207
977	Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study. <i>Schizophrenia Research</i> , 2010, 123, 273-275.	1.1	5
978	Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale. <i>Schizophrenia Research</i> , 2010, 124, 1-12.	1.1	34
979	Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2010, 49, 583-594.	0.3	86
980	Predictors of Early Worsening after Switch to Aripiprazole. <i>Clinical Drug Investigation</i> , 2010, 30, 187-193.	1.1	13
981	Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. <i>Journal of Psychopharmacology</i> , 2010, 24, 1037-1044.	2.0	118
982	Diagnostic Rating Scales and Laboratory Tests. , 2010, , 61-71.		3

#	ARTICLE	IF	CITATIONS
983	Risperidone long-acting injectable (Risperdal Consta [®]) for maintenance treatment in patients with bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1637-1658.	1.4	41
984	A Pilot Study of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence. <i>Journal of Dual Diagnosis</i> , 2010, 6, 16-24.	0.7	8
985	MDR1 gene polymorphisms and response to acute risperidone treatment. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 387-392.	2.5	35
986	Facial emotion perception in Chinese patients with schizophrenia and non-psychotic first-degree relatives. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 393-400.	2.5	29
987	Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 997-1000.	2.5	14
988	Suicidal ideation in patients with obsessive-compulsive disorder. <i>Psychiatry Research</i> , 2010, 175, 104-108.	1.7	52
989	Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics. <i>Psychiatry Research</i> , 2010, 177, 77-83.	1.7	61
990	Executive control in schizophrenia in task involving semantic inhibition and working memory. <i>Psychiatry Research</i> , 2010, 179, 259-266.	1.7	15
991	Influence of DAOA gene variants on antipsychotic response after switch to aripiprazole. <i>Psychiatry Research</i> , 2010, 178, 430-432.	1.7	9
992	Antipsychotic drug side effects for persons with intellectual disability. <i>Research in Developmental Disabilities</i> , 2010, 31, 1570-1576.	1.2	105
993	PMH51 THE COST-EFFECTIVENESS OF EARLY RESPONDERS VERSUS EARLY NON-RESPONDERS TO ATYPICAL ANTIPSYCHOTIC THERAPY. <i>Value in Health</i> , 2010, 13, A113-A114.	0.1	0
994	lloperidone for schizophrenia. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2087-2093.	0.9	6
995	Clozapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006633.	1.5	130
996	Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. , 2010, , .		58
997	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006654.	1.5	120
999	Aripiprazole. <i>Paediatric Drugs</i> , 2011, 13, 197-204.	1.3	17
1000	Movement Disorders Induced by Antipsychotic Drugs: Implications of the CATIE Schizophrenia Trial. <i>Neurologic Clinics</i> , 2011, 29, 127-148.	0.8	140
1001	Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla. <i>Biological Psychiatry</i> , 2011, 69, 19-27.	0.7	91

#	ARTICLE	IF	CITATIONS
1002	A Randomized, Double-Blind Study of Paliperidone Extended-Release in Treatment of Acute Schizophrenia in Adolescents. <i>Biological Psychiatry</i> , 2011, 70, 1179-1187.	0.7	74
1003	Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. <i>Schizophrenia Research</i> , 2011, 130, 11-19.	1.1	34
1004	Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2011, 132, 101-107.	1.1	47
1005	Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [¹¹ C]-(+)-PHNO. <i>Schizophrenia Research</i> , 2011, 131, 63-68.	1.1	78
1006	The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2011, 130, 106-113.	1.1	32
1007	Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. <i>Schizophrenia Research</i> , 2011, 132, 28-34.	1.1	17
1008	Prediction of longitudinal functional outcomes in schizophrenia: The impact of baseline motivational deficits. <i>Schizophrenia Research</i> , 2011, 132, 24-27.	1.1	128
1009	Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. <i>New England Journal of Medicine</i> , 2011, 364, 842-851.	13.9	205
1010	Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. <i>BMC Psychiatry</i> , 2011, 11, 24.	1.1	18
1011	Early intervention for psychosis. <i>The Cochrane Library</i> , 2011, , CD004718.	1.5	235
1012	Risperidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2011, , CD006626.	1.5	69
1013	Neuromotor abnormalities in neuroleptic-naive psychotic patients: antecedents, clinical correlates, and prediction of treatment response. <i>Comprehensive Psychiatry</i> , 2011, 52, 139-145.	1.5	60
1014	A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 218-226.	2.5	146
1015	Antipsychotic dose and diminished neural modulation: A multi-site fMRI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 473-482.	2.5	46
1016	A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1002-1008.	2.5	83
1017	Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. <i>Psychiatry Research</i> , 2011, 187, 42-48.	1.7	63
1018	The genetics of antipsychotic induced tremors: A genome-wide pathway analysis on the STEP&BD SCP sample. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 975-986.	1.1	19
1019	Evaluation of Side Effects using the BARS, SAS and AIMS in Pediatric Psychopharmacologic Studies. <i>European Psychiatry</i> , 2011, 26, 128-129.	0.1	1

#	ARTICLE	IF	CITATIONS
1020	Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 79.	0.7	9
1021	The impact of antipsychotic side-effects on attitudes toward medication in patients with schizophrenia and related disorders: a systematic review. <i>JB Library of Systematic Reviews</i> , 2011, 9, 791-832.	0.1	0
1022	Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 303.	1.0	37
1023	Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine. <i>Frontiers in Psychiatry</i> , 2011, 2, 22.	1.3	12
1024	Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results. <i>Clinical Medicine Insights Psychiatry</i> , 2011, 3, CMPsy.S6659.	0.4	12
1025	Evaluation of the Routine Clinical Use of the Brief Psychiatric Rating Scale (BPRS) and the Abnormal Involuntary Movement Scale (AIMS). <i>Journal of Psychiatric Practice</i> , 2011, 17, 300-303.	0.3	7
1026	Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 86-91.	0.7	53
1027	Dopamine D2 Receptor Occupancy and Clinical Effects. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 497-502.	0.7	117
1028	Interview: Pursuing the rational pharmacological treatment of schizophrenia. <i>Neuropsychiatry</i> , 2011, 1, 425-430.	0.4	0
1029	The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 31-38.	0.7	15
1030	Aripiprazole-Associated Bruxism, Akathisia, and Parkinsonism in a Bipolar Patient. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 134-135.	0.7	9
1031	Clinical and Demographic Characteristics Associated With Postural Instability in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 16-21.	0.7	15
1032	Impact of Different Antidopaminergic Mechanisms on the Dopaminergic Control of Prolactin Secretion. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 214-220.	0.7	24
1033	Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2011, 26, 11-24.	0.9	62
1034	Antipsychotic-Associated Mental Side Effects and Their Relationship to Dopamine D2 Receptor Occupancy in Striatal Subdivisions. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 507-511.	0.7	21
1035	A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 418-428.	0.7	53
1036	A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 349-355.	0.7	223
1037	Aripiprazole: A Review of its Use in the Treatment of Irritability Associated with Autistic Disorder Patients Aged 6-17. <i>Journal of Central Nervous System Disease</i> , 2011, 3, JCNDS.S4140.	0.7	11

#	ARTICLE	IF	CITATIONS
1038	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. <i>Paediatrics and Child Health</i> , 2011, 16, 590-598.	0.3	42
1039	Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. <i>Bipolar Disorders</i> , 2011, 13, 133-144.	1.1	101
1040	Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report. <i>Bipolar Disorders</i> , 2011, 13, 294-302.	1.1	39
1041	Aripiprazole versus haloperidol treatment in early-stage schizophrenia. <i>Journal of Psychiatric Research</i> , 2011, 45, 756-762.	1.5	15
1042	Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. <i>Journal of Psychiatric Research</i> , 2011, 45, 1381-1386.	1.5	62
1043	Improving delirium care in the intensive care unit: The design of a pragmatic study. <i>Trials</i> , 2011, 12, 139.	0.7	25
1044	Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study. <i>Journal of Affective Disorders</i> , 2011, 128, 83-94.	2.0	68
1045	Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. <i>Journal of Affective Disorders</i> , 2011, 129, 252-260.	2.0	60
1046	Extended-Release Quetiapine as Monotherapy for the Treatment of Adults With Acute Mania: A Randomized, Double-Blind, 3-Week Trial. <i>Clinical Therapeutics</i> , 2011, 33, 1643-1658.	1.1	39
1047	Quantifying Clinical Relevance in the Treatment of Schizophrenia. <i>Clinical Therapeutics</i> , 2011, 33, B16-B39.	1.1	94
1048	A case of mania due to cryptococcal meningitis, successfully treated with adjunctive olanzapine, in a patient with acquired immunodeficiency syndrome. <i>General Hospital Psychiatry</i> , 2011, 33, 301.e3-301.e6.	1.2	7
1049	A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. <i>Journal of Psychopharmacology</i> , 2011, 25, 685-697.	2.0	93
1050	mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial. <i>Neuroscience and Behavioral Physiology</i> , 2011, 41, 559-566.	0.2	1
1051	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , 2011, 214, 719-728.	1.5	2
1052	Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. <i>Psychopharmacology</i> , 2011, 217, 279-287.	1.5	60
1053	Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT2A receptor occupancy as measured by positron emission tomography (PET). <i>Psychopharmacology</i> , 2011, 217, 315-321.	1.5	6
1054	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. <i>Psychopharmacology</i> , 2011, 218, 733-748.	1.5	15
1055	Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. <i>Annals of General Psychiatry</i> , 2011, 10, 12.	1.2	49

#	ARTICLE	IF	CITATIONS
1056	The treatment of severe child aggression (TOSCA) study: Design challenges. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2011, 5, 36.	1.2	30
1057	Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. <i>Human Psychopharmacology</i> , 2011, 26, 543-553.	0.7	32
1058	Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study. <i>Human Psychopharmacology</i> , 2011, 26, 588-595.	0.7	5
1059	Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2245-2263.	0.9	0
1060	Switching among Antipsychotics in Everyday Clinical Practice: Focus on Ziprasidone. <i>Postgraduate Medicine</i> , 2011, 123, 135-159.	0.9	11
1061	Aripiprazole and Dehydroaripiprazole Plasma Concentrations and Clinical Responses in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 758-762.	0.7	22
1062	A Randomized Open Comparison of Long-Acting Injectable Risperidone and Treatment as Usual for Prevention of Relapse, Rehospitalization, and Urgent Care Referral in Community-Treated Patients With Rapid Cycling Bipolar Disorder. <i>Clinical Neuropharmacology</i> , 2011, 34, 224-233.	0.2	17
1063	Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related PTSD. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 493.	3.8	184
1064	Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. <i>Journal of Psychopharmacology</i> , 2011, 25, 744-754.	2.0	15
1065	Antipsikotik Kullanılan Hastalarda Akatizinin Psikiyatrik Belirtiler, Antihistaminik Etkisi ve Diğer Hareket Bozuklukları ile İlişkisi. <i>Noropsikiyatri Arsivi</i> , 2011, 48, 1-1.	0.7	0
1066	Movement disorders are associated with schizotypy in unaffected siblings of patients with non-affective psychosis. <i>Psychological Medicine</i> , 2011, 41, 2141-2147.	2.7	19
1067	Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders. <i>Psychological Medicine</i> , 2011, 41, 1279-1289.	2.7	44
1068	The heterogeneity of antipsychotic response in the treatment of schizophrenia. <i>Psychological Medicine</i> , 2011, 41, 1291-1300.	2.7	54
1069	lloperidone: A new drug for the treatment of schizophrenia. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 301-308.	0.5	29
1070	Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. <i>American Journal of Psychiatry</i> , 2011, 168, 957-967.	4.0	228
1071	Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. <i>Schizophrenia Bulletin</i> , 2011, 37, 352-361.	2.3	46
1072	Oral ziprasidone in the treatment of patients with bipolar disorders: a critical review. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 163-179.	1.3	5
1073	An Open-Label Study of Aripiprazole in Children with a Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 345-351.	0.7	20

#	ARTICLE	IF	CITATIONS
1074	Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. <i>Current Medical Research and Opinion</i> , 2011, 27, 115-122.	0.9	14
1075	A Randomized Trial of Clozapine Versus Other Antipsychotics for Cannabis Use Disorder in Patients With Schizophrenia. <i>Journal of Dual Diagnosis</i> , 2011, 7, 50-63.	0.7	41
1076	A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). <i>American Journal of Psychiatry</i> , 2011, 168, 947-956.	4.0	158
1077	Encyclopedia of Schizophrenia. , 2011, , .		2
1078	Quetiapine in Adolescents with Non-Affective Psychotic Disorders: An Open-Label Trial. <i>Pharmacopsychiatry</i> , 2011, 44, 87-95.	1.7	3
1079	Delayed-onset akathisia due to amisulpride. <i>Indian Journal of Pharmacology</i> , 2011, 43, 460.	0.4	5
1080	In vivo quantification of striatal dopamine D ₂ receptor occupancy by JNJ-37822681 using [¹¹ C]raclopride and positron emission tomography. <i>Journal of Psychopharmacology</i> , 2012, 26, 1128-1135.	2.0	17
1081	Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial. <i>Journal of Psychopharmacology</i> , 2012, 26, 1194-1200.	2.0	10
1082	Psychosis Incident Cohort Outcome Study (PICOS). A multisite study of clinical, social and biological characteristics, patterns of care and predictors of outcome in first-episode psychosis. Background, methodology and overview of the patient sample. <i>Epidemiology and Psychiatric Sciences</i> , 2012, 21, 281-303.	1.8	26
1083	The use of Enhancing Quality Use of Medication Self-Reported Questionnaire (EQUIM-SRQ) among mental health consumers: a pilot study. <i>Australasian Psychiatry</i> , 2012, 20, 327-332.	0.4	2
1084	Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-to-head comparisons. <i>Journal of Psychopharmacology</i> , 2012, 26, 15-26.	2.0	60
1085	Two 6-Week, Randomized, Double-Blind, Placebo-Controlled Studies of Ziprasidone in Outpatients With Bipolar I Depression. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 470-478.	0.7	53
1086	The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments. <i>International Clinical Psychopharmacology</i> , 2012, 27, 1.	0.9	10
1087	Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2012, 27, 267-274.	0.9	28
1088	Efficacy and safety of ziprasidone in the treatment of first-episode psychosis. <i>International Clinical Psychopharmacology</i> , 2012, 27, 184-190.	0.9	20
1089	Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 95-99.	0.7	22
1090	Cognitive Effects of a Single Dose of Atypical Antipsychotics in Healthy Volunteers Compared With Placebo or Haloperidol. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 778-786.	0.7	8
1091	An open-label pilot study of aripiprazole for male and female Veterans with chronic post-traumatic stress disorder who respond suboptimally to antidepressants. <i>International Clinical Psychopharmacology</i> , 2012, 27, 191-196.	0.9	12

#	ARTICLE	IF	CITATIONS
1092	Venlafaxine Causing Akathisia: A Case Report. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, E3-E4.	0.9	11
1093	Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 327-342.	0.7	57
1094	A Phase 2a Randomized, Parallel Group, Dose-Ranging Study of Molindone in Children with Attention-Deficit/Hyperactivity Disorder and Persistent, Serious Conduct Problems. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 102-111.	0.7	22
1095	A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. International Journal of Neuropsychopharmacology, 2012, 15, 107-118.	1.0	87
1096	Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics Journal, 2012, 12, 147-155.	0.9	31
1097	Guide to Assessment Scales in Schizophrenia. , 2012, , .		5
1098	Predictors of Response to Ziprasidone: Results from a 6-Week Randomized Double-Blind, Placebo-Controlled Trial for Acute Depressive Mixed State. Pharmacopsychiatry, 2012, 45, 152-155.	1.7	9
1099	The Effect of Simulated Auditory Hallucinations on Daily Activities in Schizophrenia Patients. Psychopathology, 2012, 45, 352-360.	1.1	6
1100	Antipsychotic Response in the First Week Predicts Later Efficacy. Neuropsychobiology, 2012, 66, 100-105.	0.9	14
1101	An Open-Label Study of Aripiprazole for Methamphetamine Induced Psychosis. Journal of Microbiology and Biotechnology, 2012, 22, 121-129.	0.9	6
1102	Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state. Journal of Psychopharmacology, 2012, 26, 303-314.	2.0	7
1103	No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol. International Clinical Psychopharmacology, 2012, 27, 114-120.	0.9	13
1104	Nicotine dependence and illness severity in schizophrenia. British Journal of Psychiatry, 2012, 201, 306-312.	1.7	78
1105	Conformance to Evidence-Based Treatment Recommendations in Schizophrenia Treatment Services. Canadian Journal of Psychiatry, 2012, 57, 317-323.	0.9	14
1106	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). , 2012, 11, CD009377.		50
1107	Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l'utilisation d'antipsychotiques de deuxième génération chez les enfants et les adolescents. Paediatrics and Child Health, 2012, 17, 22B-30B.	0.3	4
1108	Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder. International Clinical Psychopharmacology, 2012, 27, 40-54.	0.9	61
1109	Pharmacokinetics and central nervous system effects of the novel dopamine D ₂ receptor antagonist JNJ-37822681. Journal of Psychopharmacology, 2012, 26, 1119-1127.	2.0	10

#	ARTICLE	IF	CITATIONS
1110	Paliperidone Palmitate for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 1124-1127.	2.3	40
1111	Response to Second Generation Antipsychotics in Youth with Comorbid Bipolar Disorder and Autism Spectrum Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 28-33.	1.9	22
1112	Pimavanserin, a selective serotonin (5-HT) _{2A} -inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. <i>Schizophrenia Research</i> , 2012, 141, 144-152.	1.1	87
1113	P.2.e.016 Cariprazine in the treatment of acute mania in bipolar disorder: a double-blind, placebo-controlled, phase III trial. <i>European Neuropsychopharmacology</i> , 2012, 22, S285.	0.3	2
1114	A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 721-733.	0.3	24
1115	Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. <i>Psychiatry Research</i> , 2012, 199, 1-7.	1.7	9
1116	A 6-Week, Randomized, Multicentre, Open-Label Study Comparing Efficacy and Tolerability of Amisulpride at a Starting Dose of 400Åmg/day versus 800Åmg/day in Patients with Acute Exacerbations of Schizophrenia. <i>Clinical Drug Investigation</i> , 2012, 32, 735-745.	1.1	7
1117	Management of sexual dysfunction due to antipsychotic drug therapy. <i>The Cochrane Library</i> , 2012, 11, CD003546.	1.5	39
1118	Acetylcholinesterase inhibitors for schizophrenia. <i>The Cochrane Library</i> , 2012, 1, CD007967.	1.5	39
1119	Impact of symptom resolution on medication adherence in first episode psychosis. <i>Psychiatry Research</i> , 2012, 196, 45-51.	1.7	16
1120	Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 182-187.	2.5	21
1121	Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. <i>Journal of Psychiatric Research</i> , 2012, 46, 1099-1105.	1.5	118
1122	Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. <i>Comprehensive Psychiatry</i> , 2012, 53, 145-151.	1.5	90
1123	Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. <i>Journal of Affective Disorders</i> , 2012, 142, 36-44.	2.0	33
1124	Self-Reported Sedation Profile of Quetiapine Extended-Release and Quetiapine Immediate-Release During 6-Day Initial Dose Escalation in Bipolar Depression: A Multicenter, Randomized, Double-Blind, Phase IV Study. <i>Clinical Therapeutics</i> , 2012, 34, 2202-2211.	1.1	17
1125	Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. <i>Schizophrenia Research</i> , 2012, 134, 195-201.	1.1	34
1126	Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2012, 135, 116-122.	1.1	23
1127	Effect of cannabis use on the course of schizophrenia in male patients: A prospective cohort study. <i>Schizophrenia Research</i> , 2012, 137, 50-57.	1.1	63

#	ARTICLE	IF	CITATIONS
1128	Behavioral validation of avolition in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 255-261.	1.1	22
1129	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2012, , CD008016.	1.5	154
1130	Paliperidone palmitate for schizophrenia. <i>The Cochrane Library</i> , 2012, , CD008296.	1.5	28
1131	D2-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D2-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection. <i>Psychopharmacology</i> , 2012, 224, 549-557.	1.5	5
1132	Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study. <i>BMC Psychiatry</i> , 2012, 12, 162.	1.1	1
1133	Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data. <i>BMC Psychiatry</i> , 2012, 12, 51.	1.1	11
1134	A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. <i>BMC Psychiatry</i> , 2012, 12, 26.	1.1	52
1135	An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2012, 6, 23.	1.2	16
1136	Motor Deficits in Schizophrenia Quantified by Nonlinear Analysis of Postural Sway. <i>PLoS ONE</i> , 2012, 7, e41808.	1.1	59
1137	Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 617-624.	1.1	324
1139	Positron emission tomography experience with ¹⁸ F-fluoro-2-(2-azetidinylmethoxy)pyridine (¹⁸ F) in the living human brain of smokers with paranoid schizophrenia. <i>Synapse</i> , 2012, 66, 352-368.	0.6	28
1140	Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. <i>International Journal of Methods in Psychiatric Research</i> , 2012, 21, 205-221.	1.1	224
1141	Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia. <i>Human Psychopharmacology</i> , 2012, 27, 403-410.	0.7	1
1142	A Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy-Drinking Alcohol-Dependent Patients. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 406-416.	1.4	85
1143	Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: A randomized, double-blind, dose-response study. <i>Journal of Affective Disorders</i> , 2012, 136, e51-e60.	2.0	49
1144	A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. <i>Journal of Affective Disorders</i> , 2012, 136, 1143-1153.	2.0	29
1145	A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	2.0	25
1146	A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. <i>Journal of Affective Disorders</i> , 2012, 138, 247-258.	2.0	63

#	ARTICLE	IF	CITATIONS
1147	Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138â€³92). <i>Bipolar Disorders</i> , 2012, 14, 41-53.	1.1	48
1148	Medication attitudes and beliefs in patients with psychotic and affective disorders on maintenance treatment. <i>Human Psychopharmacology</i> , 2012, 27, 57-62.	0.7	13
1149	Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. <i>Psychopharmacology</i> , 2012, 219, 225-233.	1.5	24
1150	Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. <i>Psychopharmacology</i> , 2012, 219, 727-736.	1.5	38
1151	Characterization of spontaneous Parkinsonism in drug-naïve patients with nonaffective psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 131-138.	1.8	19
1152	Neurological soft signs in non-ψpsychotic patients with cannabis dependence. <i>Addiction Biology</i> , 2013, 18, 214-221.	1.4	20
1153	Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. <i>Human Brain Mapping</i> , 2013, 34, 272-282.	1.9	97
1154	Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-βbetahistine combination. <i>Psychopharmacology</i> , 2013, 226, 615-622.	1.5	61
1155	Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. <i>Psychopharmacology</i> , 2013, 225, 519-530.	1.5	104
1156	Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. <i>Journal of Autism and Developmental Disorders</i> , 2013, 43, 1773-1783.	1.7	94
1157	A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 143.	1.1	92
1158	Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD Î™Î™. <i>BMC Psychiatry</i> , 2013, 13, 38.	1.1	27
1159	Quality of life is predictive of relapse in schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 15.	1.1	71
1160	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2013, , CD006569.		18
1161	The MCIC Collection: A Shared Repository of Multi-Modal, Multi-Site Brain Image Data from a Clinical Investigation of Schizophrenia. <i>Neuroinformatics</i> , 2013, 11, 367-388.	1.5	168
1162	Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2013, 47, 670-677.	1.5	129
1163	Haloperidol versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD003082.	1.5	60
1164	Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. <i>Current Medical Research and Opinion</i> , 2013, 29, 1241-1251.	0.9	26

#	ARTICLE	IF	CITATIONS
1165	Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. <i>Journal of Psychiatric Research</i> , 2013, 47, 1590-1596.	1.5	177
1166	Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. <i>Journal of Affective Disorders</i> , 2013, 145, 83-94.	2.0	39
1167	Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample. <i>Annals of General Psychiatry</i> , 2013, 12, 28.	1.2	3
1168	Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic) Tj ETQq1 1 0.7.84314 r8T /Overlo	1.8	16
1169	Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective. <i>CNS Drugs</i> , 2013, 27, 637-652.	2.7	61
1170	Effects of antipsychotic treatment on cognition in healthy subjects. <i>Journal of Psychopharmacology</i> , 2013, 27, 374-385.	2.0	27
1171	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 65-74.	1.8	16
1172	Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study. <i>Schizophrenia Research</i> , 2013, 150, 281-288.	1.1	92
1173	Association of altered cardiac autonomic function with psychopathology and metabolic profiles in schizophrenia. <i>Psychiatry Research</i> , 2013, 210, 710-715.	1.7	23
1174	Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. <i>Schizophrenia Research</i> , 2013, 147, 95-102.	1.1	105
1175	Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study. <i>Schizophrenia Research</i> , 2013, 151, 203-208.	1.1	35
1176	Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. <i>Schizophrenia Research</i> , 2013, 145, 101-109.	1.1	151
1177	Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: A randomized, double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2013, 150, 289-296.	1.1	20
1178	Amotivation and functional outcomes in early schizophrenia. <i>Psychiatry Research</i> , 2013, 210, 665-668.	1.7	69
1179	Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes. <i>British Journal of Psychiatry</i> , 2013, 203, 215-220.	1.7	12
1180	Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: An open-label study. <i>Phytomedicine</i> , 2013, 20, 654-658.	2.3	17
1181	Early Antipsychotic Response to Aripiprazole in Adolescents With Schizophrenia: Predictive Value for Clinical Outcomes. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 689-698.e3.	0.3	23
1182	Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial. <i>Schizophrenia Research</i> , 2013, 147, 375-382.	1.1	21

#	ARTICLE	IF	CITATIONS
1183	Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study). <i>Journal of Affective Disorders</i> , 2013, 151, 899-905.	2.0	56
1184	Prospective memory predicts medication management ability and correlates with non-adherence to medications in individuals with clinically stable schizophrenia. <i>Schizophrenia Research</i> , 2013, 147, 293-300.	1.1	30
1185	Psychometric properties of the Treatment-Emergent Activation and Suicidality Assessment Profile (TEASAP) in youth with OCD. <i>Psychiatry Research</i> , 2013, 205, 253-261.	1.7	23
1186	Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. <i>Psychopharmacology</i> , 2013, 227, 615-625.	1.5	23
1187	Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. <i>Bipolar Disorders</i> , 2013, 15, 138-149.	1.1	62
1188	Movement disorders in patients with schizophrenia and a history of substance abuse. <i>Human Psychopharmacology</i> , 2013, 28, 192-197.	0.7	9
1189	A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 110-114.	2.5	13
1190	The <i>BTBD9</i> gene may be associated with antipsychotic-induced restless legs syndrome in schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 117-123.	0.7	17
1191	Quetiapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2013, , CD006625.	1.5	44
1192	Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 61-91.	1.3	22
1193	A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 131-138.	1.2	37
1194	Aripiprazole in the treatment of Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 459-474.	0.9	46
1195	MAINTENANCE TREATMENT WITH QUETIAPINE WHEN COMBINED WITH EITHER LITHIUM OR DIVALPROEX IN BIPOLAR I DISORDER: ANALYSIS OF TWO LARGE RANDOMIZED, PLACEBO-CONTROLLED TRIALS. <i>Depression and Anxiety</i> , 2013, 30, 1089-1098.	2.0	31
1196	The Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder: An 8-Week, Multicenter, Open-Label Study. <i>Clinical Drug Investigation</i> , 2013, 33, 743-753.	1.1	6
1197	Comparison of Outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE Study. <i>Psychiatric Services</i> , 2013, 64, 570-578.	1.1	12
1198	The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing. <i>American Journal of Psychiatry</i> , 2013, 170, 1413-1422.	4.0	82
1199	Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. <i>Neuropsychopharmacology</i> , 2013, 38, 492-503.	2.8	67
1200	Predicting a 'Combined Treatment Outcome' in Chronic Schizophrenia: The Role of Demographics, Symptomatology, Functioning and Subjective Well-being. <i>Pharmacopsychiatry</i> , 2013, 46, 114-119.	1.7	9

#	ARTICLE	IF	CITATIONS
1201	Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases. <i>Neuropsychopharmacology</i> , 2013, 38, 2140-2149.	2.8	36
1202	No Effects of Antidepressants on Negative Symptoms in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 686-690.	0.7	23
1203	Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 267-274.	0.9	15
1204	Atypical Antipsychotics in the Treatment of Posttraumatic Stress Disorder. <i>Clinical Neuropharmacology</i> , 2013, 36, 216-222.	0.2	17
1205	Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2013, 28, 1.	0.9	28
1206	Treatment of adolescents with early-onset schizophrenia spectrum disorders. <i>Current Opinion in Psychiatry</i> , 2013, 26, 219-230.	3.1	82
1207	Augmentation of Aripiprazole for Depressed Patients With an Inadequate Response to Antidepressant Treatment. <i>Clinical Neuropharmacology</i> , 2013, 36, 157-161.	0.2	16
1208	The nature and extent of working memory dysfunction in schizophrenia. <i>PsyCh Journal</i> , 2013, 2, 175-182.	0.5	2
1209	A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in agitated elderly patients with schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2013, 3, 314-321.	1.2	5
1210	Antidepressants and akathisia. <i>Journal of Mood Disorders</i> , 2013, 3, 162.	0.1	0
1211	Metoclopramide Induced Akathisia: A Case Report. <i>Journal of Microbiology and Biotechnology</i> , 2013, 23, 186-189.	0.9	3
1212	Disrupted Central Inhibition after Transcranial Magnetic Stimulation of Motor Cortex in Schizophrenia with Long-Term Antipsychotic Treatment. , 2013, 2013, 1-9.		4
1213	Reduced directed forgetting for negative words suggests schizophrenia-related disinhibition of emotional cues. <i>Psychological Medicine</i> , 2013, 43, 2289-2299.	2.7	14
1214	Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. <i>Human Psychopharmacology</i> , 2013, 28, 586-593.	0.7	19
1215	Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 124-133.	0.7	32
1216	Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1551-1563.	0.6	16
1217	Biological Perspectives. <i>Perspectives in Psychiatric Care</i> , 2013, 49, 149-151.	0.9	3
1218	Ziprasidone in Adolescents with Schizophrenia: Results from a Placebo-Controlled Efficacy and Long-Term Open-Extension Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 531-544.	0.7	47

#	ARTICLE	IF	CITATIONS
1219	An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 676-686.	0.7	37
1220	Administration of metoclopramide by infusion or bolus does not affect the incidence of drug-induced akathisia. <i>EMA - Emergency Medicine Australasia</i> , 2013, 25, 207-212.	0.5	10
1221	Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives. <i>Human Psychopharmacology</i> , 2013, 28, 457-465.	0.7	12
1222	Pregabalin-Induced Akathisia. <i>Annals of Pharmacotherapy</i> , 2013, 47, 592-593.	0.9	10
1223	DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. <i>Journal of Psychopharmacology</i> , 2013, 27, 343-348.	2.0	19
1224	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 665-675.	0.7	30
1225	Efficacy, Long-Term Safety, and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 545-557.	0.7	48
1226	Atypical antipsychotics for psychosis in adolescents. <i>The Cochrane Library</i> , 2013, , CD009582.	1.5	37
1227	Safety, Tolerability, and Efficacy of Quetiapine in Youth with Schizophrenia or Bipolar I Disorder: A 26-Week, Open-Label, Continuation Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2013, 23, 490-501.	0.7	22
1228	Phenomenological Differences Between Spontaneous and Drug-Related Extrapyrimal Syndromes in Patients With Schizophrenia-Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 438-440.	0.7	17
1229	Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. <i>CNS Spectrums</i> , 2013, 18, 43-54.	0.7	27
1230	Neurological examination. , 0, , 319-332.		1
1231	Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 861.	1.0	8
1232	Altered heart rate dynamics associated with antipsychotic-induced subjective restlessness in patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 989.	1.0	4
1233	A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1281.	1.0	6
1234	Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 815.	1.0	4
1235	Ziprasidone in Pediatric Bipolar Disorder: A 6-Week, Open-Label Comparison of Rapid vs. Slow Dose Titration. <i>Journal of Depression & Anxiety</i> , 2013, 02, .	0.1	0
1237	Review of depot aripiprazole for schizophrenia. <i>Patient Preference and Adherence</i> , 2013, 7, 1181.	0.8	6

#	ARTICLE	IF	CITATIONS
1238	Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1737.	1.0	1
1239	Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1381.	1.0	21
1240	A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 201.	1.0	17
1241	A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature. <i>Current Drug Safety</i> , 2014, 9, 56-59.	0.3	10
1242	The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1243.	1.0	9
1243	Patient choice as a driver of medication-switching in non-adherent individuals with bipolar disorder. <i>Patient Preference and Adherence</i> , 2014, 8, 487.	0.8	2
1244	Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. <i>Pharmacogenomics</i> , 2014, 15, 17-28.	0.6	14
1245	A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. <i>BMC Psychiatry</i> , 2014, 14, 351.	1.1	95
1246	A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 96-112.	1.3	38
1247	Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. <i>CNS Spectrums</i> , 2014, 19, 330-339.	0.7	38
1248	Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 2549-2559.	2.8	40
1249	Corrigendum to "Effectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression". <i>J. Affect. Disord.</i> 121 (1-2) (2010) 106-115. <i>Journal of Affective Disorders</i> , 2014, 168, 485-493.	2.0	14
1250	A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). <i>World Journal of Biological Psychiatry</i> , 2014, 15, 113-121.	1.3	29
1251	Association between restless legs syndrome and CLOCK and NPAS2 gene polymorphisms in schizophrenia. <i>Chronobiology International</i> , 2014, 31, 838-844.	0.9	27
1252	Characterization of the Deficit Syndrome in Drug-Naive Schizophrenia Patients: The Role of Spontaneous Movement Disorders and Neurological Soft Signs. <i>Schizophrenia Bulletin</i> , 2014, 40, 214-224.	2.3	70
1253	Attitudes Towards Antipsychotics Among Patients with Schizophrenia on First- or Second-Generation Medications. <i>Indian Journal of Psychological Medicine</i> , 2014, 36, 288-293.	0.6	13
1254	Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia. <i>Indian Journal of Psychological Medicine</i> , 2014, 36, 33-39.	0.6	10
1255	Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 265.	6.0	77

#	ARTICLE	IF	CITATIONS
1256	Human Brain Imaging of Autism Spectrum Disorders. , 2014, , 373-406.		5
1257	Comparison of Low and Moderate Dosages of Extended-Release Quetiapine in Borderline Personality Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry, 2014, 171, 1174-1182.	4.0	82
1258	Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia. Human Psychopharmacology, 2014, 29, 244-250.	0.7	10
1259	Early intervention and evaluation for adult-onset psychosis: the JCEP study rationale and design. Microbial Biotechnology, 2014, 8, 261-268.	0.9	38
1260	Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia. Acta Psychiatrica Scandinavica, 2014, 130, 290-299.	2.2	190
1261	A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Human Psychopharmacology, 2014, 29, 83-88.	0.7	18
1262	Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects. Human Psychopharmacology, 2014, 29, 203-210.	0.7	15
1263	A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1433-1442.	2.3	46
1264	A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatrica Scandinavica, 2014, 130, 61-68.	2.2	59
1265	Quetiapine versus aripiprazole in children and adolescents with psychosis - protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. BMC Psychiatry, 2014, 14, 199.	1.1	10
1266	Validity of subjective versus objective quality of life assessment in people with schizophrenia. BMC Psychiatry, 2014, 14, 365.	1.1	47
1267	Lithium as add-on to quetiapine XR in adult patients with acute mania: a 6-week, multicenter, double-blind, randomized, placebo-controlled study. International Journal of Bipolar Disorders, 2014, 2, 14.	0.8	33
1268	Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology, 2014, 29, 322-331.	0.9	25
1269	The Effects of Quetiapine on Sleep in Recovering Alcohol-Dependent Subjects. Journal of Clinical Psychopharmacology, 2014, 34, 350-354.	0.7	34
1270	Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine. Journal of Clinical Psychopharmacology, 2014, 34, 426-434.	0.7	30
1271	Community Adherence to Schizophrenia Treatment and Safety Monitoring Guidelines. Journal of Nervous and Mental Disease, 2014, 202, 6-12.	0.5	11
1272	A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia. Schizophrenia Research and Treatment, 2014, 2014, 1-5.	0.7	11
1273	Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia. Journal of Clinical Psychopharmacology, 2014, 34, 682-689.	0.7	11

#	ARTICLE	IF	CITATIONS
1274	Rapid Tranquilization of Severely Agitated Patients With Schizophrenia Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 124-128.	0.7	32
1275	Beneficial effect of low-dose mirtazapine in acute aripiprazole-induced akathisia. <i>International Clinical Psychopharmacology</i> , 2014, 29, 296-298.	0.9	15
1276	Spontaneous Parkinsonism Is Associated With Cognitive Impairment in Antipsychotic-Naive Patients With First-Episode Psychosis: A 6-Month Follow-up Study. <i>Schizophrenia Bulletin</i> , 2014, 40, 1164-1173.	2.3	61
1277	Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment. <i>International Journal of Methods in Psychiatric Research</i> , 2014, 23, 439-450.	1.1	4
1278	Safety of Paliperidone Extended-Release in Patients with Schizophrenia or Schizoaffective Disorder and Hepatic Disease. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 8, 8-20.	1.4	15
1279	Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 637.	6.0	185
1280	SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 15-21.	1.2	36
1281	Pomaglumedad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison. <i>Schizophrenia Research and Treatment</i> , 2014, 2014, 1-11.	0.7	55
1282	Drug Attitude in Adolescents. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 99-108.	0.7	13
1283	The Selective Neurokinin 3 Antagonist AZD2624 Does Not Improve Symptoms or Cognition in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 199-204.	0.7	28
1284	The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. <i>International Clinical Psychopharmacology</i> , 2014, 29, 77-85.	0.9	9
1285	Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia. <i>International Clinical Psychopharmacology</i> , 2014, 29, 45-55.	0.9	25
1286	The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: A preliminary open-label trial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014, 18, 58-62.	1.2	16
1287	The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder – A systematic review. <i>Research in Developmental Disabilities</i> , 2014, 35, 711-725.	1.2	59
1288	Postural control in restless legs syndrome with medication intervention using pramipexole. <i>Neurological Sciences</i> , 2014, 35, 199-204.	0.9	1
1289	Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. <i>Psychopharmacology</i> , 2014, 231, 357-366.	1.5	21
1290	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. <i>European Child and Adolescent Psychiatry</i> , 2014, 23, 1149-1160.	2.8	23
1291	Abnormalities in Myelination of the Superior Cerebellar Peduncle in Patients with Schizophrenia and Deficits in Movement Sequencing. <i>Cerebellum</i> , 2014, 13, 415-424.	1.4	23

#	ARTICLE	IF	CITATIONS
1292	Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2014, , CD006569.	1.5	70
1293	A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. Journal of Clinical Pharmacology, 2014, 54, 1048-1057.	1.0	36
1294	A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in Patients with Bipolar Disorder, Mixed or Depressed Phase, and Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2014, 38, 2113-2118.	1.4	41
1295	Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. British Journal of Psychiatry, 2014, 205, 135-144.	1.7	130
1296	Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry, 2014, 14, 166.	1.1	21
1297	Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents. Child and Adolescent Psychiatry and Mental Health, 2014, 8, 18.	1.2	16
1298	Psychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR16) questionnaire in patients with schizophrenia. BMC Psychiatry, 2014, 14, 247.	1.1	15
1299	Evaluation of Different Approaches for Confounding in Nonrandomised Observational Data: A Case-Study of Antipsychotics Treatment. Community Mental Health Journal, 2014, 50, 711-720.	1.1	1
1300	Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. Journal of Psychopharmacology, 2014, 28, 341-348.	2.0	3
1301	Incidences of Extrapyramidal Symptoms in Patients with Schizophrenia after Treatment with Long-Acting Injection (Depot) or Oral Formulations of Olanzapine. Clinical Schizophrenia and Related Psychoses, 2014, 7, 216-222.	1.4	7
1302	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. American Journal of Geriatric Psychiatry, 2014, 22, 1007-1016.	0.6	24
1303	A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia. Schizophrenia Research, 2014, 154, 14-22.	1.1	34
1304	Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study. European Neuropsychopharmacology, 2014, 24, 1078-1085.	0.3	21
1305	An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial. Schizophrenia Research, 2014, 152, 450-457.	1.1	155
1306	What Does Risperidone Add to Parent Training and Stimulant for Severe Aggression in Child Attention-Deficit/Hyperactivity Disorder?. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 47-60.e1.	0.3	125
1307	Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: A preliminary PET study. Psychiatry Research - Neuroimaging, 2014, 221, 231-239.	0.9	20
1308	Antagonism of the adenosine A2A receptor attenuates akathisia-like behavior induced with MP-10 or aripiprazole in a novel non-human primate model. Pharmacology Biochemistry and Behavior, 2014, 118, 36-45.	1.3	12
1309	Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. European Neuropsychopharmacology, 2014, 24, 564-574.	0.3	37

#	ARTICLE	IF	CITATIONS
1310	Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. <i>European Psychiatry</i> , 2014, 29, 191-196.	0.1	40
1311	Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2014, 157, 33-40.	2.0	26
1312	Metabolic Abnormality and Sleep Disturbance are Associated with Clinical Severity of Patients with		

#	ARTICLE	IF	CITATIONS
1328	Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 635-644.	0.7	17
1329	Role of Amisulpride Augmentation in Treatment Resistant Major Depressive Disorder: An Open Label Study from North India. <i>International Journal of Emergency Mental Health</i> , 0, s2, .	0.3	0
1330	Ultra-High-Dose Long-Acting Injectable Aripiprazole in Chronic Refractory Schizophrenia: A Case Report. , 2015, 05, .		0
1331	Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 2299.	1.0	11
1332	A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1349.	1.0	11
1333	Association Between Serum Anticholinergic Activity and Psychiatric Symptoms of Chronic Schizophrenia. <i>The Showa University Journal of Medical Sciences</i> , 2015, 27, 251-260.	0.1	0
1334	Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1299.	1.0	9
1335	A Quantitative Measure of Handwriting Dysfluency for Assessing Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 168-174.	0.7	22
1336	The quality of reporting of phase II and III trials for new antipsychotics: a systematic review. <i>Psychological Medicine</i> , 2015, 45, 467-479.	2.7	9
1337	Placebo-Controlled Trial of Valproic Acid Versus Risperidone in Children 3â€“7 Years of Age with Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 306-313.	0.7	17
1338	Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome. <i>Schizophrenia Research</i> , 2015, 166, 9-16.	1.1	120
1339	Incidence of Tardive Dyskinesia in Older Adult Patients Treated With Olanzapine or Conventional Antipsychotics. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 67-79.	1.2	11
1340	Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, doseâ€“response study. <i>Psychoneuroendocrinology</i> , 2015, 58, 130-140.	1.3	52
1341	An fMRI study of multimodal selective attention in schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 207, 420-428.	1.7	25
1342	Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. <i>Schizophrenia Research</i> , 2015, 169, 255-261.	1.1	34
1343	A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 322-331.	1.2	24
1344	Risperidone-associated adverse drug reactions and CYP2D6 polymorphisms in a South African cohort. <i>Applied & Translational Genomics</i> , 2015, 5, 40-46.	2.1	8
1345	Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 351-356.	1.1	32

#	ARTICLE	IF	CITATIONS
1346	Olanzapine/Fluoxetine Combination in Children and Adolescents With Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 217-224.	0.3	62
1347	Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. <i>Schizophrenia Research</i> , 2015, 161, 421-428.	1.1	60
1348	Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2015, 25, 295-302.	0.3	8
1349	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia—A [11C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	1.1	17
1350	Impaired subjective well-being in schizophrenia is associated with reduced anterior cingulate activity during reward processing. <i>Psychological Medicine</i> , 2015, 45, 589-600.	2.7	26
1351	Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 718-727.e3.	0.3	32
1352	Simvastatin augmentation for recent-onset psychotic disorder: A study protocol. <i>BBA Clinical</i> , 2015, 4, 52-58.	4.1	20
1353	Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 438-445.	0.8	24
1354	Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 1158-1166.	0.3	84
1355	Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, Phase III trial. <i>Journal of Affective Disorders</i> , 2015, 174, 296-302.	2.0	98
1356	Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. <i>Journal of Psychiatric Research</i> , 2015, 69, 102-109.	1.5	30
1357	Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study. <i>Journal of Psychopharmacology</i> , 2015, 29, 933-942.	2.0	3
1358	Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 276-282.	1.1	57
1359	The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: A randomized controlled trial. <i>Schizophrenia Research</i> , 2015, 166, 194-200.	1.1	29
1360	Asenapine in the treatment of older adults with bipolar disorder. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 710-719.	1.3	31
1361	Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 579-588.	1.8	5
1362	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 927.	6.0	77
1363	Do We Know If They Work and If They Are Safe. , 2015, , 27-64.		2

#	ARTICLE	IF	CITATIONS
1364	Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. <i>Schizophrenia Research</i> , 2015, 164, 149-154.	1.1	12
1365	Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2015, 172, 870-880.	4.0	158
1366	The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 71.	0.7	8
1367	A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. <i>Schizophrenia Research</i> , 2015, 164, 127-135.	1.1	295
1368	Clinical and Functional Outcomes in People With Schizophrenia With a High Sense of Well-Being. <i>Journal of Nervous and Mental Disease</i> , 2015, 203, 187-193.	0.5	10
1369	Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 535-547.	0.7	8
1370	Pharmacological management of antipsychotic-induced akathisia: an update and treatment algorithm. <i>BJ Psych Advances</i> , 2015, 21, 342-344.	0.5	1
1371	Anxiety in Patients with Schizophrenia: Epidemiology and Management. <i>CNS Drugs</i> , 2015, 29, 819-832.	2.7	114
1372	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 483-501.	1.3	26
1373	The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. <i>Bipolar Disorders</i> , 2015, 17, 63-75.	1.1	93
1374	Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv064.	1.0	1
1375	Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1485-1496.	2.8	18
1376	Rating scales to measure side effects of antipsychotic medication: A systematic review. <i>Journal of Psychopharmacology</i> , 2015, 29, 857-866.	2.0	31
1377	Brain structure and function correlates of cognitive subtypes in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2015, 234, 74-83.	0.9	64
1378	The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. <i>Psychiatry Research</i> , 2015, 229, 760-770.	1.7	20
1379	Association of a Schizophrenia Risk Variant at the <i>DRD2</i> Locus With Antipsychotic Treatment Response in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 1248-1255.	2.3	64
1380	The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 969-981.	1.4	9
1381	A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. <i>Schizophrenia Bulletin</i> , 2015, 41, 1227-1236.	2.3	100

#	ARTICLE	IF	CITATIONS
1382	Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 1020-1031.e3.	0.3	37
1383	Low Dose Loxapine: Neuromotor Side Effects and Tolerability in Autism Spectrum Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 618-624.	0.7	12
1384	Patients' subjective rating of mental health improvement in a randomised controlled trial. <i>Psychiatry Research</i> , 2015, 229, 593-595.	1.7	5
1385	Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong. <i>Schizophrenia Research</i> , 2015, 168, 99-105.	1.1	24
1386	Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. <i>BMC Psychiatry</i> , 2015, 15, 97.	1.1	41
1387	Problems in remembering to carry out future actions in first-episode schizophrenia: Primary or secondary impairment?. <i>Journal of Psychiatric Research</i> , 2015, 61, 141-149.	1.5	19
1388	A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. <i>Psychiatry Research</i> , 2015, 225, 14-30.	1.7	181
1389	Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 449-459.	2.3	65
1390	Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 900-908.	2.3	17
1391	Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach. <i>Psychiatric Quarterly</i> , 2015, 86, 107-121.	1.1	1
1392	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 69-75.	2.5	29
1393	Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: A randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. <i>Journal of Psychopharmacology</i> , 2015, 29, 69-79.	2.0	5
1394	An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 9, 198-208.	1.4	18
1395	Overview of Short-Term and Long-Term Safety of Brexpiprazole in Patients with Major Depressive Disorder and Inadequate Response to Antidepressant Treatment. <i>Current Psychiatry Reviews</i> , 2016, 12, 278-290.	0.9	18
1396	Comments on Lucire and Crotty, 2011. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, Volume 9, 85-87.	0.4	0
1397	Heavy Alcohol Drinking Associated Akathisia and Management with Quetiapine XR in Alcohol Dependent Patients. <i>Journal of Addiction</i> , 2016, 2016, 1-7.	0.9	6
1398	A case study of SMART attributes: a qualitative assessment of generalizability, retention rate, and trial quality. <i>Trials</i> , 2016, 17, 242.	0.7	9
1399	Schizophrenia Spectrum Disorders Show Reduced Specificity and Less Positive Events in Mental Time Travel. <i>Frontiers in Psychology</i> , 2016, 7, 1121.	1.1	18

#	ARTICLE	IF	CITATIONS
1400	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2095-2104.	1.0	3
1401	Efficacy and Safety of Levosulpiride Versus Haloperidol Injection in Patients With Acute Psychosis: A Randomized Double-Blind Study. <i>Clinical Neuropharmacology</i> , 2016, 39, 197-200.	0.2	6
1402	Studying medication adherence in patients with schizophrenia. <i>Middle East Current Psychiatry</i> , 2016, 23, 27-34.	0.5	5
1403	Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis. <i>CNS Drugs</i> , 2016, 30, 807-818.	2.7	36
1404	LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY. <i>Depression and Anxiety</i> , 2016, 33, 424-434.	2.0	58
1405	Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 130-140.	0.7	37
1406	The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 192-201.	0.9	46
1407	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 40.	3.8	327
1408	Examining gender difference in adult-onset psychosis in Hong Kong. <i>Microbial Biotechnology</i> , 2016, 10, 324-333.	0.9	19
1409	Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. <i>OMICS A Journal of Integrative Biology</i> , 2016, 20, 283-289.	1.0	17
1410	The ± 7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study. <i>Neuropsychopharmacology</i> , 2016, 41, 2893-2902.	2.8	29
1411	Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE). <i>BMJ Open</i> , 2016, 6, e011020.	0.8	10
1413	Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. <i>Brain and Behavior</i> , 2016, 6, e00520.	1.0	16
1414	Risperidone versus placebo for schizophrenia. <i>The Cochrane Library</i> , 2016, 12, CD006918.	1.5	24
1415	AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. <i>Schizophrenia Research</i> , 2016, 172, 152-157.	1.1	60
1416	Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. <i>Schizophrenia Research</i> , 2016, 174, 93-98.	1.1	49
1417	Predictive Motor Timing and the Cerebellar Vermis in Schizophrenia: An fMRI Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 1517-1527.	2.3	18
1418	Effects of antipsychotics on cortisol, interleukin-6 and hippocampal perfusion in healthy volunteers. <i>Schizophrenia Research</i> , 2016, 174, 99-105.	1.1	34

#	ARTICLE	IF	CITATIONS
1419	Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 469-478.	0.3	37
1420	Cariprazine in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 61-68.	0.9	56
1421	Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis. <i>Schizophrenia Research</i> , 2016, 174, 144-149.	1.1	30
1422	Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. <i>Journal of Psychiatric Research</i> , 2016, 78, 86-93.	1.5	48
1423	Neurological soft signs and cognitive functions: Amongst euthymic bipolar I disorder cases, non-affected first degree relatives and healthy controls. <i>Asian Journal of Psychiatry</i> , 2016, 22, 53-59.	0.9	8
1424	Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study. <i>Schizophrenia Research</i> , 2016, 174, 120-125.	1.1	17
1425	Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 498-502.	0.7	17
1427	Assessing and Reporting the Adverse Effects of Antipsychotic Medication. <i>Clinical Neuropharmacology</i> , 2016, 39, 29-39.	0.2	26
1428	Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study. <i>Psychopharmacology</i> , 2016, 233, 4003-4010.	1.5	7
1429	Neural correlates of prospective memory impairments in schizophrenia.. <i>Neuropsychology</i> , 2016, 30, 169-180.	1.0	12
1430	Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw122.	2.3	50
1431	Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. <i>Psychopharmacology</i> , 2016, 233, 3803-3813.	1.5	11
1432	A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 922-934.	0.7	16
1433	Determinants of cerebral hemodynamics during the Trail Making Test in schizophrenia. <i>Brain and Cognition</i> , 2016, 109, 96-104.	0.8	10
1434	Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial. <i>Schizophrenia Research</i> , 2016, 176, 231-238.	1.1	14
1435	Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw076.	1.0	51
1436	The effect and mechanisms of implementation intention in improving prospective memory performance in schizophrenia patients. <i>Psychiatry Research</i> , 2016, 244, 86-93.	1.7	16
1437	Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. <i>Psychopharmacology</i> , 2016, 233, 3503-3512.	1.5	101

#	ARTICLE	IF	CITATIONS
1438	Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. <i>Schizophrenia Research</i> , 2016, 176, 264-271.	1.1	80
1439	Haloperidol plus promethazine for psychosis-induced aggression. <i>The Cochrane Library</i> , 2016, 2016, CD005146.	1.5	51
1440	Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women. <i>JAMA Psychiatry</i> , 2016, 73, 947.	6.0	74
1441	Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. <i>CNS Spectrums</i> , 2016, 21, 393-402.	0.7	28
1442	Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw087.	1.0	15
1443	Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 597-607.	0.7	13
1444	Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder. <i>BMC Psychiatry</i> , 2016, 16, 448.	1.1	41
1445	Movement Disorders in Adults With Intellectual Disability and Behavioral Problems Associated With Use of Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 308-313.	0.7	13
1446	Incidence of Antipsychotic-Associated Side Effects. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 593-596.	0.7	4
1447	Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). <i>International Clinical Psychopharmacology</i> , 2016, 31, 323-331.	0.9	14
1448	The effect of brexpiprazole in adult outpatients with early-episode schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 307-314.	0.9	9
1449	Antiglucocorticoid and related treatments for psychosis. <i>The Cochrane Library</i> , 2016, 2016, CD006995.	1.5	13
1450	Aripiprazole for autism spectrum disorders (ASD). <i>The Cochrane Library</i> , 2016, 2016, CD009043.	1.5	92
1451	Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. <i>Journal of Affective Disorders</i> , 2016, 204, 40-47.	2.0	13
1452	Effects of aripiprazole and haloperidol on neural activation during the n-back in healthy individuals: A functional MRI study. <i>Schizophrenia Research</i> , 2016, 173, 174-181.	1.1	20
1453	The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model. <i>Psychiatry Research</i> , 2016, 238, 33-39.	1.7	7
1454	Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC. <i>Quality of Life Research</i> , 2016, 25, 925-934.	1.5	12
1455	Hemodynamic response function abnormalities in schizophrenia during a multisensory detection task. <i>Human Brain Mapping</i> , 2016, 37, 745-755.	1.9	21

#	ARTICLE	IF	CITATIONS
1456	Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase I, single-dose, randomized, open-label study. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 330-339.	1.0	63
1457	Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyrimal Symptoms in Risperidone-Treated Youth. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 471-477.	0.7	10
1458	Risperidone (depot) for schizophrenia. <i>The Cochrane Library</i> , 2016, 4, CD004161.	1.5	16
1459	Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. <i>Journal of Substance Abuse Treatment</i> , 2016, 62, 84-88.	1.5	25
1460	Neuronal substrate and effective connectivity of abnormal movement sequencing in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 67, 1-9.	2.5	8
1461	An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 271-281.	4.0	154
1463	Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. <i>Research in Developmental Disabilities</i> , 2016, 49-50, 13-21.	1.2	47
1464	Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies. <i>European Psychiatry</i> , 2016, 31, 13-19.	0.1	17
1465	A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. <i>Journal of Psychopharmacology</i> , 2016, 30, 69-77.	2.0	43
1466	An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. <i>Alcohol</i> , 2016, 53, 45-50.	0.8	12
1467	Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 1153-1163.	1.7	70
1468	Brexipiprazole: so far so good. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 39-54.	1.2	53
1469	Safety and Tolerability of Antipsychotics. , 2016, , 167-189.		2
1470	Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. <i>Journal of Affective Disorders</i> , 2016, 190, 103-110.	2.0	29
1471	Antipsychotic medication side effect assessment tools: A systematic review. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 399-409.	1.3	21
1472	The SWITCH study: rationale and design of the trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 513-521.	1.8	7
1473	Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 357-368.	1.3	72
1474	A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. <i>Schizophrenia Research</i> , 2017, 185, 80-87.	1.1	12

#	ARTICLE	IF	CITATIONS
1475	Brexiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. <i>Acta Neuropsychiatrica</i> , 2017, 29, 278-290.	1.0	22
1476	Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 4-20.	1.0	18
1477	Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis. <i>Psychiatry Research</i> , 2017, 249, 39-45.	1.7	13
1478	Lower limb flexor reflex: Comparisons between drug-induced akathisia and restless legs syndrome. <i>Neuroscience Letters</i> , 2017, 641, 40-44.	1.0	6
1479	The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 52-65.	0.7	21
1480	Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2017, 189, 126-133.	1.1	32
1481	Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Schizophrenia Research</i> , 2017, 189, 4-8.	1.1	11
1482	Tardive Dyskinesia: A Historical Perspective. <i>Journal of Psychiatric Practice</i> , 2017, 23, 121-129.	0.3	10
1483	Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. <i>Psychiatry Research</i> , 2017, 254, 112-117.	1.7	27
1484	Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. <i>Neuropsychopharmacology</i> , 2017, 42, 2259-2271.	2.8	28
1485	Aripiprazole for cocaine abstinence: a randomized controlled trial with ecological momentary assessment. <i>Behavioural Pharmacology</i> , 2017, 28, 63-73.	0.8	23
1486	Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors. <i>Asian Journal of Psychiatry</i> , 2017, 29, 148-153.	0.9	6
1487	A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 394-400.	0.7	28
1488	Low-Frequency rTMS Ameliorates Akathisia During Pregnancy. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2017, 29, 409-410.	0.9	7
1489	Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. <i>Psychopharmacology</i> , 2017, 234, 2563-2570.	1.5	27
1490	Assessments of plasma concentrations, pathology symptoms, and cognition following paliperidone treatment in schizophrenic patients previously treated with risperidone. <i>Asian Journal of Psychiatry</i> , 2017, 26, 56-57.	0.9	0
1491	Effectiveness, efficiency and efficacy in the multidimensional treatment of schizophrenia: Rethinking project. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017, 10, 4-20.	0.2	7
1492	Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 9.	0.8	20

#	ARTICLE	IF	CITATIONS
1493	Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. <i>Journal of Affective Disorders</i> , 2017, 215, 205-212.	2.0	21
1494	KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. <i>American Journal of Psychiatry</i> , 2017, 174, 476-484.	4.0	339
1495	Effects of aripiprazole and haloperidol on neural activation during a simple motor task in healthy individuals: A functional MRI study. <i>Human Brain Mapping</i> , 2017, 38, 1833-1845.	1.9	1
1496	Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control. <i>CNS Spectrums</i> , 2017, 22, 333-341.	0.7	24
1497	Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw171.	2.3	21
1498	Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. <i>Journal of Psychiatric Research</i> , 2017, 95, 299-307.	1.5	5
1499	Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. <i>BMJ Open</i> , 2017, 7, e017406.	0.8	63
1500	A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 702-707.	0.7	12
1501	Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) Serbian Language version: Inter-rater and Test-retest Reliability. <i>Scientific Reports</i> , 2017, 7, 8105.	1.6	6
1502	Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial. <i>European Neuropsychopharmacology</i> , 2017, 27, 959-969.	0.3	17
1503	Brainstem reflexes are hyperactive in patients with drug-induced akathisia. <i>Neurological Sciences</i> , 2017, 38, 1683-1689.	0.9	7
1504	Extrapyramidal symptoms in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 225-230.	0.9	3
1505	Physical Health and Drug Safety in Individuals with Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 673-683.	0.9	22
1506	A Double-Blind and Placebo-Controlled Trial of Aripiprazole in Symptomatic Youths at Genetic High Risk for Bipolar Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 864-874.	0.7	23
1507	Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). <i>The Cochrane Library</i> , 2017, 2017, CD009377.	1.5	73
1508	Multimodal Neuroimaging in Schizophrenia: Description and Dissemination. <i>Neuroinformatics</i> , 2017, 15, 343-364.	1.5	131
1509	Antipsychotic combinations for schizophrenia. <i>The Cochrane Library</i> , 2017, 2017, CD009005.	1.5	28
1510	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. <i>JAMA Neurology</i> , 2017, 74, 977.	4.5	209

#	ARTICLE	IF	CITATIONS
1511	Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, 865-876.	0.3	41
1512	Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2017, 56, 784-792.	0.3	21
1513	Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 319-328.	0.9	50
1514	Lurasidone for the treatment of irritability and anger in autism spectrum disorders. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 985-989.	1.9	13
1515	Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 332-339.	2.5	31
1516	High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 231-238.	0.7	22
1517	An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. <i>Psychiatric Services</i> , 2017, 68, 271-277.	1.1	20
1518	Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. <i>Psychopharmacology</i> , 2017, 234, 199-209.	1.5	45
1519	Pharmacokinetics and Safety Assessment of <i>l</i> -Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 151-160.	1.0	23
1520	Coupled HMM-based multimodal fusion for mood disorder detection through elicited audio-visual signals. <i>Journal of Ambient Intelligence and Humanized Computing</i> , 2017, 8, 895-906.	3.3	24
1521	One patient with schizophrenia showed reduced drug-induced extrapyramidal symptoms as a result of an alternative regimen of treatment with paliperidone 3 and 6 mg every other day. <i>SAGE Open Medical Case Reports</i> , 2017, 5, 2050313X1774283.	0.2	1
1522	Efectos secundarios de la medicaci3n antipsic3tica y calidad de vida en pacientes con esquizofrenia latinoamericanos. <i>Terapia Psicol3gica</i> , 2017, 35, 111-114.	0.2	1
1523	Risk-Confering Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 79.	1.3	19
1524	Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2045-2056.	1.0	10
1525	Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2021-2035.	1.0	9
1526	Evidence and consensus recommendations for the pharmacological management of pain in India. <i>Journal of Pain Research</i> , 2017, Volume 10, 709-736.	0.8	21
1527	Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 295-304.	1.0	28
1528	The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. <i>BMC Psychiatry</i> , 2017, 17, 305.	1.1	49

#	ARTICLE	IF	CITATIONS
1529	Rating Scales in Movement Disorders, 2017, . . .		0
1530	Medication nonadherence among South American patients with schizophrenia. Patient Preference and Adherence, 2017, Volume 11, 1737-1744.	0.8	10
1531	A protocol in action: Recovery approach for patients within high secure care: A 20+ year follow-up. Health Science Reports, 2018, 1, e21.	0.6	3
1532	The Assessment and Treatment of Antipsychotic-Induced Akathisia. Canadian Journal of Psychiatry, 2018, 63, 719-729.	0.9	48
1533	Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder. Psychiatry and Clinical Neurosciences, 2018, 72, 591-601.	1.0	12
1534	Depressive symptoms in Chinese male inpatients with schizophrenia: Prevalence and clinical correlates. Psychiatry Research, 2018, 264, 380-384.	1.7	25
1535	The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology, 2018, 235, 1923-1932.	1.5	162
1536	Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. Journal of Psychopharmacology, 2018, 32, 533-540.	2.0	19
1537	A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. International Journal of Neuropsychopharmacology, 2018, 21, 433-441.	1.0	37
1538	Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. The Cochrane Library, 2018, 2, CD000459.	1.5	21
1539	Selective noradrenaline reuptake inhibitors for schizophrenia. The Cochrane Library, 2018, 2018, CD010219.	1.5	8
1540	Vitamin E for antipsychotic-induced tardive dyskinesia. The Cochrane Library, 2018, 1, CD000209.	1.5	13
1541	Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Current Medical Research and Opinion, 2018, 34, 633-642.	0.9	44
1542	Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. The Cochrane Library, 2018, 2018, CD011057.	1.5	15
1543	Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia. International Clinical Psychopharmacology, 2018, 33, 155-162.	0.9	11
1544	Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). The Cochrane Library, 2018, 4, CD009412.	1.5	23
1545	Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry, 2018, 5, 432-442.	3.7	97
1546	Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectrums, 2018, 23, 39-50.	0.7	48

#	ARTICLE	IF	CITATIONS
1547	The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 529-540.	1.8	10
1548	Psychopharmacologic treatment of in-patients with schizophrenia: comparing forensic and general psychiatry. <i>Journal of Forensic Psychiatry and Psychology</i> , 2018, 29, 1-15.	0.6	9
1549	Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 396-404.	1.3	18
1550	Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 74-80.	1.0	28
1551	Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. <i>Schizophrenia Research</i> , 2018, 195, 122-129.	1.1	3
1552	Combining actigraphy, ecological momentary assessment and neuroimaging to study apathy in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 195, 176-182.	1.1	58
1553	Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 150-159.	0.6	12
1554	Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India – a cross-sectional study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 101-108.	1.2	6
1555	The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. <i>Journal of Affective Disorders</i> , 2018, 225, 350-356.	2.0	26
1556	Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2018, 193, 29-36.	1.1	15
1557	Prediction of self-stigma in early psychosis: 3-Year follow-up of the randomized-controlled trial on extended early intervention. <i>Schizophrenia Research</i> , 2018, 195, 463-468.	1.1	26
1558	Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 356-366.	2.5	27
1559	Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning. <i>Schizophrenia Research</i> , 2018, 200, 97-103.	1.1	36
1560	Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?. <i>Psychiatry Research</i> , 2018, 263, 238-244.	1.7	13
1561	Motor abnormalities and cognitive impairment in first-episode psychosis patients, their unaffected siblings and healthy controls. <i>Schizophrenia Research</i> , 2018, 200, 50-55.	1.1	23
1562	A 6-week, multicenter, double-blind, double-dummy, chlorpromazine-controlled non-inferiority randomized phase III trial to evaluate the efficacy and safety of quetiapine fumarate (SEROQUEL) extended-release (XR) in the treatment of patients with schizophrenia and acute episodes. <i>Psychiatry Research</i> , 2018, 259, 117-124.	1.7	2
1563	Investigating the predictors of happiness, life satisfaction and success in schizophrenia. <i>Comprehensive Psychiatry</i> , 2018, 81, 42-47.	1.5	23
1564	A longitudinal analysis of the effects of neuroticism and extraversion on subjective well-being in patients with schizophrenia. <i>Psychiatry Research</i> , 2018, 259, 538-544.	1.7	12

#	ARTICLE	IF	CITATIONS
1565	A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2018, 33, 79-87.	0.9	11
1566	Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 3179-3184.	1.0	1
1567	Efficacy of adjunctive low-dose cariprazine in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2018, 33, 312-321.	0.9	37
1568	Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. <i>BJPsych Open</i> , 2018, 4, 404-410.	0.3	3
1569	Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. <i>International Journal of Bipolar Disorders</i> , 2018, 6, 14.	0.8	15
1570	Rapid agitation control with ketamine in the emergency department (RACKED): a randomized controlled trial protocol. <i>Trials</i> , 2018, 19, 651.	0.7	5
1571	Prevalence and clinicians' awareness of psychiatric comorbidities among first episode schizophrenia. <i>Microbial Biotechnology</i> , 2018, 12, 1128-1136.	0.9	6
1572	Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS): Rationale, Design, and Characteristics. <i>Frontiers in Psychiatry</i> , 2018, 9, 662.	1.3	2
1573	Translation and cultural adaptation of Glasgow Antipsychotic Side-effects Scale (GASS) in Arabic. <i>PLoS ONE</i> , 2018, 13, e0201225.	1.1	7
1574	The general facilitation effect of implementation intentions on prospective memory performance in patients with schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2018, 23, 350-363.	0.7	7
1575	Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. <i>International Journal of Physical Medicine & Rehabilitation</i> , 2018, 06, .	0.5	0
1576	Correlates of sleep irregularity in schizophrenia. <i>Psychiatry Research</i> , 2018, 270, 705-714.	1.7	27
1577	Very Low-Dose Mirtazapine (7.5 mg) in Treatment of Acute Antipsychotic-Associated Akathisia. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 609-611.	0.7	9
1578	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 1090-1101.	1.0	16
1579	No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2018, 9, 349.	1.3	5
1580	Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. <i>Psychiatry Research</i> , 2018, 269, 746-752.	1.7	17
1581	Efficacy and Safety of Atypical Antipsychotics in Bipolar Disorder With Comorbid Substance Dependence: A Systematic Review. <i>Clinical Neuropharmacology</i> , 2018, 41, 181-191.	0.2	8
1582	The validity and sensitivity of PANSS in treatment-resistant schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 420-431.	2.2	17

#	ARTICLE	IF	CITATIONS
1583	White matter integrity associated with severity reductions in positive symptoms after amisulpride treatment in drug-free patients with schizophrenia. <i>Neuroscience Letters</i> , 2018, 685, 131-136.	1.0	8
1584	Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 701-712.	1.0	8
1585	Impaired Midline Theta Power and Connectivity During Proactive Cognitive Control in Schizophrenia. <i>Biological Psychiatry</i> , 2018, 84, 675-683.	0.7	43
1586	Objective investigation of activity preference in schizophrenia: A pilot study. <i>Psychiatry Research</i> , 2018, 267, 551-559.	1.7	1
1587	Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review. <i>Frontiers in Neurology</i> , 2018, 9, 435.	1.1	7
1588	Isolated vocal akathisia—Does it exist?. <i>Asian Journal of Psychiatry</i> , 2018, 36, 64-65.	0.9	0
1589	Incidence of akathisia after postoperative nausea and vomiting prophylaxis with droperidol and ondansetron in outpatient surgery. <i>European Journal of Anaesthesiology</i> , 2018, 35, 966-971.	0.7	8
1590	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011883.	1.5	8
1591	The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. <i>Journal of Affective Disorders</i> , 2018, 241, 425-432.	2.0	12
1592	Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1403-1410.	1.3	13
1593	Mirtazapine adjunct for people with schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011943.	1.5	5
1594	Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquilisation. <i>Journal of Psychopharmacology</i> , 2018, 32, 601-640.	2.0	38
1595	Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths. <i>JAMA Psychiatry</i> , 2018, 75, 788.	6.0	54
1596	Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 185-197.	1.2	11
1597	Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 317-326.	0.7	25
1598	Longitudinal association between motor and obsessive compulsive symptoms in patients with psychosis and their unaffected siblings. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 257-268.	1.8	5
1600	Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 622.	3.8	53
1601	Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 43-53.	0.9	19

#	ARTICLE	IF	CITATIONS
1602	Patterns of altered brain structure and function underlying neurological soft signs in schizophrenia spectrum disorders. <i>Human Brain Mapping</i> , 2019, 40, 5029-5041.	1.9	28
1603	Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 269-276.	1.4	22
1604	Effects of Tobacco Smoking Status on Verbal Learning and Memory in Patients With Schizophrenia and Non-Psychiatric Controls. <i>American Journal on Addictions</i> , 2019, 28, 503-511.	1.3	4
1605	Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. <i>Journal of Psychiatric Research</i> , 2019, 117, 1-6.	1.5	7
1606	Mind wandering in schizophrenia: A thought-sampling study. <i>Consciousness and Cognition</i> , 2019, 74, 102774.	0.8	6
1607	Implications of Antipsychotic Use. <i>Nursing Clinics of North America</i> , 2019, 54, 595-608.	0.7	7
1608	Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE). <i>European Neuropsychopharmacology</i> , 2019, 29, 1397-1407.	0.3	14
1609	Efficacy of low-dose D ₂ /D ₃ -partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2195-2203.	1.0	5
1610	The remediation effects of working memory training in schizophrenia patients with prominent negative symptoms. <i>Cognitive Neuropsychiatry</i> , 2019, 24, 434-453.	0.7	6
1611	The nature of bradykinesia in schizophrenia treated with antipsychotics. <i>Psychiatry Research</i> , 2019, 273, 537-543.	1.7	6
1612	Aripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: Protocol for the VERBATIM randomized controlled trial. <i>Microbial Biotechnology</i> , 2019, 13, 1373-1381.	0.9	10
1613	Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia. <i>Journal of Affective Disorders</i> , 2019, 246, 745-753.	2.0	19
1614	A customized adherence enhancement program combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania: A pilot study methodological report. <i>Heliyon</i> , 2019, 5, e01763.	1.4	4
1615	A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 203-209.	0.7	15
1616	Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2019, 209, 50-57.	1.1	27
1617	Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia. <i>Neurology and Therapy</i> , 2019, 8, 215-230.	1.4	16
1618	Facets of shared decision-making on drug treatment for adults with an eating disorder. <i>International Review of Psychiatry</i> , 2019, 31, 332-346.	1.4	9
1619	Diagnostic and symptom interviews for adults. , 2019, , 355-393.		2

#	ARTICLE	IF	CITATIONS
1620	Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1917-1924.	2.8	24
1621	Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. <i>American Journal of Psychiatry</i> , 2019, 176, 439-448.	4.0	85
1622	A pilot study of brexpiprazole for bipolar depression. <i>Journal of Affective Disorders</i> , 2019, 249, 315-318.	2.0	25
1623	A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 620-627.	0.7	20
1624	Interventions for prodromal stage of psychosis. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	43
1625	Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2019, 34, 76-83.	0.9	170
1626	Effects of 6-Week Use of Very Low Nicotine Content Cigarettes in Smokers With Serious Mental Illness. <i>Nicotine and Tobacco Research</i> , 2019, 21, S38-S45.	1.4	33
1627	Measuring process indicators and adverse events to assess the quality of care for inpatients with psychosis. <i>Journal of Mental Health</i> , 2021, 30, 564-570.	1.0	0
1628	Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 428-433.	0.7	14
1629	Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 597-603.	0.7	7
1630	Compliance in schizophrenia spectrum disorders. <i>International Clinical Psychopharmacology</i> , 2019, 34, 298-304.	0.9	6
1631	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 550-560.	0.7	10
1632	Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 153-157.	0.7	8
1633	Model-Guided Antipsychotic Dose Reduction in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 329-335.	0.7	14
1634	A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. <i>Acta Neuropsychiatrica</i> , 2019, 31, 27-35.	1.0	21
1635	A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16-week randomized placebo-controlled trial for participants concurrently treated with risperidone. <i>Schizophrenia Research</i> , 2019, 204, 295-303.	1.1	52
1636	Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. <i>Schizophrenia Research</i> , 2019, 204, 282-288.	1.1	39
1637	Anticipatory pleasure for future rewards is attenuated in patients with schizophrenia but not in individuals with schizotypal traits. <i>Schizophrenia Research</i> , 2019, 206, 118-126.	1.1	15

#	ARTICLE	IF	CITATIONS
1638	A prospective study of adverse effects of antipsychotics in adolescents with schizophrenia during a 6-month follow-up. <i>International Clinical Psychopharmacology</i> , 2019, 34, 33-36.	0.9	1
1639	Machine learning for predicting psychotic relapse at 2-5 years in schizophrenia in the national FACE-SZ cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 8-18.	2.5	27
1640	The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. <i>Journal of Affective Disorders</i> , 2019, 246, 217-223.	2.0	7
1641	Reward-driven decision-making impairments in schizophrenia. <i>Schizophrenia Research</i> , 2019, 206, 277-283.	1.1	26
1642	Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. <i>Psychopharmacology</i> , 2019, 236, 723-730.	1.5	6
1643	Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. <i>Schizophrenia Research</i> , 2019, 206, 400-406.	1.1	9
1644	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 598-605.	2.8	207
1645	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 226-234.	2.5	12
1646	Clinical utility of the dual n-back task in schizophrenia: A functional imaging approach. <i>Psychiatry Research - Neuroimaging</i> , 2019, 284, 37-44.	0.9	16
1647	Implementation intention training for prospective memory in schizophrenia: A 3-month follow-up study. <i>Schizophrenia Research</i> , 2019, 206, 378-385.	1.1	8
1648	Predicting first-episode psychosis patients who will never relapse over 10 years. <i>Psychological Medicine</i> , 2019, 49, 2206-2214.	2.7	22
1649	Cross-sectional examination of extrapyramidal side effects in a specialist palliative care inpatient unit. <i>BMJ Supportive and Palliative Care</i> , 2019, 9, 271-273.	0.8	1
1650	Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later. <i>CNS Drugs</i> , 2019, 33, 1-8.	2.7	13
1651	Using an Integrated Care Pathway for Late-Life Schizophrenia Improves Monitoring of Adverse Effects of Antipsychotics and Reduces Antipsychotic Polypharmacy. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 84-90.	0.6	6
1652	Detecting Unipolar and Bipolar Depressive Disorders from Elicited Speech Responses Using Latent Affective Structure Model. <i>IEEE Transactions on Affective Computing</i> , 2020, 11, 393-404.	5.7	24
1653	Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. <i>Neuropharmacology</i> , 2020, 168, 107634.	2.0	48
1654	Cell-Coupled Long Short-Term Memory With $\Delta\Delta$ -Skip Fusion Mechanism for Mood Disorder Detection Through Elicited Audiovisual Features. <i>IEEE Transactions on Neural Networks and Learning Systems</i> , 2020, 31, 124-135.	7.2	13
1655	Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 383-400.	0.6	57

#	ARTICLE	IF	CITATIONS
1656	Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. <i>Bipolar Disorders</i> , 2020, 22, 372-384.	1.1	201
1657	Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 308-316.	1.3	14
1658	Subjective-Objective Sleep Discrepancy in Schizophrenia. <i>Behavioral Sleep Medicine</i> , 2020, 18, 653-667.	1.1	11
1659	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. <i>Child and Adolescent Mental Health</i> , 2020, 25, 79-94.	1.8	0
1660	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 349.	6.0	226
1661	Metformin addition vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. <i>World Psychiatry</i> , 2020, 19, 69-80.	4.8	68
1662	Revisiting anticipatory hedonic processing in patients with schizophrenia: An examination between representation activation and maintenance. <i>Schizophrenia Research</i> , 2020, 216, 138-146.	1.1	3
1663	A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. <i>Journal of Affective Disorders</i> , 2020, 263, 386-395.	2.0	18
1664	Neurological soft signs in schizophrenia spectrum disorders are not confounded by current antipsychotic dosage. <i>European Neuropsychopharmacology</i> , 2020, 31, 47-57.	0.3	5
1665	Randomized, double-blind, 6-week non-inferiority study of lurasidone and risperidone for the treatment of schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 336-343.	1.0	9
1666	Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. <i>Neuropsychopharmacology</i> , 2020, 45, 887-901.	2.8	41
1667	Psychotic Disorders. <i>Current Clinical Psychiatry</i> , 2020, , .	0.2	7
1668	The effect of implementation intentions on prospective memory performance in patients with schizophrenia: A multinomial modeling approach. <i>Schizophrenia Research</i> , 2020, 215, 120-125.	1.1	5
1669	Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093757.	1.2	10
1670	Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study. <i>CNS Spectrums</i> , 2022, 27, 118-128.	0.7	11
1671	Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial. <i>BJPsych Open</i> , 2020, 6, e126.	0.3	3
1672	Efficacy and safety of once-monthly Risperidone ISM ^Â in schizophrenic patients with an acute exacerbation. <i>NPJ Schizophrenia</i> , 2020, 6, 37.	2.0	15
1673	Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <i>American Journal of Psychiatry</i> , 2020, 177, 1168-1178.	4.0	72

#	ARTICLE	IF	CITATIONS
1674	L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	0.9	0
1675	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2020, 2020, CD008016.	1.5	56
1676	Structural Connectivity-Based Parcellation of the Dopaminergic Midbrain in Healthy Subjects and Schizophrenic Patients. <i>Medicina (Lithuania)</i> , 2020, 56, 686.	0.8	4
1677	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1439-1458.	2.3	22
1678	Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study. <i>BMC Psychiatry</i> , 2020, 20, 199.	1.1	11
1679	Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. <i>CNS Spectrums</i> , 2020, 26, 1-10.	0.7	13
1680	Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2020, 301, 111085.	0.9	11
1681	Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis. <i>Journal of Psychopharmacology</i> , 2020, 34, 914-919.	2.0	3
1682	Psychiatric Emergencies for Clinicians: Emergency Department Management of Acute Drug-Induced Akathisia. <i>Journal of Emergency Medicine</i> , 2020, 58, 922-926.	0.3	2
1683	Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference. <i>Journal of Psychopharmacology</i> , 2020, 34, 820-828.	2.0	12
1684	Validation and extension of the Motivation and Pleasure Scale-Self Report (MAP-SR) across the schizophrenia spectrum in the Chinese context. <i>Asian Journal of Psychiatry</i> , 2020, 49, 101971.	0.9	12
1685	Moving forward: distinct sensorimotor abnormalities predict clinical outcome after 6 months in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2020, 36, 72-82.	0.3	13
1686	To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. <i>Trials</i> , 2020, 21, 147.	0.7	41
1687	Using accelerometer as a diagnostic tool to detect drug-induced parkinsonism (DIP) secondary to first-generation anti-psychotic medications. <i>Australasian Psychiatry</i> , 2020, 28, 348-353.	0.4	5
1688	Measurement based care in schizophrenia – Feasibility in routine clinical practice. <i>Asian Journal of Psychiatry</i> , 2020, 49, 101954.	0.9	6
1689	Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia. <i>Acta Neuropsychiatrica</i> , 2020, 32, 153-158.	1.0	7
1690	Pharmacological intervention for people at risk of psychotic disorder. , 2020, , 371-381.		1
1691	Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders. <i>Journal of Dual Diagnosis</i> , 2020, 16, 208-217.	0.7	10

#	ARTICLE	IF	CITATIONS
1692	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 217-229.	1.0	40
1693	Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence. <i>Pharmacotherapy</i> , 2020, 40, 565-574.	1.2	18
1694	Proxy WHO Disability Assessment Schedule 2.0 Is Clinically Useful for Assessing Psychosocial Functioning in Severe Mental Illness. <i>Frontiers in Psychiatry</i> , 2020, 11, 303.	1.3	11
1695	Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. <i>International Clinical Psychopharmacology</i> , 2020, 35, 147-156.	0.9	21
1696	HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2345.	1.8	16
1697	Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. <i>Frontiers in Psychiatry</i> , 2020, 11, 237.	1.3	5
1698	Drug-Drug-Induced Akathisia: Two Case Reports. <i>Case Reports in Psychiatry</i> , 2020, 2020, 1-5.	0.2	1
1699	Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 240-249.	0.7	30
1700	A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD. <i>Journal of Attention Disorders</i> , 2020, 25, 108705472090908.	1.5	4
1701	Discerning undifferentiated anxiety from syndromal anxiety in acute-phase schizophrenia. <i>Annals of General Psychiatry</i> , 2020, 19, 26.	1.2	7
1702	A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. <i>New England Journal of Medicine</i> , 2020, 382, 1497-1506.	13.9	192
1703	Neurological Signs at the First Psychotic Episode as Correlates of Long-Term Outcome: Results From the AESOP-10 Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 118-127.	2.3	20
1704	Towards safer risperidone prescribing in Alzheimer's disease. <i>British Journal of Psychiatry</i> , 2021, 218, 268-275.	1.7	9
1705	Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST report. <i>Depression and Anxiety</i> , 2021, 38, 185-195.	2.0	4
1706	Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 25-30.	0.7	12
1707	Stability of Verbal Fluency in Outpatients with Schizophrenia. <i>Psychiatry Research</i> , 2021, 295, 113528.	1.7	5
1708	Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study. <i>Neurology and Therapy</i> , 2021, 10, 121-147.	1.4	4
1709	Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. <i>Frontiers in Neurology</i> , 2020, 11, 610614.	1.1	5

#	ARTICLE	IF	CITATIONS
1710	First-Episode & Early Psychosis in Transition-Age Youth. , 2021, , 277-310.		0
1711	Akathisia. , 2021, , 133-133.		0
1712	Safety and tolerability of lumateperone 42Âmg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophrenia Research, 2021, 228, 198-205.	1.1	16
1713	Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 555-565.	1.0	16
1714	Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 236-251.	0.3	42
1715	A Network of Psychopathological, Cognitive, and Motor Symptoms in Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2021, 47, 915-926.	2.3	16
1716	Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics. Clinical Psychopharmacology and Neuroscience, 2021, 19, 117-124.	0.9	6
1717	Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial. Schizophrenia Bulletin, 2021, 47, 1108-1115.	2.3	24
1718	Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. New England Journal of Medicine, 2021, 384, 717-726.	13.9	136
1719	Prospective Long-Term Cohort Study of Subjects With First-Episode Psychosis Examining Eight Major Outcome Domains and Their Predictors: Study Protocol. Frontiers in Psychiatry, 2021, 12, 643112.	1.3	12
1720	Measurement of Motivation States for Physical Activity and Sedentary Behavior: Development and Validation of the CRAVE Scale. Frontiers in Psychology, 2021, 12, 568286.	1.1	13
1721	Characteristics and outcomes of patients admitted to the first psychiatric intensive care unit in Egypt. South African Journal of Psychiatry, 2021, 27, 1527.	0.2	1
1722	Protocol of guided antipsychotic reduction to reach minimum effective dose (<sc>GARMED</sc>) in patients with remitted psychosis based on pragmatic design. Microbial Biotechnology, 2022, 16, 178-185.	0.9	7
1723	Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 957-970.	1.0	25
1724	Dynamic Attention Regulation for Prospective Goals in Schizophrenia. Clinical Psychological Science, 2021, 9, 1035-1044.	2.4	2
1725	Effect of Varenicline on Tardive Dyskinesia: A Pilot Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 355-360.	0.9	1
1726	Different trajectories of neurological soft signs progression between treatment-responsive and treatment-resistant schizophrenia patients. Journal of Psychiatric Research, 2021, 138, 607-614.	1.5	4
1727	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. European Neuropsychopharmacology, 2021, 47, 74-85.	0.3	7

#	ARTICLE	IF	CITATIONS
1728	Increased Glutamate Plus Glutamine in the Right Middle Cingulate in Early Schizophrenia but Not in Bipolar Psychosis: A Whole Brain 1H-MRS Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 660850.	1.3	8
1729	Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2021, 288, 191-198.	2.0	7
1730	Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features. <i>Schizophrenia Research</i> , 2022, 243, 364-371.	1.1	34
1731	Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia. <i>BJPsych Open</i> , 2021, 7, e121.	0.3	3
1732	Psychopathological Symptom Load and Distinguishable Cerebral Blood Flow Velocity Patterns in Patients With Schizophrenia and Healthy Controls: A Functional Transcranial Doppler Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 679021.	1.3	6
1733	A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. <i>Schizophrenia Research</i> , 2021, 232, 45-53.	1.1	25
1734	Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese. <i>Frontiers in Psychiatry</i> , 2021, 12, 702720.	1.3	4
1735	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, 14, 157-163.	1.0	9
1736	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2021, 14, 157-163.	0.2	4
1737	The Impact of THC and CBD in Schizophrenia: A Systematic Review. <i>Frontiers in Psychiatry</i> , 2021, 12, 694394.	1.3	34
1738	Safety and Efficacy of High-Dose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 681418.	1.3	5
1739	Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110275.	2.5	3
1740	Antipsychotics withdrawal in adults with intellectual disability and challenging behaviour: study protocol for a multicentre double-blind placebo-controlled randomised trial. <i>BMC Psychiatry</i> , 2021, 21, 439.	1.1	2
1741	Patient, family and provider views of measurement-based care in an early-psychosis intervention programme. <i>BJPsych Open</i> , 2021, 7, .	0.3	11
1742	Intrinsic neural network dynamics in catatonia. <i>Human Brain Mapping</i> , 2021, 42, 6087-6098.	1.9	22
1743	Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 1098-1106.	4.0	46
1744	Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. <i>PLoS ONE</i> , 2021, 16, e0257129.	1.1	22
1745	Case Report: Changes in Regional Cerebral Blood Flow in Chronic Akathisia of a Depressed Patient Before and After Electroconvulsive Therapy Treatment. <i>Frontiers in Psychiatry</i> , 2021, 12, 728265.	1.3	1

#	ARTICLE	IF	CITATIONS
1746	Serum hepcidin / ferroportin levels in bipolar disorder and schizophrenia. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 68, 126843.	1.5	8
1747	Barnes Akathisia Scale. , 2021, , 591-592.		0
1748	A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy. <i>Archives of General Psychiatry</i> , 2000, 57, 553-559.	13.8	431
1749	Akathisia With Combined Use of Midodrine and Promethazine. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1997.	3.8	8
1751	Neuroleptic Drugs and Their Management. , 2002, , 68-83.		1
1752	Antipsychotic Side-Effect Rating Scales in Schizophrenia. , 2012, , 45-53.		1
1753	Positron Emission Tomography, Receptors, and Schizophrenia. , 1995, , 252-262.		1
1754	The Neuroprotective Efficacy of Vitamins. , 2010, , 505-553.		3
1755	Pharmacology Effects and Side Effects. , 2008, , 221-263.		4
1758	Neuromotor dysfunction in early psychosis. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 113-21.	0.6	3
1760	Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 516-525.	0.7	42
1761	A Comparison of Fluvoxamine and Fluoxetine in the Treatment of Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 373-378.	0.7	41
1762	Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 407-418.	0.7	616
1763	Olanzapine Plasma Concentrations and Clinical Response in Acutely Ill Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 472-477.	0.7	104
1764	Low-Dose Mianserin in Treatment of Acute Neuroleptic-Induced Akathisia. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 253-254.	0.7	22
1765	Positron Emission Tomographic Analysis of Dose-Dependent MDL 100,907 Binding to 5-Hydroxytryptamine-2A Receptors in the Human Brain. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 317-323.	0.7	33
1766	Gradual Withdrawal of Long-Term Anticholinergic Antiparkinson Medication in Chinese Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 141-148.	0.7	20
1767	Psychomotor, Cognitive, Extrapyramidal, and Affective Functions of Healthy Volunteers During Treatment With an Atypical (Amisulpride) and a Classic (Haloperidol) Antipsychotic. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 209-221.	0.7	91

#	ARTICLE	IF	CITATIONS
1768	Acute Mania: Haloperidol Dose and Augmentation With Lithium or Lorazepam. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 500-505.	0.7	42
1769	Adverse Effects of High-Dose Olanzapine in Treatment-Refractory Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 382-384.	0.7	22
1770	Risperidone for the Treatment of Stuttering. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 479-482.	0.7	76
1771	Efficacy of Clozapine in the Treatment of Atypical Antipsychotic Refractory Schizophrenia: A Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 103-104.	0.7	9
1772	The Relation of Social Support-Seeking to Quality of Life in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2001, 189, 258-262.	0.5	28
1774	Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 367-373.	0.7	146
1775	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	0.6	12
1776	Long-Term Use of Mood Stabilizers and Its Impact on the Quality of Life of Chinese Patients With Schizophrenia. <i>Clinical Neuropharmacology</i> , 2009, 32, 16-21.	0.2	3
1778	Smoking and Schizophrenia: Is Symptom Profile Related to Smoking and which Antipsychotic Medication is of Benefit in Reducing Cigarette use?. , 0, .		4
1779	Akathisia: a life-threatening side effect of a common medication. <i>BMJ Case Reports</i> , 2013, 2013, bcr2012007713-bcr2012007713.	0.2	13
1780	Compliance therapy in psychotic patients: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 1996, 312, 345-349.	2.4	524
1781	Unusual morphology of scapulae: incidence and dimensions of ossified ligaments and supraspinous bony tunnels for clinical consideration. <i>Singapore Medical Journal</i> , 2016, 57, 29-32.	0.3	7
1782	Antipsychotic Medication Induced Movement Disorders: The Case of Amanuel Specialized Mental Hospital, Addis Ababa, Ethiopia. <i>American Journal of Psychiatry and Neuroscience</i> , 2014, 2, 76.	0.0	10
1783	Olanzapine Versus Placebo in the Treatment of Acute Mania. <i>American Journal of Psychiatry</i> , 1999, 156, 702-709.	4.0	456
1785	Abnormal Movements in Never-Medicating Indian Patients with Schizophrenia. <i>British Journal of Psychiatry</i> , 1996, 168, 221-226.	1.7	91
1786	Early detection of antipsychotic side-effects. <i>Psychiatric Bulletin</i> , 1999, 23, 657-660.	0.3	2
1787	Use of serotonin antagonists in the treatment of neuroleptic-induced akathisia. <i>Psychiatric Bulletin</i> , 2000, 24, 348-351.	0.3	2
1789	Tardive Syndromes. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1081-1098.	0.4	6

#	ARTICLE	IF	CITATIONS
1790	Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient. American Journal of Case Reports, 2016, 17, 880-882.	0.3	13
1791	Long-Stay Psychiatric Patients: A Prospective Study Revealing Persistent Antipsychotic-Induced Movement Disorder. PLoS ONE, 2011, 6, e25588.	1.1	44
1792	No Association of a Set of Candidate Genes on Haloperidol Side Effects. PLoS ONE, 2012, 7, e44853.	1.1	7
1793	Prevalence and Correlates of Cigarette Smoking among Chinese Schizophrenia Inpatients Receiving Antipsychotic Mono-Therapy. PLoS ONE, 2014, 9, e88478.	1.1	25
1794	Neuroleptic-Induced Akathisia and Violence: A Review. Journal of Forensic Sciences, 2003, 48, 1-3.	0.9	28
1796	Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial. Medical Journal of the Islamic Republic of Iran, 2017, 31, 90-95.	0.9	2
1797	Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders. Neuropsychiatric Disease and Treatment, 2005, 1, 89-108.	1.0	10
1798	Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment, 2007, 3, 219-235.	1.0	56
1799	Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges. Current Neuropharmacology, 2017, 15, 789-798.	1.4	65
1800	A Neuroanatomical Basis for the Frequency of Discrete Spontaneous Activities in Schizophrenia. Open Neuroimaging Journal, 2009, 3, 48-53.	0.2	2
1801	CLINICAL ASSESSMENT OF TICS. Psychological Reports, 2001, 89, 48.	0.9	3
1802	NEUROBEHAVIORAL ASSESSMENT OF CHILDREN AND ADOLESCENTS ATTENDING A DEVELOPMENTAL DISABILITIES CLINIC. Psychological Reports, 2004, 95, 1079.	0.9	3
1803	Treatment of tardive akathisia with clonidine.. Kurume Medical Journal, 1990, 37, 185-187.	0.0	8
1804	Prevalencia de la depresi3n en Espa±a: An±lisis de los ±ltimos 15 a±os. European Journal of Investigation in Health, Psychology and Education, 2015, 5, 267.	1.1	12
1805	Quantitative analysis of motor disturbances in schizophrenic patients. Dialogues in Clinical Neuroscience, 2006, 8, 123-130.	1.8	23
1806	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technology Assessment, 2016, 20, 1-46.	1.3	25
1807	Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technology Assessment, 2017, 21, 1-56.	1.3	28
1808	Neural Effects of Ziprasidone Monotherapy in First-Episode Schizophrenia: A Longitudinal Study using fMRI and a Procedural Learning Paradigm. Clinical Schizophrenia and Related Psychoses, 2008, 1, 317-327.	1.4	3

#	ARTICLE	IF	CITATIONS
1809	Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 2, 136-146.	1.4	4
1810	A Brief Overview of Iatrogenic Akathisia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2010, 3, 226-236.	1.4	7
1811	Concomitant Psychotropic Medication Use During Treatment of Schizophrenia Patients: Longitudinal Results from the CATIE Study. <i>Clinical Schizophrenia and Related Psychoses</i> , 2011, 5, 124-134.	1.4	19
1812	Olanzapine for Psychotic Conditions in the Elderly. <i>Psychiatric Annals</i> , 2000, 30, 191-196.	0.1	35
1813	Akathisia: Case Presentation and Review of Newer Treatment Agents. <i>Psychiatric Annals</i> , 2014, 44, 391-396.	0.1	7
1814	Ziprasidone-Induced Angioedema. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1054.	1.1	9
1815	Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 526-539.	1.1	121
1816	A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II). <i>Journal of Clinical Psychiatry</i> , 2010, 71, 163-174.	1.1	250
1817	Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 627-643.	1.1	129
1818	Analysis of Suicidality in Pooled Data From 2 Double-Blind, Placebo-Controlled Aripiprazole Adjunctive Therapy Trials in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 548-555.	1.1	13
1819	Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 295-303.	1.1	57
1820	Extended Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1042-1048.	1.1	58
1821	How to Interpret Findings Concerning Newly Approved Antipsychotic Agents. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e27.	1.1	1
1822	Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 170-179.	1.1	56
1823	Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 507-515.	1.1	60
1824	The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1224-1232.	1.1	45
1825	Prospective Trial of Customized Adherence Enhancement Plus Long-Acting Injectable Antipsychotic Medication in Homeless or Recently Homeless Individuals With Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 1249-1255.	1.1	33
1826	Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1224-1231.	1.1	137

#	ARTICLE	IF	CITATIONS
1827	Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1232-1240.	1.1	135
1828	Cariprazine in Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1574-e1582.	1.1	134
1829	Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 324-331.	1.1	106
1830	Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	38
1831	Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	1.1	12
1832	Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 273-281.	1.1	86
1833	Effectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 580-588.	1.1	108
1834	Adherence to Conventional and Atypical Antipsychotics After Hospital Discharge. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 354-360.	1.1	105
1835	Vitamin B6 Treatment in Acute Neuroleptic-Induced Akathisia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1550-1554.	1.1	36
1836	Efficacy and Tolerability of Ziprasidone Versus Risperidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1624-1633.	1.1	70
1837	Risperidone and Paroxetine Given Singly and in Combination for Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1715-1719.	1.1	84
1838	A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Quetiapine or Lithium as Monotherapy for Mania in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 111-121.	1.1	309
1839	A Randomized, Observer-Blind, Controlled Trial of the Traditional Chinese Medicine Yi-Gan San for Improvement of Behavioral and Psychological Symptoms and Activities of Daily Living in Dementia Patients. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 248-252.	1.1	300
1840	Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1184-1190.	1.1	52
1841	Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1289-1297.	1.1	139
1842	Sexual Function and Gonadal Hormones in Patients Taking Antipsychotic Treatment for Schizophrenia or Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 361-367.	1.1	77
1843	Equivalent Switching Dose From Oral Risperidone to Risperidone Long-Acting Injection. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1218-1225.	1.1	83
1844	Vitamin B6 Treatment for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1648-1654.	1.1	71

#	ARTICLE	IF	CITATIONS
1845	Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1867-1875.	1.1	139
1846	The Effect of Antipsychotic Medication on Neuromotor Abnormalities in Neuroleptic-Naive Nonaffective Psychotic Patients. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	26
1847	Safety and Tolerability of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Subjects (6â€“17 Years Old). <i>primary care companion for CNS disorders, The</i> , 2011, 13, .	0.2	27
1848	Agomelatine-Induced Akathisia in a 38-Year-Old Woman With Depression. <i>primary care companion for CNS disorders, The</i> , 2014, 16, .	0.2	3
1849	Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. <i>Indian Journal of Psychiatry</i> , 2016, 58, 311.	0.4	13
1850	Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study. <i>Industrial Psychiatry</i> , 2014, 23, 27.	0.3	10
1851	A study of physical anhedonia as a trait marker in schizophrenia. <i>Industrial Psychiatry</i> , 2018, 27, 235.	0.3	2
1852	A preliminary study of association of genetic variants with early response to olanzapine in schizophrenia. <i>Indian Journal of Psychiatry</i> , 2018, 60, 10.	0.4	4
1853	Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine. <i>Psychiatry Investigation</i> , 2012, 9, 422.	0.7	10
1854	Beneficial Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases. <i>Psychiatry Investigation</i> , 2013, 10, 417.	0.7	12
1855	Haplotype Association of the <i>MAP2K5</i> Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia. <i>Psychiatry Investigation</i> , 2018, 15, 84-89.	0.7	6
1856	BakÄ±mevinde kalan Å“izofreni hastalarÄ±nda yaÅ“am kalitesi ve depresyon. <i>Dusunen Adam</i> , 2015, , 213-221.	0.0	8
1857	Tardive dyskinesia in long term hospitalized patients with schizophrenia. <i>Dusunen Adam</i> , 2016, , 259-265.	0.0	3
1858	Psychoactive drug use in an institution for intellectually handicapped persons (for editorial) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5</i>	0.8	24
1859	A Placebo-controlled Trial of Folate with B12 in Patients with Schizophrenia with Residual Symptoms in Ethiopia Using a Sequential Parallel Comparison Design. <i>British Journal of Medicine and Medical Research</i> , 2014, 4, 4090-4104.	0.2	4
1860	Applied monitoring for tardive dyskinesia and other extrapyramidal side effects. <i>Mental Health Clinician</i> , 2012, 1, 159-163.	0.5	1
1861	Long-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2013, 11, 132-136.	0.9	13
1862	Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 261-269.	0.9	7

#	ARTICLE	IF	CITATIONS
1863	The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4371-4382.	2.0	5
1864	Neurological Soft Signs in Cannabis Use Disorder with or without Psychosis: A Comparative Study from India. <i>Journal of Dual Diagnosis</i> , 2021, 17, 1-10.	0.7	0
1865	Comparison of Aripiprazole Versus Haloperidol for the Treatment of Childhood and Adolescent Non-Affective Psychotic Disorders. <i>Eastern Journal of Psychiatry</i> , 2021, 16, 77-82.	0.0	0
1866	Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 773-779.	0.9	0
1867	Predictores del cumplimiento de la medicaci3n neurol3ptica entre pacientes internos con esquizofrenia: un an3lisis de la funci3n discriminante. <i>European Psychiatry (Ed Espa3ola)</i> , 2002, 9, 21-27.	0.0	0
1868	Calidad de vida y costes de tratamiento en pacientes ambulatorios esquizofr3nicos tratados con neurol3pticos depot. <i>European Psychiatry (Ed Espa3ola)</i> , 2002, 9, 226-235.	0.0	0
1869	Predictores del incumplimiento terap3utico en varones con primer episodio de esquizofrenia, trastorno esquizofreniforme y trastorno esquizoafectivo. <i>European Psychiatry (Ed Espa3ola)</i> , 2002, 9, 373-379.	0.0	0
1870	Clinical Relevance of Quantitative Measurements of Drug-induced Extrapyramidal Symptoms. <i>The Showa University Journal of Medical Sciences</i> , 2003, 15, 57-66.	0.1	0
1871	Risperidona en la esquizofrenia cr3nica: un estudio de cambio al descubierto con verificaci3n detallada y seguimiento de dos a3os de pacientes en medicaci3n depot. <i>European Psychiatry (Ed)</i> Tj ETQq0 0 0 r0BT /Overlock 10 Tf 5		
1872	Supporting People and their Families During Psychopharmacotherapy. , 2004, , 164-177.		0
1874	¿Merece la pena cambiar de antipsic3ticos convencionales a at3picos a pacientes ambulatorios esquizofr3nicos cl3nicamente estables con s3ntomas residuales, efectos secundarios, o ambas cosas, de leves a moderados? Un estudio prospectivo distribuido al azar con olanzapina. <i>European Psychiatry (Ed Espa3ola)</i> , 2005, 12, 247-249.	0.0	0
1877	Kapitel 8 Literaturverzeichnis. , 2007, , 167-196.		0
1878	Un ensayo comparativo doble ciego distribuido al azar de amisulprida frente a olanzapina durante 2 meses en el tratamiento de sujetos con esquizofrenia y depresion comorbida. <i>European Psychiatry (Ed)</i> Tj ETQq0 0 0 r0BT /Overlock 10	0.0	0
1879	Diagnostic Rating Scales and Psychiatric Instruments. , 2008, , 79-90.		0
1883	Akathisia. , 2010, , 16-19.		0
1884	Comorbidity of anxiety disorders in schizophrenia: relationship with sociodemographic and clinical variables. <i>Dusunen Adam</i> , 2010, , 18-24.	0.0	0
1885	Health-Related Quality of Life Impairment in Schizophrenia and Related Disorders as a Target for Neuroprotective Therapy. <i>American Journal of Neuroprotection and Neuroregeneration</i> , 2010, 2, 48-57.	0.1	1
1887	Escitalopram-Induced Severe Akathisia. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010, 12, .	0.6	3

#	ARTICLE	IF	CITATIONS
1888	The impact of antipsychotic side-effects on attitudes toward medication in patients with schizophrenia and related disorders: a systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2011, 9, 791-832.	1.7	0
1890	Randomized Controlled Trials of Olanzapine Treatment of Borderline Personality Disorder: Two Similar Studies With Different Results. Journal of Clinical Psychiatry, 2011, 72, 1363-1365.	1.1	2
1892	Rating Scales and Diagnostic Schemata. , 2014, , 1-3.		0
1893	Extrapyramidale Nebenwirkungen bei neuroleptischer Therapie. , 1990, , 215-238.		2
1894	Psychometrie, Rating-Skalen, Evaluation. , 1992, , 131-159.		0
1895	Klinik. , 1992, , 81-183.		0
1896	PET Examination of Central D2 Dopamine Receptor Occupancy in Relation to Extrapyramidal Syndromes in Patients Being Treated with Neuroleptic Drugs. , 1993, 10, 94-100.		19
1897	IBZM-SPECT zur Darstellung der D2-Rezeptorokkupanz unter Risperidon. , 1996, , 675-677.		0
1898	Biological Predictors of Antipsychotic Treatment Response. Handbook of Experimental Pharmacology, 1996, , 389-444.	0.9	0
1899	CLINICAL ASSESSMENT OF ADVENTITIOUS MOVEMENTS. Psychological Reports, 1998, 83, 739.	0.9	2
1900	Un caso de acatisia inducida por paroxetina y una revisi3n de la acatisia inducida por SSRI. European Psychiatry (Ed Espa±ola), 1998, 5, 400-402.	0.0	0
1901	Efectividad de la clozapina en un servicio psiqui±trico en Italia. European Psychiatry (Ed Espa±ola), 1999, 6, 124-127.	0.0	0
1902	Early experience of the use of olanzapine across three rehabilitation services. Psychiatric Bulletin, 1999, 23, 480-483.	0.3	0
1903	Severe Restlessness in a Woman Being Treated for Depression. Psychiatric Annals, 2015, 45, 100-102.	0.1	0
1904	Assessment of Extrapyramidal Symptoms and Hyperprolactinemia with Risperidone in Schizophrenic patients and Evaluation of their Management. Gratis Journal of Biomedical Sciences, 2015, 1, .	0.0	0
1905	Common side effect management. , 0, , 225-234.		0
1906	Rapid onset Akathisia with low dose Aripiprazole- Two Case Reports. Indian Journal of Pharmacy Practice, 2015, 8, 136-138.	0.1	1
1907	Uzun s¼re antipsikotik tedavisi alan mental retardasyonlu hastalarda tardiv diskinezi. Dusunen Adam, 2016, , 60-66.	0.0	0

#	ARTICLE	IF	CITATIONS
1908	TARDIVE DYSKINESIA AND OTHER EXTRAPYRAMIDAL SYMPTOMS ASSOCIATED WITH ARIPIPRAZOLE: A CASE SERIES. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2016, 5, 3229-3235.	0.1	1
1909	Clinical Predictors of Extrapyrarnidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	4
1910	Escitalopram-induced severe akathisia leading to suicide attempt. <i>Industrial Psychiatry</i> , 2019, 28, 315.	0.3	2
1911	An exploratory study from eastern India on neurological soft signs and spontaneous movement disorders in schizophrenia spectrum disorders. <i>Open Journal of Psychiatry and Allied Sciences</i> , 2019, 10, 3.	0.4	1
1912	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2020, , 1-56.		0
1913	Antipsychotics: Motor Side Effects. <i>Current Clinical Psychiatry</i> , 2020, , 185-200.	0.2	0
1914	Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?. <i>Bulletin of Siberian Medicine</i> , 2020, 18, 36-43.	0.1	1
1916	Identification of Risk Factors Associated with Aripiprazole-induced Acute Akathisia. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2020, 46, 414-420.	0.0	0
1917	Outcome Measurement in Schizophrenia: Challenges and Barriers. , 2020, , 91-124.		1
1918	The Treatment of the Dually Diagnosed: Intellectual Disability and Severe Psychopathology. <i>Autism and Child Psychopathology Series</i> , 2020, , 475-504.	0.1	0
1919	Neurocognitive impairments in patients with schizophrenia and schizophrenia spectrum disorders: cluster analysis results. <i>V M Bekhterev Review of Psychiatry and Medical Psychology</i> , 2020, , 45-51.	0.1	3
1920	Group 2 Medications: FDA-Approved Antipsychotics and Mood Stabilizers. , 2021, , .		0
1921	CYP2D6 Genotyping and Antipsychotic-Associated Extrapyrarnidal Adverse Effects in a Randomized Trial of Aripiprazole Versus Quetiapine Extended Release in Children and Adolescents, Aged 12â€“17 Years, With First Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 667-672.	0.7	2
1922	The Role of Antipsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia. <i>Psychiatry</i> , 2020, 18, 32-38.	0.2	0
1924	Trazodone as an Alternative Treatment for Neuroleptic-Associated Akathisia. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 611-614.	0.7	4
1925	Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. <i>Ukrains Kyi Visnyk Psykhonevrolohii</i> , 2020, , 27-37.	0.0	0
1926	Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. <i>Journal of Psychiatry and Neuroscience</i> , 2003, 28, 293-9.	1.4	18
1927	An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study. <i>Journal of Psychiatry and Neuroscience</i> , 1995, 20, 287-96.	1.4	3

#	ARTICLE	IF	CITATIONS
1928	The side effects of antipsychotic drugs and patients' quality of life: patient education and preference assessment with computers and multimedia. <i>Proceedings</i> , 1993, , 17-21.	0.4	5
1929	Prevalence and correlates of insomnia and its impact on quality of life in Chinese schizophrenia patients. <i>Sleep</i> , 2009, 32, 105-9.	0.6	55
1930	Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. <i>Psychiatry</i> , 2010, 7, 17-24.	0.3	5
1931	Olanzapine in the treatment of schizophrenia : an open label comparative clinical trial from north India. <i>Indian Journal of Psychiatry</i> , 2001, 43, 257-63.	0.4	9
1932	Drug-induced akathisia - a preliminary report. <i>Indian Journal of Psychiatry</i> , 1992, 34, 159-61.	0.4	2
1933	Antipsychotic-induced movement disorders: evaluation and treatment. <i>Psychiatry</i> , 2005, 2, 36-41.	0.3	16
1934	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. <i>Paediatrics and Child Health</i> , 2011, 16, 590-8.	0.3	16
1935	A survey of the tardive dyskinesia induced by antipsychotic drugs in patients with schizophrenia. <i>Iranian Journal of Psychiatry</i> , 2010, 5, 159-63.	0.4	2
1939	An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder. <i>Psychopharmacology Bulletin</i> , 2016, 46, 8-17.	0.0	4
1940	A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder. <i>Psychopharmacology Bulletin</i> , 2012, 45, 5-30.	0.0	0
1941	Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study. <i>Psychopharmacology Bulletin</i> , 2011, 44, 5-31.	0.0	1
1942	Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia. <i>Psychopharmacology Bulletin</i> , 2011, 44, 54-72.	0.0	8
1943	A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder. <i>Psychopharmacology Bulletin</i> , 2016, 46, 8-23.	0.0	13
1944	Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. <i>Psychopharmacology Bulletin</i> , 2011, 44, 18-31.	0.0	34
1945	Risk Factors for Tremor in a Population of Patients with Severe Mental Illness: An 18-year Prospective Study in a Geographically Representative Sample (The Curacao Extrapyramidal Syndromes Study XI). <i>Tremor and Other Hyperkinetic Movements</i> , 2017, 7, 468.	1.1	0
1946	Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia -. <i>Psychopharmacology Bulletin</i> , 2017, 47, 77-109.	0.0	2
1947	Effect of Vitamin B6 Versus Propranolol on Antipsychotic-Induced Akathisia: A pilot Comparative Double-blind Study. <i>Iranian Journal of Pharmaceutical Research</i> , 2018, 17, 130-135.	0.3	3
1948	Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Psychopharmacology Bulletin</i> , 2018, 48, 62-80.	0.0	14

#	ARTICLE	IF	CITATIONS
1949	Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report. <i>Psychopharmacology Bulletin</i> , 2019, 49, 80-83.	0.0	0
1950	Struggling to find Effective Pharmacologic Options for Akathisia? B-CALM!. <i>Psychopharmacology Bulletin</i> , 2021, 51, 72-78.	0.0	1
1951	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e044656.	0.8	0
1952	Long-term efficacy and safety of once-monthly Risperidone ISMÂ® in the treatment of schizophrenia: Results from a 12-month open-label extension study. <i>Schizophrenia Research</i> , 2022, 239, 83-91.	1.1	5
1953	Characterizing the sensorimotor domain in schizophrenia spectrum disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 1097-1108.	1.8	12
1954	A systematic review of the prognostic value of motor abnormalities on clinical outcome in psychosis. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 691-705.	2.9	17
1956	Motor Behavior is Relevant for Understanding Mechanism, Bolstering Prediction, And Improving Treatment: A Transdiagnostic Perspective. <i>Schizophrenia Bulletin</i> , 2022, 48, 741-748.	2.3	10
1957	Aggressive and violent behavior in a population of psychiatric inpatients. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 1997, 32, 428-434.	1.6	39
1958	The effect of antipsychotic-induced extrapyramidal disorders on patientâ€™s compliance with schizophrenia (a clinical case). <i>Bulletin of Siberian Medicine</i> , 2022, 20, 211-217.	0.1	0
1959	Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532110643.	1.2	0
1960	Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction. <i>Schizophrenia Research</i> , 2022, 239, 160-167.	1.1	5
1961	The Important Role of Motivation and Pleasure Deficits on Social Functioning in Patients With Schizophrenia: A Network Analysis. <i>Schizophrenia Bulletin</i> , 2022, 48, 860-870.	2.3	16
1962	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 703-714.	1.3	2
1963	Long-term safety and effectiveness of open-label lurasidone in antipsychotic-NaÃve versus previously treated adolescents with Schizophrenia: A post-hoc analysis. <i>Schizophrenia Research</i> , 2022, 240, 205-213.	1.1	3
1964	Effectiveness and optimal duration of early intervention treatment in adult-onset psychosis: a randomized clinical trial. <i>Psychological Medicine</i> , 2022, , 1-13.	2.7	3
1965	Analgesic Effects of Oxycodone in Combination With Risperidone or Ziprasidone: Results From a Pilot Randomized Controlled Trial in Healthy Volunteers. <i>Frontiers in Pain Research</i> , 2022, 3, 752256.	0.9	0
1966	Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	0
1967	Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	3

#	ARTICLE	IF	CITATIONS
1968	Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapiramidal Syndromes Study XIV. <i>Schizophrenia Bulletin</i> , 2022, 48, 766-773.	2.3	1
1969	Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. <i>Acta Neuropsychiatrica</i> , 2022, 34, 282-288.	1.0	2
1970	A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. <i>Asian Journal of Psychiatry</i> , 2022, 72, 103121.	0.9	7
1971	Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 143-152.	0.7	3
1972	Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109412.	1.6	3
1973	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e044656.	0.8	8
1974	Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. <i>NPJ Schizophrenia</i> , 2021, 7, 63.	2.0	39
1975	Handedness as a neurodevelopmental marker in schizophrenia: Results from the FACE-SZ cohort. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 525-536.	1.3	5
1976	Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia. <i>European Psychiatry</i> , 2022, 65, 1-35.	0.1	4
1978	Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, , 1.	1.8	2
1979	Use of olanzapine for elderly patients with psychotic disorders: a review. <i>Annals of Clinical Psychiatry</i> , 2001, 13, 201-13.	0.6	8
1980	Risperidone in Treatment-Refractory Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 1374-1379.	4.0	121
1981	Dyspraxia and agnosia in schizophrenia. <i>Behavioural Neurology</i> , 1993, 6, 49-54.	1.1	8
1983	Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. <i>Journal of Psychopharmacology</i> , 2022, 36, 637-644.	2.0	2
1984	Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
1985	Cariprazine Use in Combination With a Mood Stabilizer in First Episode Mania. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	2
1986	Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric psychiatry unit. <i>International Psychogeriatrics</i> , 2022, 34, 919-928.	0.6	3
1987	Efeitos extrapiramidais e estado nutricional associado ao uso de antipsicóticos em pacientes internados em um hospital de referência psiquiátrica, Belém-Pará. <i>Research, Society and Development</i> , 2022, 11, e29311729895.	0.0	0

#	ARTICLE	IF	CITATIONS
1992	Gender Differences in the Psychopharmacological Treatment of Forensic In-Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	0
1993	Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1994	Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 1273-1283.	2.3	5
1995	Midodrine exacerbates promethazine-induced akathisia. <i>FASEB Journal</i> , 2006, 20, .	0.2	0
1996	Aripiprazole vs risperidone head-to-head effectiveness in first-episode-non-affective-psychosis: A 3-month randomized, flexible-dose, open-label clinical trial. <i>International Journal of Neuropsychopharmacology</i> , 0, .	1.0	0
1997	Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia. <i>International Clinical Psychopharmacology</i> , 2023, 38, 45-56.	0.9	4
1998	Interleukin-6 in schizophrenia is associated with negative symptoms, side effects of therapy and smoking: results of a pilot study. <i>V M Bekhterev Review of Psychiatry and Medical Psychology</i> , 2022, 56, 47-55.	0.1	1
2000	The association of serum folate levels with schizophrenia symptoms. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2022, 122, 128.	0.1	1
2002	Pharmacological interventions for prevention of weight gain in people with schizophrenia. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	7
2003	Behavioural phenotypes of intrinsic motivation in schizophrenia determined by cluster analysis of objectively quantified real-world performance. , 2022, 8, .		0
2004	26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic). <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 453-458.	0.7	0
2005	Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 434-443.	0.7	2
2006	Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study. <i>Schizophrenia Research</i> , 2022, 250, 31-38.	1.1	3
2007	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. , 2022, , 305-359.		0
2008	Towards Multimodal Dialog-Based Speech & Facial Biomarkers of Schizophrenia. , 2022, , .		3
2009	Subtyping chronic catatonia: Clinical and neuropsychological characteristics of progressive periodic catatonia and chronic system catatonias vs. non-catatonic schizophrenia. <i>Schizophrenia Research</i> , 2022, , .	1.1	1
2010	Balanced time perspective and its relationship with clinical and cognitive symptoms in schizophrenia. <i>Personality and Individual Differences</i> , 2023, 202, 112003.	1.6	0
2011	Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial. <i>Current Neuropharmacology</i> , 2023, 21, 424-436.	1.4	0

#	ARTICLE	IF	CITATIONS
2012	Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report. SAGE Open Medical Case Reports, 2022, 10, 2050313X2211397.	0.2	0
2013	The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders. Drug Metabolism and Personalized Therapy, 2022, .	0.3	2
2014	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. The Cochrane Library, 2022, 2022, .	1.5	6
2015	Akathisia after chronic usage of synthetic cathinones: A case study. Frontiers in Psychiatry, 0, 13, .	1.3	0
2016	Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics, 2023, 151, .	1.0	5
2017	History of learning disorders is associated with worse cognitive and functional outcomes in schizophrenia: results from the multicentric FACE-SZ cross-sectional dataset. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 1773-1783.	1.8	1
2018	Outcome Prediction for Patients with Bipolar Disorder Using Prodromal and Onset Data. Applied Sciences (Switzerland), 2023, 13, 1552.	1.3	0
2019	Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study. Frontiers in Pharmacology, 0, 14, .	1.6	0
2020	Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2023, 21, 57-67.	0.9	2
2021	Meta-analysis of the effects of adjuvant drugs in co-occurring bipolar and substance use disorder. Revista De PsiquiatrÃa Y Salud Mental, 2023, , .	1.0	0
2022	Tic Reduction Following Heat-Induced Dehydration in Gilles de la Tourette Syndrome (TS). , 0, , .		0
2023	Adjunctive lumateperone (<sc>ITI</sc>â€007) in the treatment of bipolar depression: Results from a randomized <sc>placeboâ€controlled</sc> clinical trial. Bipolar Disorders, 2023, 25, 478-488.	1.1	6
2024	Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. American Journal of Psychiatry, 2023, 180, 241-251.	4.0	11
2025	Drug-Induced Movement Disorders. Seminars in Neurology, 2023, 43, 035-047.	0.5	2
2026	A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS Drugs, 2023, 37, 337-350.	2.7	6
2027	Age or age of onset: which is the best criterion to classify late-life depression?. International Clinical Psychopharmacology, 0, Publish Ahead of Print, .	0.9	1
2028	Systematic Review of Psychotropic Adverse Drug Event Monitoring Tools for Use in Long-Term Care Facilities. Journal of the American Medical Directors Association, 2023, , .	1.2	0
2029	Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. European Neuropsychopharmacology, 2023, 72, 40-49.	0.3	2

#	ARTICLE	IF	CITATIONS
2031	Scales for Antipsychoticâ€Associated Movement Disorders: Systematic Review, Critique, and Recommendations. <i>Movement Disorders</i> , 2023, 38, 1008-1026.	2.2	2
2043	Treatments for Medication-Induced Movement Disorders. , 2023, , 1-12.		0